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Abstract 
Frailty, the increased vulnerability of an individual to stressors, and sarcopenia, the loss of 
muscle mass with age, share many of the same clinical outcomes, associations and 
suggested pathophysiology.  The pathophysiology of both conditions is incompletely 
characterised but it is postulated the immune system is central to development and 
propagation.  Previous work has demonstrated dysregulation in the function of 
neutrophils with an individual’s increasing age and the PI3kinase signalling pathway is 
implicated in this process.  This study aimed to describe neutrophil function and 
inflammation in a group of frail older adults and correlate parameters of frailty with 
immunesenescence.         
40 healthy young, 40 healthy older, and 37 frail older adults were recruited to three 
groups; all individuals were extensively characterised clinically.  A further 73 healthy 
young adults were recruited for ultrasound assessment of muscle.      
Ultrasound was reviewed as a diagnostic technique in the identification of sarcopenia 
using a simple scanning protocol to produce the bilateral anterior thigh thickness (BATT).  
The BATT was measured in a reference population, 113 in total, and proposed criteria for 
the identification of low muscle mass in older adults was based on this reference 
population. Ultrasound echogenicity correlated with muscle strength in a frail older adult 
population.  
   
Muscle biopsy using a percutaneous needle biopsy technique was found to be not 
feasible in this study’s recruited frail older adult population.  This was secondary to both 
contraindications to muscle biopsy, such as anticoagulation and muscle depth.      
Neutrophils exhibit a frailty related decline in migratory accuracy towards 
chemoattractants; this was both independent of age and associated with physical (grip 
strength) and cognitive parameters (Stroop Interference) of frailty.  Incubation of 
neutrophils from frail older adults with PI3kinase inhibitors class 1A δ and class 1B γ 
restored migratory accuracy and this presents a novel therapeutic target for management 
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Research into healthy ageing is increasingly recognised as vitally important.  Life 
expectancy is increasing and it is estimated that in the UK by 2030 men aged 65 will live 
on average to 88 and women to 91 (1).  A rising life expectancy coupled with falling birth 
rates increases the proportion of older people in the population as a whole.   By 2050, the 
World Health Organisation predicts that there will be two billion people aged over 60, 
and 395 million people living to be 80 (2). 
The concept of healthy ageing is an emerging topic and is based on healthy life 
expectancy: the average number of years that a person can expect to live in full health by 
taking into account years lived in less than full health due to disease and/or injury (2).  
Healthy life expectancy is therefore lower than actual life expectancy.  Healthy life 
expectancy at birth in England is currently 63.4 for men and 64.1 for women compared to 
a life expectancy of 79.5 for men and 83.2 and women (3).  Men can therefore expect to 
live 16 years and women 19 years in poor health.  Whilst both life expectancy and healthy 
life expectancy have increased the difference between the two has not diminished; time 
spent living in poor health has not improved with advances in medicine.  
Frailty is a term that has been used to describe some of the components of unhealthy 








The concept of frailty has been recognised for many years but its emerging importance as 
a hallmark of ageing has led to a more rigorous medical definition of physical frailty.     
‘A medical syndrome with multiple causes and contributors that is characterized by 
diminished strength, endurance, and reduced physiologic function that increases an 
individual’s vulnerability for developing increased dependency and/or death’(4).   
The definition recognises that frailty increases an individual’s risk for an adverse outcome 
such as falls, infections or death. It also alludes to frail individuals living closer to the 
threshold of an adverse outcome due to their reduced physiological reserve.       
1.2.2 Models of frailty 
The definition describes the syndrome but does not explain or interpret the condition 
and therefore two intrinsically different models of frailty have been proposed in an 
attempt to operationalise the syndrome.   
The first model, the Frailty Phenotype model, was proposed by Fried and colleagues in 
2001 (5).  This proposes that a step-wise increase in self-reported disability is analogous 
with an increasing frailty state and correlates with adverse health outcomes such as 
death, hospitalisation and falls (5).  Fried demonstrates that the presence of 3 
components, out of a total of 5, has predictive power in identifying mortality risk.  She 
extrapolates this to suggest that the presence of 3 components in a person identifies 
them as frail and the presence of 1 or 2 components as pre-frail (5).  The model has been 




attempt has been made to assess the reliability of the phenotype (6).  The variations in 
the measurement of the different components within each study leads to some 
ambiguity on the accuracy of the validation studies.  The concurrent or predictive validity 
has been assessed in 17 different samples or cohorts (6).    
Conversely Rockwood and colleagues suggested that frailty was not a present or absent 
phenomenon but best described as a dynamic, continuous process.  He proposed the 
Frailty Index in 2001 (7).  The most striking difference was that any variable could be 
included as long as it was associated with adverse health outcomes, increased in 
prevalence with age into the tenth decade and had a prevalence of at least 1% which did 
not saturate in older age (7).  Using this model he proved there was a greater correlation 
of time to death with frailty index rather than age (7).  The frailty index has also been 
widely tested for validity against poor outcomes but not for reliability (6).  The concurrent 
or predictive validity has been assessed in 13 different samples or cohorts (6).        
1.2.3 Complementary but different models 
The Frailty Phenotype, as suggested by the name, is a model of physical parameters 
including only physical consequences. The Frailty Index can be considered to be a more 
global assessment of health and using this model frailty it often described as an 
accumulation of deficits rather than a present or absent phenomenon.     
One of the difficulties in comparing the models and ultimately deciding upon the most 
elegant and clinically applicable model is that each model describes a slightly different 
population.  The frailty index has better discriminatory ability for people with moderate 




frailty and the inclusion of cognitive and psychosocial markers rather than solely relying 
on physical markers.  There are also higher rates of frailty reported with the frailty index, 
likely due to the continuous nature of the model (9). This may make it a better objective 
marker of deficit accumulation and in the assessment of the efficacy of an intervention.  
The frailty phenotype may have utility in identifying older adults at risk of disability.  It 
has been suggested that these assessment instruments should not be considered as 
alternatives, but rather as complementary.  However, a recent systematic review of 
frailty interventions in community dwelling older adults found that none of the fourteen 
studies included used the Frailty Index to identify frailty (10).  This suggests researchers 
are not utilising the models appropriately perhaps because of a perceived difficulty with 
utilising the Frailty Index in practice.   
1.3 Sarcopenia 
Sarcopenia, the syndrome of loss of muscle mass and strength, is considered by many as 
the physical manifestations of frailty or perhaps even a pre-cursor state if it is present 
without frailty.  Definitions of sarcopenia have evolved over time reflecting greater 
understanding of the condition.  The current broadly accepted definition includes the 
effects on function as well as including muscle mass and strength.   
 ‘A syndrome characterised by progressive and generalised loss of skeletal muscle mass 
and strength with a risk of adverse outcomes such as physical disability, poor quality of 
life and death.’(11) 
Similar to the frailty phenotype the European Working Group on Sarcopenia in Older 




and severe sarcopenia depending on the presence of certain criteria.  They suggest that 
pre-sarcopenia is characterised by low muscle mass with no impact on muscle strength or 
physical performance (11).  Whereas sarcopenia is low muscle mass with either low 
muscle strength or low physical performance and severe sarcopenia is the presence of all 
three criteria (11). 






The inclusion of both muscle mass and strength within the definition of sarcopenia has 
partially occurred in response to extensive research which has shown that whilst loss of 










The categorisation of sarcopenia by severity: pre-sarcopenia, sarcopenia and 
severe sarcopenia.  Pre-sarcopenia is characterised by low muscle mass with no 
impact on muscle strength or physical performance.  Sarcopenia is low muscle 
mass with either low muscle strength or low physical performance and severe 





decline in strength is more rapid than the concomitant loss of muscle mass.  Goodpaster 
et al demonstrated in a community dwelling population aged between 70 and 79 that 
muscle mass declines at 0.5-2% per annum compared to 2-4% loss of muscle strength 
(12).  Thus age-related changes in the quality of the muscle may be as important as the 
reduced mass and reduced muscle quality, notably loss of type II fibres, reduced 
mitochondrial mass and increased fat infiltration, may contribute to loss of muscle 
strength and power (13).     
However, ambiguity in the literature regarding definitions of strength and power may 
account for the non-linear relationship between the loss of muscle mass and strength.  
Isometric strength is the force or torque produced by a muscle at a constant length 
contraction; there is no change in the muscle fibre length and no movement of the joint 
occurs.  This correlates well with muscle mass.  Alternatively, power is dynamic, force 
during movement, and is affected by not only muscle mass but other neuromuscular 
components such as denervated type 2 muscle fibres.  These terms are often used 
interchangeably and therefore data should be interpreted with reference to the original 
methods.   
Figure 2 demonstrates a pictorial depiction of the potential contributors to sarcopenia.  
Potentially a more inclusive definition of sarcopenia may incorporate the loss of muscle 






Figure 1.2 - Age related changes occurring within the muscle from a whole muscle level 










Age related changes occurring within the muscle from a whole muscle level 
through to a cellular level and their impact on muscle mass, quality, strength and 




1.4 Identification of frailty and sarcopenia in clinical practice 
Identification of frailty and sarcopenia in research is different to the diagnosis of the 
syndromes in clinical practice due to constraints both on time and resources.  In research 
the gold standard for identifying: frailty is either Frailty Phenotype or Frailty Index and, 
for sarcopenia it is measuring all three criteria.  In clinical practice frailty has often been a 
diagnosis of the physician’s judgement based on their interpretation of the condition and 
sarcopenia is rarely diagnosed.  However, recently diagnostic and screening tools have 
evolved to improve the accuracy of diagnosis in both frailty and sarcopenia.   
The accuracy of different screening tools in the diagnosis of frailty was recently evaluated 
in a systematic review (14).  Whilst this was a systematic review of a relatively large 
number of participants, 3261, all of these participants are from a total of just three 
studies, therefore introducing bias.  Additionally all of the screening tests were also 
measured solely against the frailty phenotype which reports lower rates of frailty than 
the frailty index.  It is therefore not clear whether the reference population is an accurate 
representation of frailty.  The review demonstrated that both the sensitivity and 
specificity of the PRISMA 7 were high but wide confidence intervals suggest this may not 
be reproducible.  The gait speed, using a 0.8m/s cut off, also had a very high sensitivity 
but lower specificity as did a timed get up and go test.  Gait speed and timed get up and 
go reflect a physical phenotype of frailty whereas; PRISMA 7 encompasses multiple 
domains, mobility, social support and health and is therefore more akin to the Frailty 
Index.  The systematic review also reported on a general practitioner’s clinical judgement 
of frailty in an individual, the Groningen Frailty Indicator, a 15 item questionnaire, 




specificity values.  All these tools had been assessed only once in a single population and 
therefore it is problematic to extrapolate these results to consider all populations (14).          
Two diagnostic tests that assess both the presence and absence of frailty as well as 
severity are the Clinical Frailty Scale (CFS) and the Edmonton Frail Scale (EFS).  The CFS 
can be completed following a comprehensive geriatric assessment and to an extent 
reflects clinical judgement (15).  It has been validated as an adverse outcome predictor in 
hospitalised older adults (16, 17).  The EFS was designed to be utilised by practitioners 
not trained in comprehensive geriatric assessment (18).  It has been used to identify 
frailty in a number of studies (19, 20).    
A single screening test has been proposed for sarcopenia, SARC-F.  This is a short 
questionnaire comprising of 5 questions focused on the negative consequences of 
sarcopenia.  It has been validated in a number of American cohorts in one single study.  
The study demonstrated an increased risk of mortality, hospitalisation and falls.  The 
authors suggested that SARC-F could be utilised much like a FRAX score, identifying those 
who should have further assessment to make a diagnosis of sarcopenia (21).  The 
EWGSOP suggest an algorithm for the diagnosis of sarcopenia which negates the need to 
measure muscle mass in all individuals (22).  Whilst this reduces the resources required 
for the diagnosis of sarcopenia it does mean individuals with pre-sarcopenia, a condition 
that is likely to have greater potential for reversal, will not be diagnosed.        
The recent introduction of the electronic frailty index (EFI) to general practice in the UK 




screening tests.  The EFI is also based on the Frailty Index and incorporates assessment of 
multiple domains (23).    
1.5 Clinical relationship between frailty and sarcopenia 
The relationship between frailty and sarcopenia is not yet fully characterised but these 
conditions share many of the same clinical outcomes, associations and suggested 
pathophysiology.    Sarcopenia is considered a component of physical frailty but frailty is 
not considered a component of sarcopenia and there is considerable overlap between 
the defining criteria of the Frailty Phenotype and sarcopenia.  Sarcopenia is often 
considered a pre-cursor syndrome or the physical component to frailty.             
Sarcopenia is reported to be twice as common as frailty in the general population (24), 
However the prevalence of both conditions is dependent on population and definition.  
Using the EWGSOP definition and criteria of sarcopenia the prevalence ranges from 4.6%, 
community dwelling men in the UK aged 68-76 (25), to 68%, male Italian nursing home 
residents over 70 (26).  A recent systematic review of frailty prevalence in a community 
population (27) reported the range to be 4.0%, independently mobile men over 65 (28), 
to 59.1%, community dwelling Dutch older than 70 (29).  The calculated weighted 
average of frailty as defined using the Frailty Phenotype is 9.9% (27).      
Research has shown that in frail community dwelling adults the most common positive 
Fried criteria was slow gait speed (43%) and weakness (54%), the functional defining 
criteria of sarcopenia (30).  It has also been reported that the relative risk of developing 
weakness and low activity was higher than developing any other frailty defining criteria 




theoretically while it is possible to have frailty without sarcopenia clinically it is unlikely.  
However, two recent reports investigating the concordance of frailty and sarcopenia in 
community populations demonstrated that frailty was more common than sarcopenia 
and the concordance between frailty and sarcopenia was poor (32, 33).  This is the only 
literature investigating the concordance of frailty and sarcopenia but is contrary to 
previous understanding and may reflect the population studied and the tools used rather 
than generalisable data.  Nevertheless, if repeated studies demonstrate that concordance 
between the two conditions is incomplete it could suggest different pathophysiological 
pathways for sarcopenia and frailty which result in a common endpoint.     
Importantly both frailty and sarcopenia are considered partly reversible conditions.  
Several epidemiological studies have shown that whilst transition between lesser and 
greater frailty is always the most frequent outcome, a number of participants will 
transition from greater to lesser frailty (34-37).  Health status and baseline function is 
important, as those with poor mobility at baseline in a longitudinal study experienced 
faster acceleration of their frailty than those with good mobility (34).  These studies did 
not investigate factors such as recent acute illness which could cause periods of 
temporary frailty but do demonstrate the fluctuating nature of the syndrome.  The 
reversal of frailty has also been demonstrated in intervention studies.  A multifactorial 
intervention in community dwelling frail adults resulted in a significant difference in 
frailty prevalence between the two groups who were identical at baseline.  Whilst the 
intervention significantly reduced the prevalence of frailty and improved mobility this 
was not associated with change in mortality or hospitalisation, important clinical 




positive frailty criteria at baseline assessment, for example those scoring for weight loss 
would be assessed and managed by a dietician, consistent with a personalised medicine 
approach. Importantly, this study reported an actual reduction in diagnosis of frailty in 
the intervention group not just a slowing of progression (38).  It is also possible to 
improve components of frailty and sarcopenia.  Several resistance exercise programmes 
have documented improvements in gait speed and strength in groups of frail older adults 
(39, 40), with programmes of 8-12 weeks able to reverse loss of muscle strength 
equivalent to that lost over 20 years (39).  However, there is a degree of variability in the 
reported outcomes with resistance exercise programmes and this can be explained by the 
incorrect use of terminology.  Fiatarone reported improvements in muscle strength with 
a short resistance exercise programme but the outcomes measured where actually power 
and likely to reflect neuromuscular improvements rather than improvement in isometric 
strength or muscle mass (39).  Changes in muscle mass and isometric strength are likely 
to take much longer particularly in older adults and this is important to consider in both 
study design and clinical interventions.             
Clinical outcomes in frailty and sarcopenia are similar.  They are both associated with 
increased mortality, hospitalisation, falls, loss of independence and mobility.  The Frailty 
Index had a better correlation with time to death than age thus proving its value as a tool 
in geriatric medicine in the original concept paper.  The original Frailty Phenotype paper 
reported that at three year follow up of older adults identified as frail at baseline: 18% 
had died, 59% had been hospitalised and 28% had fallen.  The odds and hazard ratios of 
falls, fractures and death in severely frail individuals has been reported as: 1.54 (1.34-




adults with sarcopenia who had fallen in a 2 year follow up period (42) and a reported 
odds ratio of 4.42 for falls in older adults with sarcopenia (43).  The reported hazard ratio 
of death is 2.99 in older adults with sarcopenia (44).  The differences in reporting styles 
and utilised definitions make it difficult to compare the two syndromes and draw 
conclusions about causality, concordance and chronicity.       
1.6 The ageing immune system, frailty and sarcopenia 
The pathophysiology of both sarcopenia and frailty is complex.  Proposed models for both 
syndromes incorporate multiple causes, inter-relationships and elaborate pathways (11, 
45).  However, both syndromes are incompletely characterised and there is insufficient 
understanding of the underlying cellular mechanisms driving the development and 
maintenance of states of frailty and sarcopenia.  Sarcopenia is better understood than 
frailty largely due to its effects being concentrated on a single system, the neuromuscular 
system, and for this reason it has been suggested as a physical model of frailty.    
The role played by the immune system in frailty is believed to be fundamental in the 
development and maintenance of a frailty state, but it remains mostly uncharacterised.  
There is also increasing evidence that inflammation is important in the development of 
sarcopenia and frailty.  This thesis investigates the relationship between frailty, 
sarcopenia, immunesenescence and inflammageing, in particular characterising 
neutrophil function in frail older adults.  The introduction therefore, proceeds to discuss: 
neutrophil function and muscle homeostasis in health with particular reference to the 
PI3kinase/Akt pathway, immunesenescence and inflammageing in frailty and, proposed 





1.7 Neutrophil function in health   
Neutrophils are an essential component of the innate immune system providing a 
response to pathogens or injury once recruited.  They are also the most abundant 
leukocyte and comprise 60-70% of the complete leukocyte population (46).   
Neutrophils are granulocytes and are produced in the bone marrow from progenitor and 
precursor cells they then mature in the bone marrow before being released into the 
circulatory system (47) (48).  The process of maturation is regulated by cytokines, for 
example G-CSF; upregulation of cytokines during periods of infection results in increased 
numbers of neutrophils in the circulation.  Mature neutrophils leaving the bone marrow 
are quiescent and are activated on contact with cytokines and other regulatory proteins.  
A neutrophil’s half-life is believed to be just 8-12 hours unless activated (49, 50). In a 
healthy host neutrophils exist entirely in the circulatory system present in two 
populations, the circulating pool, neutrophils free to circulate within the bloodstream and 
the marginated pool, neutrophils that roll along the endothelium of small vessels through 
certain organs (49).  They are able to indefinitely switch populations.  The number 
present within each population is tightly regulated resulting in a neutrophilia as a 
response to infection (50).  Neutrophils enter tissue in response to infection or injury 
(51).  Once within the tissue they migrate to the target site, recruit and activate other 
cells of the immune system providing a near immediate response to invading pathogens 
or injury (52).  Neutrophils are either removed from the tissue by macrophages or 
undergo reverse transmigration back in to the circulation (53-55). Neutrophils that 
remain quiescent throughout their life-span return to the marginated pool and undergo 




The neutrophil has a variety of functions which enable it to effectively provide an 
appropriate immune response.  Neutrophils produce a variety of anti-microbial peptides 
including: cationic peptides and proteins that bind to microbial membranes, enzymes 
and, proteins that deprive microorganisms of essential nutrients (56).  They also secrete 
reactive oxygen species(ROS)(57).  The peptides and ROS cause damage to biomolecules 
which result in metabolic defects in the pathogen (and also collateral host tissue).  
Neutrophils are capable of phagocytosis and through a receptor mediated process of 
internalisation remove both pathogens and debris from host tissue (56).  During an active 
form of neutrophil death they extrude neutrophil extracellular traps(NETs)(56).  The NETs 
are comprised of proteins and chromatin which is capable of binding, disarming and 
killing pathogens extracellularly independently of phagocytosis(58).  The neutrophil does 
not provide a completely targeted response and consequently causes collateral damage 
to host tissues.  Neutrophils are also involved within immune cross-talk and produce 
cytokines and chemokines to attract a further immune response (56).  The initial 
response is to recruit further neutrophils via IL-8 (59).  They are also able to attract 
monocytes, macrophages, dendritic cells, natural killer cells and lymphocytes.  Secretion 
of IL-1β and TNFα induce other cells within the host tissue to produce chemoattractants 
(60, 61).  Importantly neutrophils are also central to the resolution of inflammation.  
Apoptosis of the neutrophil and phagocytosis of the dead neutrophils by macrophages 
initiates the release of anti-inflammatory IL-10 and TGFβ (62).   
1.7.1 Neutrophil migration  
The primary function of neutrophil to migrate to the source of infection or injury and 




system to the affected tissue.  This process relies on cell surface adhesion molecules 
which bind the neutrophil to the endothelium and then allow it to migrate through the 
endothelium to reach the affected tissue.  This process has a number of steps with 
various cell surface adhesion molecules becoming vital at different points (63).  This 
process is described in Figure 1.3. 













Neutrophil adhesion cascade.  Depiction of neutrophil and endothelial interaction including the 
adhesion molecules responsible for mitigating the different stages during transmigration of 




The capture of neutrophils to the endothelium is mediated by L-selectin, P-selectin and E-
selectin on the endothelial cell interacting with P-selectin glycoprotein 1 (PSGL1) on the 
neutrophil (63-65).  Blood flowing through the circulatory system creates a ‘sheer stress’ 
environment which supports the adhesion of these molecules (66).  PSGL1, which is 
present on all neutrophils, will bind to all three selectins.  E-selectin and P-selectin are 
both expressed by inflamed endothelial cells.  The binding of L-selectin to PSGL1 prompts 
adherent neutrophils to facilitate secondary capture of further neutrophils (63, 67).  The 
binding of P-selectin to PSGL-1 results in upregulation of expression of β2 integrins on the 
surface of the neutrophils.  (See Table 1.1 for more in depth description of the role of the 
cell surface receptors.)  The upregulation of β2 integrins promotes L-selectin 
downregulation and β2 integrins become the predominant signalling and adhesion 
molecule.  This induces a change in the neutrophil and allows it to reach its full signalling 
potential (46).   
Once the neutrophil has engaged with the endothelium it starts to roll slowly at a speed 
of 40μm/sec along the endothelial surface (68).  This is facilitated by selectin binding and 
new bonds are formed before old bonds are released to prevent the neutrophil from 
floating away in the circulatory system.  Slow rolling only occurs when the neutrophil 
comes into contact with inflamed endothelium.  It is defined as a speed below 5μm/sec 
(68).  The deceleration occurs due to the increased number of E-selectins expressed on 
the surface of the endothelium which increases the number of potential binding sites for 
PSGL-1.  During rolling and slow rolling MAC-1 and LFA-1 expressed on the neutrophils 




Arrest of the neutrophil rolling occurs following exposure of the endothelial cells to 
inflammatory cytokines which induces them to express adhesion molecules and 
synthesise chemokines on luminal surfaces.  LFA-1 and MAC-1 bind to ICAM-1 and VCAM-
1 expressed by the endothelial cells.  LFA-1 displays increased avidity following 
stimulation.  Chemokines on the luminal surfaces bind to glycol-protein coupled 
receptors (GPCRs) and induce conformational changes of ligands almost instantaneously 
(63).  Signalling both, inside-out and outside-in, occurs which modulates the affinity of 
the integrins for the ligand (69).  Strengthening of the neutrophil adhesion occurs with 
ligand induced integrin clustering which causes a conformational change and causes rapid 
arrest of neutrophil rolling under ‘sheer stress’.   
Following adhesion the neutrophil crawls along the endothelium.  This is Mac-1 and 
ICAM-1 dependent and is important physiologically as it allows the neutrophil to find a 
suitable place to transmigrate through the endothelium (70, 71).   
To reach the affected tissue neutrophils need to migrate from the circulatory system 
across the endothelium.  This occurs via a process called transmigration either 
transcellular, through the endothelial cell, or paracellular, between the endothelial cells 
(63).  Paracellular migration through the endothelial cells takes between two to five 
minutes but penetrating the endothelial to cell basement membrane takes much longer, 
five to fifteen minutes (63).  Paracellular migration is triggered by luminal 
chemoattractants and endothelial cell adhesion molecules engagement with neutrophil 
ligands (72).  A transmigratory cup, a projection of endothelial cells rich in ICAM-1 and 




minority of cells and under certain conditions such as inflammation, is rapid and takes 
less than one minute.  This is believed to be facilitated by a vesiculo-vacular organelle (73, 
74).     
Multiple neutrophil adhesion molecules are expressed on the cell surface during 
activation.  Table 1.1 describes and explains some of the roles of the cell surface 





















CD11a Α subunit of LFA-1 
LFA-1 = membrane 
glycoprotein 
 
Cell to cell adhesion by interaction with ICAM-1. 
Also binds to ICAM-2 and ICAM-3 (70, 71) 
CD11b Α subunit of Mac-1 
Mac-1 = membrane 
glycoprotein 
 
Cell to cell adhesion by interaction with ICAM-1 
Also binds to C3bi and extracellular matrix 
proteins (70, 71) 
CD18 Β2 integrin. 
Binds with CD11a to 
produce LFA-1 
Binds with CD11b to 
produce Mac-1 
Marker of activation in neutrophils (70, 71) 
CD16 Fcγ RIII, low affinity 
receptor for IgG 
Increased abundance with neutrophil priming 
Constantly shed by activated neutrophils.  
Activates secretion of ROS (57) 
CD29 Β1 chain. 
Glycoprotein. 
Β chain of VLAs 
Cell to cell adhesion (75) 
CD49f Α subunit. 
Binds with CD29 to 
form VLA-4 
VLA-4 binds to laminin.  Involved in adhesion 
and chemotaxis. (63) 
CD62L L-selectin Upregulated by inflammatory stimuli.   
Activates CD18 function. 
Involved in activation, and interstitial migration 
(76, 77) 
CD63 Transmembrane 
superfamily of protein 
Stored in cytoplasmic granules and exported to 
cell surface on activation. 
Increases the cell surface expression of Mac-1  
(63) 
Α9β1 Integrin Role in stabilising neutrophil adhesion.   
Binds to VCAM-1 (63) 
 
1.7.2 Primed neutrophils 
Neutrophils can exist in three separate states, quiescent, primed and activated.   
Table describing and explaining the role of some of the important cell surface receptors and their role 




Neutrophils leave the bone marrow in a quiescent state and circulate through the blood 
stream awaiting activation or apotosis.  A quiescent neutrophil is in an un-activated state 
but is capable of becoming both primed and activated (78).  A primed neutrophil 
produces a response, which can be up to ten times larger, than a quiescent neutrophil on 
exposure to a stimulant (79).  Therefore, in some situations it is advantageous to prime 
neutrophils before they are stimulated.  Quiescent, primed and activated neutrophils are 
often described using a traffic light analogue – red, orange and green.  This depicts the 
readiness of primed neutrophils to produce a response.         
Quiescent neutrophils are primed after exposure to certain cytokines (49), activated 
endothelial cells (80) or bacterial products (81).  The underlying cell signalling 
mechanisms are complex and not fully characterised but primarily involve PI3Kγ 
activation and PtdIns (3,4,5) P3 generation (82).  Due to the diversity of the agents that 
can induce priming it is likely there are multiple intracellular mechanisms.  This theory is 
affirmed by the differences in the intensity of response and variable time courses of the 
manifestations of priming depending on the agent used (80, 81, 83).        
Primed neutrophils are structurally and functionally different to quiescent neutrophils. 
The differences, which are discussed below, change the behaviour of the neutrophil and 
its behaviour becomes closer in nature to that of a macrophage.  
Primed neutrophils have enhanced oxidative burst on exposure to a secondary stimulus 
compared to quiescent cells.  Oxidative burst in neutrophils is characterised by the 
production of superoxide, hydrogen peroxide and hypochlorous acids.  Free oxidative 




and myeloperoxidase (84).  The enhanced respiratory burst witnessed in priming occurs 
due to the translocation and assembly of cytosolic components of NADPH oxidase 
enzymes (85).  The state of a neutrophil, quiescent, primed or activated, is determined by 
their amount of oxidative burst.   
Primed neutrophils undergo a change in shape with a stiffer central region compared to 
the leading edge and tail region (86).  This allows easier passage through the endothelium 
which is fundamental to their ability to reach the site of pathogen or injury.  This change 
in shape also results in increased sequestration in the pulmonary capillary bed which is 
important to their function in vivo (87, 88).  Primed neutrophils express neutrophil 
integrins in increased numbers and shed CD62L to enhance their adhesion to 
endothelium (89).  The primed neutrophils also undergo some degranulation and lipid 
mediator release but this is modest when compared to the respiratory burst (90).  
Priming of neutrophils inhibits the apoptosis of the cell.  LPS and GM-CSF, in particular, 
delay the onset of programmed cell death whereas TNFα shows a bimodal distribution 
(91).   
There is evidence from both in vivo and in vitro experiments that neutrophils can be de-
primed and revert back to a quiescent state (83, 92-94).  In vivo there is some evidence 
that this is related to the pulmonary vasculature but it can also occur without anatomical 
help in vitro.  In vivo experiments have utilised mathematical modelling and reviewed the 
proportion of primed neutrophils entering the pulmonary and leaving the pulmonary 
vasculature (92-94).  In vitro experiments have demonstrated that priming and de-




activation factor (PAF) has been shown to produce a maximal priming effect after ten 
minutes of stimulation whereas priming with TNFα takes longer with a maximal priming 
effect seen at thirty minutes.  The same experiments have also demonstrated a 
difference in time to de-priming, with a rapid course seen in PAF stimulation and a 
plateau effect then de-priming occurring with TNFα.  Once a neutrophil has returned to 
the quiescent state it is then possible to re-prime the neutrophil and this has been 
demonstrated in vitro (83). 
1.8 PI3Kinase 
Fundamental to both neutrophil function and muscle homeostasis is the 
phosphoinositide 3-kinase Akt (PI3K/Akt) pathway. 
1.8.1 PI3Kinase Family 
PI3K are a family of structurally related enzymes divided into three distinct functional 
classes on the basis of the protein domain structure and associated regulatory subunits 
(95).  There are eight different mammalian isoforms of PI3K (96).  All classes of PI3K 
phosphorylate 3’ position hydroxyl of the inositol group to synthesise three distinct 
phosphoinositides (97).  The downstream effects of the phosphoinositides are broadly 
divided into localised membrane remodelling, for example the GTPases Rac1 and Rho1 
which coordinate dynamic organisation of the actin cytoskeleton and membrane localised 
signalling, for example the AKT/mTORC1 pathway (97).  Class 1 PI3K are involved in cell 
signalling, class 2 PI3K in both cell signalling and membrane trafficking and class 3 PI3K in 




domain-containing inositol phosphatase 1 (SHIP) and phosphatase and tensin homologue 
(PTEN)(98).  SHIP and PTEN convert PIP3 back to PIP2 (99).     
Within each class there are different isoforms denoted by different catalytic or regulatory 
subunits.  Class 1 has 4 different catalytic subunits: p110α, p110β, p110γ and p110δ and 
five different regulatory subunits: p85α, p85β, p55α, p101 and p84 (97).  Whilst the 
catalytic subunit generates phosphoinositide the regulatory subunit acts to both 
transport the catalytic subunit around the cell and to provide negative regulation of the 
catalytic subunit (97).  Class 1 can be further divided into class 1A, PI3Kα, PI3Kβ and PI3Kδ 
and class 1B, PI3Kγ(97).  Class 1A isoforms are catalytic subunits p110α, p110β and p110δ 
bound to the regulatory subunits p85α, p85β or p55γ (97).  These isoforms can be 
recruited by a phosphorylated tyrosine kinase receptor (97).  Recruitment by a 
phosphorylated tyrosine kinase receptor causes a class 1A PI3K to translocate from the 
cytosol to the inner leaflet of the plasma membrane only here it has access to PIP2(97).  
Recruitment also initiates a conformational change to p85 regulatory subunit which 
negates its inhibitory effect on the catalytic subunit (97).  The Class 1B isoforms are the 
catalytic subunit p110γ bound to either the regulatory subunit p101 or p84 (97).  These 
isoforms are activated by the heterotrimeric G protein coupled receptor(GPCR)(97).  
Chemokines bind to GCPRs and therefore class 1B isoforms provide the primary response 
to chemokines (100).  Class 1 PI3K elicit signalling responses which regulate cell growth, 
proliferation, survival metabolism and autophagy (101) and cortical F-actin dynamics 
fundamental to both chemotaxis and phagocytosis (102, 103).  The class 1 isoforms share 




to functions within immune cells but p110α and p110β are more ubiquitously expressed 
(97).       
1.8.2 PI3Kinase pathway in neutrophils 
The PI3K/Akt pathway is crucial to the majority of the functions of the neutrophil but 
different isoforms are essential for different functions: chemotaxis, phagocytosis and 
reactive oxygen species production (ROS)(104).  P110δ has the greatest proportion of 
PI3K isoforms within neutrophils (δ 90%, γ 2%, β 4%, α 4%)(105).  PI3K within an inactive 
neutrophil is evenly spread throughout the cell on surface signalling PI3K localises to the 
cell’s leading edge (105).  Neutrophils contain approximately 25 phosphoinositide 
effector molecules and AKT is the key effector (105).   
Chemotaxis, the accurate migration of a cell along a chemoattractant gradient, occurs 
following the activation of class one isoforms of PI3K by chemoattractants.  The class 1 
isoforms p110γ and p110δ are the most important in chemotaxis with p110γ providing a 
chemotactic response to brief stimuli whereas p110δ provides a delayed and less intense 
response to longer stimuli (105). Similar to the PI3K pathway within muscles this induces 
PI3K to produce PIP3 (106).  PIP3 via phosphorylation of Akt then initiates a pathway to 
produce actin polymerisation which pushes the cell forwards (107, 108).  A gradient of 
PIP3 is maintained within the cell by the negative regulatory effect of PTEN and SHIP1 and 
leads to actomyosin contractility allowing the release of the cell at the rear propelling the 




Phagocytosis of pathogens by neutrophils is also dependent upon the PI3K pathway 
although this is often considered to be regulated by an alternative class of PI3K.  The 
activation of PI3K by association with tyrosine phosphorylated adaptor proteins allows 
PI3K to form PIP3 which is fundamental in the rearrangement of the actin cytoskeleton 
and the subsequent formation of pseudopodia(109).  The fundamental role of PI3K in 
phagocytosis of large particles has been demonstrated in practice with PI3K inhibitors 
(110).  The PI3K/Akt pathway is also central to the production of reactive oxygen species 
and apoptosis by the downstream Akt substrate BCL-2 antagonist of cell death (BAD) 
(111) in addition to a role within cytokine release (112).  Reduced oxidative burst and an 
anti-apoptotic effect has been demonstrated in PI3K p110γ knock out mice (113). 
1.9 Muscle 
Sarcopenia is the result of the complicated interplay between muscle size and strength 
and physical function.  Whilst the role of ‘muscle quality’ is increasingly evident as 
fundamental to the syndrome of sarcopenia muscle size is a pre-requisite to the 
diagnosis.  Muscle size is determined by the complex relationship between muscle 
synthesis and muscle degredation.  Our current understanding of the regulation of 
muscle mass is predominately based on data from animal studies, with much less known 
of the key regulatory processes in human muscle. Studies in rodents suggest that muscle 
synthesis is intrinsically linked with muscle atrophy via the PI3k-Akt pathway which is 
central to both processes (114).  The role of the PI3k-Akt pathway in muscle homeostasis 











1.9.1 PI3Kinase pathway in muscle homeostasis 
Homeostasis of muscle mass is the balance between muscle synthesis and muscle 
degradation.  Muscle degradation is a term which broadly describes the loss of muscle via 
both reduction in muscle fibre size (atrophy) and reduction in the number of muscle 
The PI3kinase/Akt pathway in muscle.  Stimulation of the IGF-1R upregulates PI3k which in 




fibres (hypoplasia).  Hypoplasia is believed to occur secondary to motor neurone death 
and muscle fibre denervation and atrophy secondary to the proteolytic pathways (13).  Of 
the four major proteolytic pathways present in muscle cells two, autophagy lysosomal 
and ubiquitin proteasome pathway, have PI3K/Akt signalling central to their functional 
ability (115).    
Muscle synthesis is activated by insulin-like growth factor 1 (IGF-1) binding to IGF-1 
receptor which triggers the activation of its internal tyrosine kinase and results in 
autophosphorylation (114).  This generates a docking site for insulin receptor substrate 
(IRS) which once docked is phosphorylated by the IGF-1 receptor (114).  The 
phosphorylated IRS acts as a further docking site to recruit and activate PI3K (114).  
Activated PI3K phosphorylates cell membrane phospholipids and generates 
phosphoinositide 3,4,5 triphosphate (PIP3)(114).  PIP3 acts as a docking and 
phosphorylation site for Akt (114).  The activated Akt indirectly promotes the mammalian 
target of rapamycin (mTOR) which in turn phosphorylates S6 kinase and other factors 
which promote protein synthesis via translation initiation and elongation (114).  There 
are multiple modulators of the pathway both intrinsic and extrinsic, up and down 
regulating.  Extrinsic regulators: amino acids can directly activate mTORC1 (116, 117) 
whereas beta adrenergic agents (118) and Wnt7a both upregulate PI3K/Akt pathway 
(119).  Intrinsic regulators include S6 kinase 1 inhibiting IRS (120) and mTORC2 
upregulating Akt (121).   
Muscle atrophy via both the ubiquitin proteasome pathway and autophagy lysosomes is 




induces the ubiquitin E3 ligases atrogen-1 (MAFbx) and muscle RING finger protein-1 
(MuRF-1) (122) which cause myofibril degradation via the ubiquitin proteasome pathway.  
FoxO also regulates ATG genes which promote mitochondrial degradation via autophagy 
(123).  As expected there are multiple modulators of these pathways and arguably the 
most important is the effect of Akt on FoxO:  activated Akt phosphorylates FoxO and 
transports it from the nucleus to the cytoplasm preventing it from inducing either E3 
ligases or ATG genes (124-126).  Myostatin, via the action of Smad 2 and 3, upregulates 
FoxO (127) and muscle disuse produces neuronal nitric oxide synthase (nNOS) which 
enhances FoxO3 mediated transcription of E3 ligases (128).  TNFα directly upregulates 
the NFκβ pathway via IKK and produces MuRF-1 which causes myofibril degradation via 
the ubiquitin proteasome pathway (129, 130).    
1.9.2 Muscle homeostasis in sarcopenia 
The majority of studies investigating sarcopenia in humans have suggested that loss of 
muscle mass is primarily driven by a blunted synthetic response to both feeding and 
exercise, termed anabolic resistance (131-133). Moreover, there is little data to suggest 
that atrogenes or ubiquitin proteasomal degradative pathways are enhanced in older 
adults, indeed in the fasted state (when protein breakdown is at its highest) there is no 
difference in protein turnover or signalling through synthetic pathways such as Akt 
between young and old adults (134). The contribution of each pathway towards atrophy 
in sarcopenia remains unclarified with conflicting evidence from various human and 
mammal model studies (135).  The ubiquitin proteasome pathway is known to be 
activated in disuse, fasting and denervation as well as inflammatory conditions such as 




sarcopenia so despite varying experimental data it is difficult to discount the effect of the 
ubiquitin proteasome pathway in sarcopenia.  The measurement of a 1.5 to 2 fold 
increase in mRNA levels of atrogenes (ubiquitin E3 ligases) in sarcopenic muscles, in 
comparison to the ten-fold increase seen in other catabolic conditions (136), conforms 
with the idea that sarcopenia is an insidious syndrome rather than a rapid catabolic state.       
Anabolic and catabolic pathways may be relevant in periods of extreme inactivity, such as 
bed rest, and in chronic inflammatory states, such as chronic obstructive pulmonary 
disease (COPD). In a recent 5 day bed rest study in well characterised healthy young and 
old subjects, leg lean mass and strength were reduced only in the old subjects. Both 
subject groups had blunted mTORC1 signalling and increased MURF1 expression in 
skeletal muscle after bed rest, but only the older group had reduced amino acid induced 
protein synthetic rates and increased atrogene expression (137).  A study investigating 
the effect of resistance training in participants with COPD, a chronic inflammatory 
condition, demonstrated higher levels of MAFbx and MURF1 protein expression 
(atrogenes) and increased phosphorylation of p70s kinases (138).  These studies suggest a 
decrease in muscle synthesis and an increase in muscle degradation (dysregulated muscle 
homeostasis) is seen with inactivity and chronic inflammatory conditions.  
Patients with sepsis are subject to both periods of extreme inactivity and a pro-
inflammatory state and could therefore be considered a model of accelerated ageing 
(139).  Following sepsis and admission to critical care 70-100% of patients reported 




functionality.    This group deserves further study for a link between inflammation and 
sarcopenia.     
1.9.3 PI3kinase pathway in sarcopenia 
The importance of the PI3K/Akt/FoxO pathway in muscle homeostasis was discussed in 
section 1.9.1 and has been demonstrated in mice models.  Transgenic mice 
overexpressing Akt in skeletal muscle displayed muscle hypertrophy (114) and after 
denervation maintained their muscle bulk suggesting they underwent less atrophy (141).  
Conversely Akt 1 and Akt 2 knock out mice display a severe growth deficiency and 
evidence of muscle atrophy similar to that seen in IGF-1 receptor deficient mice (142).  
Transgenic mice overexpressing FoxO had reduced muscle mass and had a significantly 
decreased number of type 1 and 2 fibres compared to the wild type.  Interestingly they 
also displayed reduced spontaneous activity (143). 
Myoblasts deficient in the PI3kinase catalytic subunit p110α isoform had decreased 
activation of AKT and myoblasts deficient in p110β had increased activation of AKT (144) 
suggesting different roles for the PI3K isoforms within muscle synthesis.  Long term 
dosing of healthy animals with PI3K isoform inhibitors did not cause weight loss but mice 
dosed with either pan PI3K inhibitors or p110α inhibitors displayed impaired weight gain 
compared to controls (145).  Different concentration of PI3K isoforms exist in muscle 
stimulated with insulin dependent on birth weight (146) suggesting lasting environmental 





1.10 Immunesenescence and inflammageing 
The role played by the immune system in frailty and sarcopenia is believed to be 
fundamental in the development and maintenance of both a frailty and sarcopenic state, 
but it remains mostly uncharacterised.   
1.10.1 Overview of immunesenescence and inflammageing 
The decline in immune function with age, termed immunesenescence, is well 
documented and includes increased susceptibility to infections, reduced vaccination 
responses in older adults and increased risk of chronic inflammatory diseases such as 
Rheumatoid Arthritis (147-149).  Examples of changes to the immune system with age are 
reported in Table 1.2.  The changes displayed by neutrophils with ageing are discussed in 
greater depth in section 1.10.2. 
Immunesenescence includes inflammaging, the presence of a low-grade chronic systemic 
pro-inflammatory state with age (150, 151).  Inflammaging is characterised by increased 
levels (typically 2-4 fold those seen in healthy young subjects), of pro-inflammatory 
cytokines such as interleukin 1β(IL-1β), interleukin 6 (IL-6) and tissue necrosis factor alpha 
(TNFα) as well as c-reactive protein (CRP), and a reduced serum level of anti-
inflammatory cytokines including interleukin 10 (IL-10) (150) and IL-1ra.  The factors 
driving inflammaging are multiple and can include increased output of pro-inflammatory 
cytokines by resting monocytes (152-154), reduced IL-10 production by regulatory 
lymphocytes (155), increased adiposity leading to production of pro-inflammatory 
adipokines such as leptin and reduced anti-inflammatory adipokines such as adiponectin 
(156), reduced physical activity with age (157), senescent cells which build up with age 




Table 1.2 - Changes to the adaptive and innate immune system with age 
 Immune Cell Immune Cell Changes 
Adaptive B Cells  Reduction of the proportion of naïve B cells despite 
no changes to absolute number leading to a 
reduction in the diversity of the B cell repertoire 
(159, 160) 
T Cells  Involution of the thymus and the subsequent 
reduction in number of naïve T cells leaving the 
thymus (43, 44) 
 Contracted repertoire of both CD4+ and CD8+ T cells 
(161, 162) 
Innate Monocytes  Increased absolute number (47) 
 Reduction in cytokine production (48)  
Macrophages  Decrease in function 
Natural Killer 
Cells 
 Increase in absolute number 
 Reduction in production of cytokines and 
chemokines on activation 
Dendritic 
Cells 
 Reduction in function 
 
  
1.10.2 Neutrophil dysfunction in ageing 
In healthy older adults the function of the neutrophil is altered.  Neutrophil migration is 
impaired by reduction in the velocity, or chemotaxis, and persistence of movement (163).  
This is hypothesised to result in both an increased time for the neutrophil to reach the 
site of infection and more importantly increased obligate host tissue damage (164).  
Neutrophils from older adults also demonstrate impaired phagocytosis (165), impaired 
apoptosis (165) and impaired actin polymerisation (50).  The accumulation of these 
defects dictates that a neutrophil in an older adult takes longer to reach its target, 
damages more of the host tissues and on reaching the target has impaired ability to 
destroy the pathogens.  Poor neutrophil function is present in chronic inflammatory 
diseases, such as chronic obstructive pulmonary disease (COPD), and it is suggested that 




frailty and sarcopenia, which are associated with inflammaging, will display even poorer 
neutrophil function than healthy older adults (166).             
1.10.3 Models 
There has been little fundamental mechanistic research investigating the immune system 
in frailty in its truest sense.  Therefore, it is necessary to consider models of frailty and 
draw conclusions where possible.  Some of the models of frailty that have been utilised in 
research are discussed below.   
Population based studies have demonstrated that the incidence of infection and 
subsequent mortality is higher in populations of frail people. Nursing homes represent a 
population where frailty can be assumed without direct measurement.  The prevalence of 
pneumonia in a nursing home population is thirty times higher than the general 
population (167, 168).  Population based studies have identified that frailty is associated 
with inflammageing and immunesenescence (169-172). As HIV could lead to the same 
characteristics of immunesenescence in older individuals, the identification of a 
subpopulation of HIV patients with frailty has led to comparison cohort studies between 
HIV patients with frailty and those without (173). These studies focus upon the adaptive 
immune system and T cells in particular.  Conversely, centenarians have been employed 
as a model of successful ageing (174, 175).   
Sarcopenia has been suggested as a human model of physical frailty.  It is a more tangible 
concept than frailty and is easier to utilise in a research setting.  It has been proposed it 




Murine models have been developed to investigate sarcopenia and frailty using either 
cell signalling pathway knock out models or accelerated ageing models.  The pathogen 
free IL-10 homozygous deletion mouse displays changes in muscle fibre size, growth and 
the proportions of type 1 and 2 muscle fibres (176).  In addition to these changes 
accelerated ageing models also display additional features of ageing such as osteoporosis 
and alopecia.  A valid murine frailty index has been developed to improve murine frailty 
research (177).  However, defining frailty in mice is problematic and the index relies 
heavily on measuring body composition and, haemodynamic and metabolic parameters; 
this does not reflect a global review of frailty.      
 This mouse model develops increased muscle weakness and decreased activity levels.  
Murine models offer an alternative investigative approach to frailty and sarcopenia and 
could be utilised for work that is difficult or unethical to complete in humans for example: 
muscle work, response to pathogens, cognitive function investigation.  These models 
offer an excellent and unique opportunity to study frailty in vivo but lack the 
sophistication and subtleties of frailty in humans.  Frailty in humans is a condition which 
is affected by both the dysregulation of multitudes of internal biological factors and 
external factors such as environmental, political and social conditions.  This complex 
dysregulation of multiple biological systems and the interplay between the individual and 
their wider environment is impossible to replicate in a single gene knock out mouse 
model.                      
 1.10.4 Inflammageing, frailty and sarcopenia 
Inflammageing is a state of discrete chronic inflammation.  A positive association has 




frail populations (169-171, 178).  High levels of IL-6 predict disability and mortality, which 
are significant outcomes within frailty, in older community dwelling adults (179-181). 
Peripheral blood mononuclear cells (PBMCs) from frail older adults produce greater 
amounts of IL-6 on stimulation compared to non-frail counterparts (182).   
Inflammatory and immunological biomarkers of frailty have been used in a variety of 
settings to predict poor outcomes (183, 184) The Biomarker Frailty Index incorporates 
markers of inflammation and immunesenescence as well as haematological and genetic 
markers.  This model is associated with mortality and at low levels of frailty is better than 
the frailty index at predicting mortality (183).  
Investigation of the individual components of sarcopenia and frailty has demonstrated 
both an association with inflammageing and inflammageing predating a loss of physical 
function.  Cross-sectional studies have demonstrated an association of high levels of IL-6 
and TNFα with low muscle mass and strength (185) and low levels of CRP with high grip 
strength (186).  Longitudinal studies have shown that higher levels of IL-6 predict 
reduction in fat free mass, a hallmark of sarcopenia (187).  Higher levels of IL-6 and CRP at 
baseline equate to a two to threefold greater risk of losing more than 40% of grip 
strength over a 3-year follow up (188). TNFα mRNA and protein levels are higher in frail 
older adults.  It was also demonstrated that this could be reversed with an exercise 
program, which correlated with an increase in muscle strength (189).   
In centenarians IL-6 -174 GG genotype, associated with higher plasma levels of IL-6, is 
under represented and IL-10 -1082 CC, associated with higher plasma levels of IL-10, are 




The direct actions of IL-6 on pathways of muscle breakdown and synthesis are yet to be 
fully characterised but there is some evidence that suggests it can act via the ubiquitin 
proteasome pathway.  IL-6 is associated with increased ubiquitin protein and mRNA 
(190), E3 ligase protein and mRNA (191) and proteasome activity (192).  In addition IL-6 
can induce insulin resistance which suppresses Akt and muscle synthesis (193, 194).  The 
literature also suggests that down-regulation of IL-10 could cause frailty and sarcopenia 
by the effects on muscle quality and the subsequent effect on physical activity and 
weakness.    
The frailty murine model, pathogen free IL-10 homozygous deletion mouse, has increased 
levels of IL-6 at 50 weeks and phenotypically displays increased muscle weakness and 
decreased activity levels in comparison to the wild type (195). In murine models the 
exogenous administration of TNFα results in anorexia and weight loss in the mouse via 
the leptin pathway (196, 197).  The up-regulation of leptin and the resultant anorexia 
causes decreased muscle synthesis due to reduced amino acids availability for protein 
synthesis (198).  TNFα can also directly result in weight loss (199).  TNFα activation of the 
transcription factor nuclear factor kappa light chain enhancer of activated B cells (NF-κB) 
results in myofibre atrophy and activation of the ubiquitin-proteosome pathway (129, 
130, 200).  Similar to IL-6 TNFα induces insulin resistance which suppresses the Akt-mTOR 
pathway of protein synthesis (201).  This suggests that TNFα could be contributing to the 
development of frailty and sarcopenia via a number of pathways, direct muscle 




The limited data available demonstrates that frailty is associated with a state of chronic 
inflammation. There is also some evidence that inflammageing predates a diagnosis of 
frailty suggesting a causative role but without rigorous longitudinal investigation of frailty 
and inflammation the relationship between the conditions is uncharacterised.  
1.10.5 Innate immunity, frailty and sarcopenia 
A small number of studies have demonstrated a dysregulation of the innate immune 
system in frailty.  Frail adults have raised white cell and neutrophil count (within normal 
limits).  This remains significantly elevated even after adjustment for common 
confounders (202-204).  Raised neutrophils are also associated with low levels of physical 
activity and frailty (205).  High white cell count can predict frailty at a ten year follow up 
(206).  An association has been demonstrated between frailty and the upregulation of 
monocytic expression of CXCL 10 gene which codes for a potent pro-inflammatory 
chemokine (207).  A single study has investigated the function of innate immune cells in a 
defined frail older adult population; this demonstrated that nursing home residents in 
comparison to community dwelling older adults had significantly elevated pattern 
recognition receptors TLR 4, reduced adhesion markers CD11b and CD18 and, reduced 
production of chemokines and cytokines CCL4, CCL20 and IL-8 both at baseline and 
stimulation (208).    
1.10.6 Cellular mechanisms contributing to neutrophil dysfunction in frailty 
Older adults and frail older adults both have higher levels of circulating cytokines with 
increased values seen in a frail population compared to a healthy older population (169, 
170, 195).  The increased levels of circulating cytokines in older and frail older adults can 




spending less time as quiescent cells when compared to neutrophils from healthy 
younger adults.  This hypothesis is supported by evidence that there is increased 
spontaneous ROS production in neutrophils from older adults (209) and from frail older 
adults (210); there is also an increased superoxide anion concentration within neutrophils 
from older adults.  The proposed continual cycle of priming and de-priming is 
hypothesised to be detrimental to both the immune function and internal tissues causing 
further damage and perpetuating the cycle.  There is evidence from multiple chronic 
inflammatory diseases that activated neutrophils cause tissue damage via release of 
tissue damaging molecules, molecules that promote inflammation and cytokines (211).  A 
surrogate marker for neutrophil degranulation Aα-Val360 has been validated as a sensitive 
measure of systemic neutrophil proteinase activity (212) and this has been demonstrated 
to be raised in a healthy older adult population (163). 
Multiple studies have demonstrated that neutrophils from older subjects have poorer 
function and this contributes to immunesenescence.  In part this could be related to the 
neutrophils ability to respond to priming.  Neutrophils from younger subjects primed with 
GM-CSF demonstrated enhanced chemotaxis but neutrophils from older adults primed 
with GM-CSF did not show enhanced capabilities (213).  A separate study showed that 
superoxide anion levels were lower after priming in older neutrophils compared to 
younger neutrophils at earlier time-points.  At the later time-point of 48 hours the older 
neutrophils had higher superoxide anion levels (214).  This suggests a difference in 
response to priming with a decreased maximal response and delayed de-priming 




The number of circulating neutrophils is raised in the frailty state (210, 215) but the 
mechanisms and characteristics of this relative neutrophilia are unknown.  Increased 
release of neutrophils from the bone marrow in response to an inflammageing state 
would result in increased immature neutrophils but a functional deficit in the clearing 
mechanism of aged neutrophils would result in a shift in the neutrophil population 
towards senescent neutrophils.  Senescent neutrophils upregulate CXCR4 and 
downregulate CXCR2 on their cell surface (216).         
Verschoor demonstrated that there are an increased proportion of immature band 
neutrophils in frail older adults; immature neutrophils are released in response to 
infection or inflammation (210).  The study also showed an increased frequency of HLA-
DR expression in neutrophils from frail older adults which is associated with tissue 
infiltrating neutrophils and suggests an increased proportion of neutrophils undergoing 
reverse trans-endothelial migration (210).  This may represent the unbalancing of 
homeostasis; to maintain the number of neutrophils with the best functional response an 
increased number of immature neutrophils and senescent neutrophils are required.                   
The integrin CD11b which is fundamental in the process of neutrophil adhesion to the 
endothelial cell wall has been studied both in a frail older adult population with 
conflicting results.  CD11b was raised in nursing home residents identified as frail using a 
CFS and this was associated with increasing TNFα concentrations in serum (210).  
Conversely a different study investigating CD11b in nursing home residents found it to be 
lower than healthy older adults (208).  Analysis of the reported methods does not offer 




populations using similar methods.  The most striking difference is that only the first 
study verified frailty in its study sample.  However, there is a very high prevalence of 
frailty in nursing home populations suggesting both study populations were frail.   
 Neutrophils are central to the healing process in muscle damage and research has 
demonstrated in a number of models of muscle injury that neutrophils are recruited to 
the site of the injury within a couple of hours (217-219).  However, it is believed that in 
addition to a role in healing neutrophils also cause secondary damage to healthy muscle 
and it has been shown that muscle damage is reduced when functioning neutrophils are 
prevented from migrating to the damaged tissue (220, 221).  The original studies used an 
ischaemia and reperfusion model but subsequent studies have utilised a muscle stretch 
injury model and directly visualised the muscle damage under the microscope (222).  As 
muscle ages it becomes more susceptible to injury and as a person ages dysregulation of 
entire systems, for example balance and cognition, result in a greater number of injuries.  
It can be postulated that muscle injury in an older person in a state of inflammaging 
would cause secondary damage to healthy muscle by aberrantly migrating neutrophils 
resulting in myocyte apoptosis, loss of muscle fibres and their replacement by fat.  This 
loss of muscle quality and mass could result in the functional losses of physical weakness 
and slowness of sarcopenia.        
1.10.7 Adaptive immunity and frailty 
A small number of studies have described the dysregulation of the adaptive immune 




A prospective review of response to vaccination showed a reduction in adaptive immune 
function in frail individuals (223). However, the study did not attempt to investigate the 
individual roles of T and B cells in poor response to vaccination.  Initial work into frailty in 
HIV patients demonstrated higher levels of frailty in HIV positive patients compared to 
non-HIV infected age matched controls (224) and subsequently that CD4+ T cell count can 
predict the development of frailty in HIV positive men independent of HAART and plasma 
viral load (173). Research into T cell subset expression in frailty has revealed conflicting 
results, particularly in the investigation of CD4:CD8 ratio which has both been positively 
(215, 225) and inversely associated with frailty (226, 227).  The association of CMV with 
frailty is also unclear.  Frailty has been associated with higher titres of CMV IgG (228, 229) 
and also higher levels of CD8+CD28- T cells (225, 227).  CD8+CD28- T cells are highly 
associated with seropositivity to persistent infections such as CMV.  However, it has also 
been reported that CMV infection does not appear to determine the age-related increase 
in serum markers of inflammation (230) and, furthermore the extremely high prevalence 
of CMV in all older adults make all these data difficult to interpret. Only one study has 
investigated the B cells of a frail population and showed that with increasing age the 
diversity of the B cell population decreases and this correlates with poor health (231). 
1.11 Relationships between frailty, sarcopenia, immunesenescence and inflammageing 
To date there is limited research describing a direct relationship between frailty, 
sarcopenia and immunesenescence or inflammageing.  However, initial results have 
demonstrated an association of frailty and sarcopenia with a state of chronic 
inflammation and dysregulation of both the innate and adaptive immune system.  It has 




suggesting a causative role.  Figure 1.5 demonstrates a theoretical pathophysiological 





Figure 1.5 - Relationships between inflammaging, sarcopenia and frailty 
Proposed relationships between inflammageing, sarcopenia and frailty.  Disuse and decreased physical activity lead to increased 
adipose tissue and decreased muscle size which in turn leads to increased production of myokines such as IL-6.  This is proposed to 
drive cachexia and muscle breakdown leading to sarcopenia and frailty.     
Selective loss of 
type II fibres 




1.12 PI3kinase/Akt pathway, immunesenescence, frailty and sarcopenia 
Dysregulation of the PI3K/Akt pathway with ageing could be a fundamental mechanism 
via which inflammaging, sarcopenia and ultimately frailty occurs and could explain some 
of the complex interplay between the three conditions.  The central role the pathway 
plays in muscle synthesis and atrophy via various pathways is likely to contribute to the 
muscle loss experienced in sarcopenia.  Studies have already demonstrated that 
neutrophils from PI3Kγ deficient mice have impaired migration and respiratory burst 
(232).  Not only does this result in a poorer immune response to a pathogen with the 
associated increased localised and systemic damage but results in increased localised 
tissue damage (233).  The PI3K/Akt pathway is also fundamental to the removal of primed 
neutrophils from circulation via apoptosis (213).  Dysregulation of the PI3K/Akt pathway 
in this instance will allow neutrophil death by necrosis with the subsequent release of 
tissue damaging proteases (57).  The delay in neutrophil death will propagate the ongoing 
functions of the neutrophil including release of cytokines and chemokines, in particular 
TNFα and IL-6 (57).  These cytokines, fundamental to the process of inflammaging, will 
both exacerbate the increased muscle breakdown via the NFKB ubiquitin proteasome 
pathway and dysregulate the PI3K/Akt/FoxO pathway of protein synthesis and 
breakdown further via the inhibitory effect of cytokines on the IGF-1 initiated pathways.  
The cytokines will also act to recruit further neutrophils potentiating a vicious circle of 
forward feedback. 
Recent data from our group has identified the mechanism underlying reduced 




reduced activation of PI3K in response to chemoattractants. This reduced signalling was 
found to be due to constitutive PI3K signalling and selective pharmacological inhibition of 
PI3Kγ or PI3Kδ restored neutrophil migratory accuracy (163). Moreover, the reduced 
neutrophil chemotaxis was associated with increased systemic inflammation in the older 
donors, most likely due to the tissue damage that occurs during neutrophil migration. 
However, there was no consideration in this study of the effect of frailty on neutrophil 
function.  It is plausible that the dysregulation of PI3K already demonstrated in the 
neutrophils of healthy older adults could be occurring concurrently with the 
dysregulation of PI3K/Akt/FoxO pathway in muscle.  The dysregulation could be either, 
driving sarcopenia and immunesenescence which then descends into frailty and 
inflammaging, or as a direct consequence of immunesenescence and sarcopenia.  Figure 
1.6 demonstrates the relationship between dysregulation of PI3k-Akt pathway in 











Figure 1.6 - Relationships between dysregulation of PI3k-Akt pathway in neutrophils 
and muscle during sarcopenia and frailty 
   
 
 
The identification of the PI3K/Akt pathway as a probable contributor to sarcopenia and 
immunesenescence is particularly relevant as there is potential for modification of this 
pathway resulting in improvement of function.  This has been successfully demonstrated 
using PI3K inhibitors during the chemotaxis of neutrophils of a healthy older cohort (163).  
Statins have also been demonstrated to improve neutrophil migration in vitro in milder 
infections (234).   Statins reduce the production of all products down-stream of 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) including isoprenoid.  Isoprenoid is 
Proposed relationships between the dysregulation of PI3kinase-Akt pathway in neutrophils 




utilised by cells for post-translational modification and activation of small GTP-ases such 
as Ras and Rho (235).  These molecules are essential in a number of immune cell 
functions such as adhesion and migration and importantly are also down-stream of the 
PI3kinase-Akt pathway (235).  Adjuvant statins were associated with survival benefit in 
hospitalised patients with community acquired pneumonia including a cohort of older 
adults (236).  Statins target a downstream effector of PI3kinase and may offer a 
therapeutic option for immunesenescence in frailty.  Angiotensin converting enzyme 
inhibitors (ACEi) are another potential therapeutic intervention for sarcopenia and 
immunesenescence.  Prospective cohort studies have shown that women taking ACEi, in 
comparison to no anti-hypertensives and different anti-hypertensives, had improved 
muscle strength and walking speed (237).  Suggesting that an ACEi can attenuate muscle 
loss and quality in an older population.  This effect is attributed to the effect angiotensin 
has on reducing local IGF-1 production and impaired insulin signalling and consequently 
the downstream effects on PI3K/Akt pathway (238).  Similarly an immune-modulatory 
role for ACEi has been demonstrated with evidence from large clinical trials (239).        
1.13 Conclusions 
The historical difficulties of definition, measurement and modelling in both sarcopenia 
and frailty in addition to the fundamental difficulties of investigating complex, multi-
factorial syndromes has led to a lack of information regarding the pathophysiological 
causes of frailty and sarcopenia.  Whilst there is some limited research into associations 
there is very little investigating more complex pathways attempting to link the two 
syndromes.  The suggested link of increased systemic inflammation could explain the 




migration potentially contributing to inflammaging and tissue damage associated with 
the sarcopenia of frailty. Further research on the cell pathways connecting inflammaging, 
sarcopenia and frailty would help to better understand these conditions and progress to 
potential novel therapies for frailty and sarcopenia which could include modulation of 
PI3k to correct neutrophil chemotaxis.      
The historical difficulties of definition, measurement and modelling in both sarcopenia 
and frailty in addition to the fundamental difficulties of investigating complex, multi-
factorial syndromes has led to a lack of information regarding the pathophysiological 
causes of frailty and sarcopenia.  Whilst there is some limited research into associations 
there is practically none investigating more complex pathways attempting to link the two 
syndromes.  The suggested link of a dysregulated PI3K/Akt pathway can elegantly explain 
the relationship between sarcopenia and immunesenescence and how it can spiral into 
frailty.  
1.14 Structure of this thesis  
The studies presented in this thesis were performed to examine some of the relationships 
between frailty, sarcopenia, immunesenescence and inflammageing and in particular 
consider the involvement of the intracellular pathway, PI3kinase-Akt pathway.   
Chapter 3 presents a new ultrasound scanning protocol and criteria for the identification 
of low muscle mass in sarcopenia.  This was necessary due to the absence in the 
literature of recommended criteria for the identification of low muscle mass using 




Chapter 4 reports on the feasibility of muscle biopsy in healthy and frail older adults using 
a percutaneous needle muscle biopsy technique.   
Chapter 5 examines one, neutrophil migration towards chemoattractants and two, the 
changes to chemotaxis that occur following: incubation with PI3kinase inhibitors, 
incubation with pooled plasma from healthy and frail older adults, priming with TNFα.  It 
also investigates potential mechanisms for witnessed differences including: receptor 
expression, reactive oxygen species and neutrophil state.   
Chapter 6 describes frailty within each of the groups and examines the relationships 
between different definitions of frailty and sarcopenia.  It also investigates the 


































All studies reported in this thesis were approved by the Solihull ethics committee 
(15/WM/0002).  Participants were recruited to three groups: healthy young adults, 
healthy older adults and frail older adults.  40 participants were recruited to the healthy 
young and older adult groups and 37 participants were recruited to the frail older adult 
group.  The criteria for recruitment are described in table 2.1.  All participants needed to 
be able to provide written informed consent.    
Table 2.1 - Criteria for recruitment 
 
Group Age Clinical Criteria 












1. Able to provide informed written 
consent.  
2. Absence of 
 Significant respiratory symptoms 
including breathlessness and 
cough 
 Diagnosis of chronic disease 
including Diabetes, COPD, 
Asthma, Interstitial Lung disease, 
Bronchiectasis 
 Haematological or solid organ 
malignancy 
 Immunosuppressive medications 
Frail Older Adults >65 1. Able to provide informed written 
consent 
2. Identified as frail on Frailty Index  
(FI> 0.2) 
3. Absence of  
 Haematological or solid organ 
malignancy 
 Immunosuppressive medications 
Table describing the clinical criteria for recruitment to each group: healthy young adults, 





The healthy young adults were recruited from the University of Birmingham using 
approved advertisement.  The healthy older adults were recruited from the ‘1000 Elders’ 
database.   
The frail older adults were recruited from three sources.  The method of recruitment and 
involvement within the study for the frail older adult participants is described in Figure 
2.1.    






Figure describing the three routes of recruitment of frail older adults to the 
study.  From left to right: participants recruited from a general geriatrics clinic, 
participants recruited from the 1000 Elders group and participants recruited 
from medical wards (all medically optimum with no evidence of inter-current 




2.3 Clinical Characterisation  
The identification and diagnosis of frailty requires rigorous assessment and information 
from multiple aspects of a participant’s life encompassing the biological, psychological, 
social and functional.  Copies of all the assessments can be found in the appendix within 
the Case Report Form (CRF) or additional documents.       
2.3.1 Cognitive Assessments 
Two methods of cognitive assessment were selected: Addenbrook’s Cognitive 
Examination III (ACE-III) (240) and Stroop Colour and Word Test (241).   
The ACE-III tests five domains: attention, memory, fluency, language and visuo-spatial.  It 
has good validity and reproducibility for a relatively short test (administration of the tests 
take approximately 15 minutes) (240).  The Stroop Colour and Word Test is a 
psychological test developed to test ability to process information and respond 
appropriately (242).  
2.3.2 Nutritional Assessments  
The mini Nutritional Assessment was chosen to assess nutritional status; poor nutrition 
has been shown to be contribute to frailty (243).  The assessment comprises of six 
questions and is considered a screening tool for malnutrition.. 
2.3.3 Physical Function Assessments 
Physical function was assessed by the Short Physical Performance Battery (SPPB)(244).  
The SPPB comprises of three tasks evaluating different aspects of physical performance.  
The SPPB has been modified for use in the clinical study as the original protocol includes a 
2.44 metre walk course; for simplification and reduction of duplicity time over a 4 metre 




2.3.4 Assessments of Independence  
The Katz ADL was used to assess basic activities of daily living and Lawton IADL to assess 
independent living skills.  These assessments are extensively used both clinically and in 
research and can be used in a community, hospitalised or clinic population (245, 246).  
The Katz and Lawton assessments are brief questionnaires evaluating important activities 
of independence.   
2.4 Frailty Identification 
There is currently no consensus for a gold standard model for diagnosing frailty either in 
clinical practice or research. Therefore, due to the uncertainties in frailty research this 
study has included six frailty identification tools as described in table 2.2.  All assessments 
are included within the CRF in the appendix.  
Table 2.2 -Summary of frailty identification methods 
 Tests Cut Points for Frailty 
Frailty Identification PRISMA 7 (14) = > 3  
Gait speed (14) < 0.8m/sec 
Clinical Frailty Scale (15) = > 5  
Edmonton Frail Scale (18) = > 12 (6-11 Vulnerable) 
Diagnosis in Research Frailty Phenotype (5) = > 3 




2.4.1 Frailty Identification Methods 
The gait speed is a good indicator of physical function and is utilised in other assessments 
present in the study: diagnosis of sarcopenia, short physical performance battery and 
diagnosis of frailty by Fried Phenotype (14).  PRISMA 7, in contrast to gait speed reflects 
Table summarising the different frailty identification methods included within the 




multiple domains, mobility, social support and health, and is therefore more akin to the 
Frailty Index rather than the Frailty Phenotype (14).  The Edmonton Frail Scale (EFS) is 
also a multi-dimensional approach to the assessment of frailty whereas the Clinical Frailty 
Scale (CFS) is based on a clinician’s global assessment of an individual with standardised 
criteria.  
2.4.2 Frailty Diagnosis in Research  
Frailty Phenotype and Frailty Index have both been included as tools to identify frailty in 
research.  The Frailty Phenotype criteria are described in table 2.3 and the variables 
included in Frailty Index are described in table 2.4.  The Frailty Phenotype describes 
physical characteristics identifying a frail individual; individuals positive in two criteria are 
considered pre-frail and those positive in three criteria are considered frail (5).  The 
Frailty Index is a compound measure incorporating multiple criteria (7).  Traditionally 
frailty measured by the Frailty Index is considered a continuous variable rather than a 
present or absent phenomenon; however, a score greater than 0.2 has been described as 










Table 2.3 - Criteria for Fried frailty phenotype 
Frailty Phenotype Fried Criteria Study Criteria 
Weight Loss Unintentional weight loss of 10 lbs 
(4.5kg) in the last year 
Standard parameters from 
original paper (5). 
Exhaustion How often did you feel in the last 
week that: 
a) Everything was an effort 
b) Could not get going 
0-rarely, 1-some of the time, 2-
moderate amount of time, 3-most 
of the time 
Standard parameters from 
original paper (5). 
(Modified from CES-D scale.) 
Weakness Grip strength in the lowest 20% 
after adjustment for gender and 
BMI. 
Standard parameters from 
original paper (5). 
Slowness Walk speed in the slowest 20% after 
adjustment for gender and height 
Calculated speeds from 
original paper applied to a 4 
metre rather than 15 foot 
walk course (5).   
Low Activity In the lowest 20% of calories 
expended per week using 
Minnesota Leisure Time Physical 
Activity Questionnaire 
Parameter as measured in 
Frailty Intervention Trial 
(248).  
(Positive for all three - No 
weight bearing physical 
activity, more than 4 hours 
spent sitting per day, short 





Table explaining the original criteria included in the Fried frailty phenotype and how 
these have been modified for this study.  The statement ‘standard parameters from 
original paper’ pertains to the quoted cut points from the original Fried paper not the 




Table 2.4 - Variables included in Frailty Index 
Domain FI Variable Rockwood 
Variable 
Scoring Criteria 
Medical Stroke Yes Y=1, N=0 
Myocardial Infarction Yes Y=1, N=0 
Congestive Cardiac Failure Yes Y=1, N=0 
Diabetes Mellitus Yes Y=1, N=0 
COPD Yes Y=1, N=0 
Cancer Yes Y=1, N=0 
Polypharmacy No >10=1, 4-10=0.5, <4=0 
Continence  No Partially/totally incontinent=1, Lose control of urine when don’t want 
to =0.5, No concerns with continence = 0 
Self-reported health  Yes 1,2 = 1, 3=0.5, 4,5= 0 
Self-reported weight loss – 
in the last year have you 
lost more than 4.5kg? 
Yes Y=1, Clothing is looser = 0.5, N=0 
BMI Yes <18.5 or >30=1, 25-30=0.5 
Physician assessment of 
CFS 
No 7,8=1, 6=0.75, 5=0.5, 4=0.25, 1,2,3=0 
Food intake No Severe decrease=1, Moderate decrease=0.5, No decrease=0 
Psychological Self-reported low mood - 
do you often feel sad or 
depressed? 





Bathing Yes Needs help =1, Independent=0 (use Katz scoring system but reversed) 
Dressing Yes Needs help =1, Independent=0 (use Katz scoring system but reversed) 
Transferring Yes Needs help =1, Independent=0 (use Katz scoring system but reversed) 




Independence Toileting Yes Needs help =1, Independent=0 (use Katz scoring system but reversed) 
Finances Yes Needs help =1, Independent=0 (use Lawton scoring system but 
reversed) 
Shopping Yes Needs help =1, Independent=0 (use Lawton scoring system but 
reversed) 
Housework Yes Needs help =1, Independent=0 (use Lawton scoring system but 
reversed) 
Meal Preparation Yes Needs help =1, Independent=0 (use Lawton scoring system but 
reversed) 
Medications Yes Needs help =1, Independent=0 (use Lawton scoring system but 
reversed) 
Cognition Addenbrooke’s Cognitive 
Examination 
Yes <82=1, >82=0 
Physical 
Function 
Walk Speed Yes Frailty phenotype ‘slowness’ positive=1, <0.8=0.5, >0.8=0 
Falls in last year No Y=1, N=0 
Everything is an effort Yes Most of the time =1, Moderate amount of time =0.75, Some of the 
time =0.5, None of the time =0 
Trouble getting going Yes Most of the time =1, Moderate amount of time =0.75, Some of the 
time =0.5, None of the time =0 
Handgrip Yes Lowest 20% for gender/BMI = 1, Highest 80% for gender/BMI =0 
  
Table describing the variables included in the Frailty Index and the criteria for scoring.  All variables summed together and divided by 30 to 




2.4.3 Frailty Diagnosis in Clinical Practice 
The Clinical Frailty Scale (CFS) (15) and the Edmonton Frail Scale (EFS) (18) were both 
included as identification tools as the CFS is more likely to be used by geriatricians and 
the EFS by other practitioners.      
The CFS, is based upon a comprehensive geriatric assessment (CGA) and only really 
appropriate for use by a geriatrician or persons trained in the use of CGA.  The CGA 
includes an assessment of multiple domains: medical, psychological, social circumstances, 
functional capacity and environment.  
The EFS is a quick method of diagnosis which does not require the clinician to have any 
experience in CGA and was originally intended for general practitioners (18).  In theory 
this is more akin to the Frailty Index than the Frailty Phenotype and includes assessment 
of several domains: cognition, general health, functional independence, social support.  
The EFS has been slightly modified for this study, again to avoid duplicity.  Functional 
performance in the original paper was assessed by a timed get up and goes but this has 
been substituted for a SPPB another assessment of functional performance.   
2.5 Sarcopenia 
A diagnosis of sarcopenia requires measurement of muscle mass, muscle strength and 
physical function.  Table 2.5 summarises the tools and equipment utilised to identify 























BATT –  
Women < 38.55mm Men 
< 54.36mm 




using the NIH 
toolbox protocol 
Women:  
  BMI ≤ 23 ≤ 17 kg  
  BMI 23.1–26 ≤ 17.3 kg  
  BMI 26.1–29 ≤ 18 kg  
  BMI > 29 ≤ 21 kg 
Men: 
  BMI ≤ 24 ≤ 29 kg  
  BMI 24.1–26 ≤ 30 kg  
  BMI 26.1–28 ≤ 30 kg  
  BMI > 28 ≤ 32 kg 




 <0.8 m/sec 
 
   
2.6 Ultrasound as a diagnostic tool in sarcopenia 
2.6.1 Participant protocols 
Depending on the participant there were three different protocols; the protocols are 
explained in greater detail below in table 2.6.  The muscle thicknesses measured by the 
different sonographers and using different machines were not measured independently 
of each other.    
 
 
Table summarising the methods of diagnosis for each different component of sarcopenia 




Table 2.6 – Protocols adhered to within study subsections 
 Protocol 1 Protocol 2 Protocol 3 
































and anterior thigh 
subcutaneous tissue 
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and anterior thigh 
subcutaneous tissue 
bilaterally and  







Quantitative ultrasound scanning and image capture were completed using two different 
diagnostic sonography machine Acuson Antares Premium Edition (Siemens) and Voluson-i 
(GE Healthcare).  These machines use slightly different software settings were chosen to 
closely match. The MSK factory setting was used on the Siemens Acuson and this 
corresponded well to the ‘Muscle’ factory setting of the Voluson-i scanner. Both 
ultrasound machines used a gain of   -3dB and a magnification factor of x1. A depth of 5-
7cm could be achieved on both ultrasound machines to ensure all tissues scanned were 
fully depicted on the screen.   
Table describing the three protocols used with the study sub-section including the 
sonographer, muscle thicknesses measured and the ultrasound machines (manufacturers 




Multi-frequency transducers were used with each machine, however the frequency of 
each probe was standardised throughout the study.  A Vf7-3 probe was used with the 
Siemens Acuson scanner; this is able to produce a frequency between 3-7MHz and 
therefore, achieve acceptable penetration in the anterior thigh. This probe was used in its 
7.27MHz linear array capacity.  An SP10-16-RS probe was used with the Voluson-i scanner 
and is able to produce a frequency between 7-18MHz.  SP10-16-RS is a wide band, multi-
frequency linear transducer. This probe was used in its 15-16MHz capacity in the Muscle 
factory setting mode.  Contact gel (Aquasonic 100, Parker Laboratories, Inc., USA) was 
applied to the skin to minimise distortion of images from excess compression of the skin 
and subcutaneous tissue. 
2.6.3 Participant position 
The anterior thigh was measured with participants sitting at an angle greater than 45 
degrees with knees resting comfortably in extension near the natural resting position of 
10–20°.  A purpose designed cushion placed under the knee was used for positioning and 
participants were instructed to relax their muscles during the examination.  
The arm was measured with participants sat on the edge of a couch with their arms 













2.6.4 Sites for ultrasound measurement 
The identification of locations to be scanned was informed from previous work (249, 250) 
but modified for inclusion in this study.  A pen mark was made at the locations described 
below and extended transversely to identify the anterior surface location.  The rectus 
femoris, vastus intermedius and subcutaneous tissue of the thigh were all captured in the 
same image.  This image was captured at 50% of the femur length (greater trochanter to 
the lateral condyle of the femur) on the anterior surface of the thigh.  Figure 2.3 for 
pictorial depiction.  In some participants it was impossible to capture complete images of 
both muscles and the subcutaneous tissue due to greater muscle or fat bulk in their thigh.  
In these participants an alternative probe with a lower frequency was used to gain 
sufficient depth to image all the muscles. 
Position for scanning lower limbs Position for scanning upper limbs 
Hand drawn figure depicting the positioning of participants for both upper and 




The biceps brachii image was captured at 60% proximal humerus length (acromial 
process of the scapula and the lateral epicondyle of the humerus) on the anterior surface 
of the upper limb (participant in anatomical position).  
The anterior forearm image was captured at 30% proximal radius length (styloid process 
and the head of the radius) on the anterior surface of the upper limb (participant in 
anatomical position).   






Hand drawn figure depicting the anatomical sites and landmarks for ultrasound 
measurements in the lower and upper limb.   
50% 
30% 




2.6.5 Ultrasound measurements    
The depths of the muscles were measured in millimetres on freeze frame images using 
the ultrasound machine software.  These images were also saved and exported for 
grayscale analysis.  All images were scanned in the transverse plane (251). Care was taken 
to avoid exerting excessive pressure on the imaged tissue.  In this position three images 
were captured bilaterally.  Maximal muscle thickness was measured as the distance 
between the superficial and deep fascia at the widest distance.  (Figure 2.4)  Images were 
repeated if there was poor concordance between the values and the average value used 
in analysis.  The images were saved and exported for further analysis.   
The boundaries used for muscle depth measurements were as follows (superficial  
deep): 
 Anterior Subcutaneous Tissue: skin-fat interface to fat-fascia interface with rectus 
femoris  
 Rectus femoris: fat-fascia interface to deep fascia-fascia interface with vastus 
intermedius 
 Vastus intermedius: fasica-fasica interface with rectus femoris to fascia-bone 
interface with femur  
 Anterior forearm: fat-fascia interface to muscle/fascia-bone interface with ulna  




Where applicable, fascia was not included in the depth measurements (e.g., 
measurement of rectus femoris would begin deep to the superficial fascia and end 
superficial to the deep fascial boundary). 











A – Sites of depth measurements in anterior thigh.  Depth measurements appear as 
broken yellow line. Letters correspond to the different tissue measurements.  A – 
subcutaneous tissue, B – rectus femoris, C – vastus intermedius 
B – Sites of muscle depth measurement in anterior forearm. Depth measurement of 
anterior forearm appears as broken yellow line. Depth of forearm muscle to ulna 
appears as red solid line (unrecorded measurement).   
C – Sites of muscle depth measurement in proximal upper arm.  Depth measurement 
of biceps brachii appears as broken yellow line.  
 
 




2.6.6 Ultrasound echogenicity 
To assess for intramuscular adipose tissue exported ultrasound images were analysed on 
Image J (Version 1.51, US National Institute of Health, USA) using an adapted protocol 
from a recent paper (252).  The greyscale value was obtained by defining a region of 
interest for analysis.  The rectangular marquee tool was used to define a region of 
interest within the fascial borders of the rectus femoris.  Due to the potential differences 
in echogenicity secondary to the depth of tissue only the rectus femoris was analysed.  
The captured images had been optimised for muscle measurement and in some instances 
there are areas of loss of contact.  Any areas of loss of contact were excluded from the 
region of interest.  The largest rectangle possible was used due to the observed 
heterogeneity of muscle quality within participants.  The mean echo intensity of this 
region was calculated (black = 0, white = 255).  The values from all available images were 













2.7 Blood samples 
Blood samples were all taken peripherally using the BD vacutainer® Safety-Lok™ system 
of blood collection.  Blood was collected in sterile vacutainers (BD biosciences).  All blood 
samples were processed within 30 minutes of collection.  The type of vacutainer used for 
collection was dependent on the experiments to be performed, as described in table 2.7. 
Table 2.7 - Table describing types of vacutainers used for each experiment   
Colour of tube Additive Experiments 
Green Lithium heparin Isolation of neutrophils 
Chemotaxis 
Neutrophil phenotyping  
Western Blotting 
IL-8 and fMLP expression 
Plasma samples 




Unless described otherwise RPMI was supplemented with GPS (L-Glutamin, 100 units of 
penicillin and 0.1mg streptomycin per ml).  
2.9 Isolation of neutrophils 
Neutrophil Isolation was carried out using a Percoll gradient method (253), for rapid 
separation of minimally activated neutrophils (254).  Peripheral blood, collected in 
lithium heparin vacutainers, was transferred to 50ml Falcon tubes.  2% dextran 
(Pharmacosmos) was added to the blood at a ratio of one to six (dextran:blood) and 
gently inverted.  This was then incubated for 30 minutes generating leukocyte rich 
plasma, layered above the sedimented red blood cells.  The plasma layer was removed 




and layered onto a Percoll density gradient (pH 8.5-9.5; GE Healthcare), 80% Percoll 
(2.5ml) under 56% Percoll (5ml).  The gradients were spun for 20 minutes at 280g in a 
freestanding centrifuge (Jouan C3i Centrifuge, DJB Labcare) with no break or acceleration 
at 20oc.  (Figure 2.5)   









Following centrifuge the neutrophils, resident at the 80-56% interface, were removed 
with a Pasteur pipette and transferred to sterile RPMI-1640 media (Sigma Aldrich).  This 
was pelleted by spinning in a centrifuge at 350g for 10 minutes at 20oc (Jouan C3i 
Centrifuge, DJB Labcare).  Following centrifugation the supernatant was discarded and 
the cells resuspended in RPMI-1640 media (Sigma Aldrich).  Purity was determined by 
cytospin, regularly greater than 95%, and viability was determined by trypan blue 
exclusion, regularly greater than 98%.         
Resultant layers in a Percoll density gradient following spin in centrifuge for 20 




2.10 Migratory accuracy of neutrophils 
1.125% bovine albumin (Life Technologies) was added to neutrophils at a concentration 
of 2.0x106.  Coverslips (22x22mm, VWR International) were cleaned by acid washing 
(0.4M H2SO4) and then coated with 7.5% bovine albumin fraction (Life Technologies).  
400μl of neutrophil suspension at 2x106 was added dropwise to the cleaned and coated 
coverslips and left for 20 minutes.  Concurrently the Insall Chamber (Weber Scientific 
International Ltd, Teddington) was washed with RPMI-1640 media (Sigma Aldrich) and 
loaded with RPMI-1640 media (Sigma Aldrich).  After 20 minutes the excess fluid from the 
coverslip was removed by simple inversion.  The coverslip was then immediately inverted 
over the Insall Chamber.  The RPMI-1640 was removed from the Insall Chamber using 
blotting paper and replaced with either RPMI-1640, the vehicle control, or 10 nM fMLP 
(Sigma Aldrich) or 100 nM IL-8 (R&D), chemoattractants.  (Figure 2.6)  The gradient was 
allowed to develop over at least a minute before commencing video microscopy.  The 

















Chemotaxis was assessed using real-time video microscopy.  Images were captured by a 
Leica DMI6000B with DFC360FX camera which captured 36 frames over a 12 minute 
period with a 20 second delay between frames.  The images were analysed using Image J 
software (Wayne Rasband, NIH, Bethesda).  The slice remover plug-in was used to 
produce a series of 18 images from the original 36 exported from the microscope. The 
manual tracking plug-in was used to track the movement of ten randomly selected 








of travel  
Insall chamber with inverted coverslip.  Neutrophils adhered to the bovine serum 
albumin on the coverslip during period of incubation.  Coverslip inverted over both 
wells initially filled with RPMI.  RPMI in outer ‘A’ shaped well removed with blotting 
paper and replaced with chemoattractant to establish a gradient over the bridge for 




Image J and a random number generator (RANDOM.ORG). Only neutrophils deemed to 
be migrating by morphology and those that did not collide with other neutrophils were 
analysed. Neutrophils were deemed to be migrating if there was a leading edge visible, 
there was movement of more than half a cell length and there was no visible pinning of 
part of the neutrophil that might prevent full migration. Four parameters were assessed: 
chemokinesis, chemotaxis, directional persistence and chemotactic index.   
Chemokinesis, also described as the speed of a cell, is the distance travelled by a cell 
between two frames measured in μm/min.  This is the non-specific movement of the cell 
in any direction.   
Chemotaxis of the neutrophil is the migrational speed of the cell in a consistent direction 
towards the chemoattractant source also measured in μm/min.  This is a measure of the 
speed of migration towards a chemoattractant source.   
Directional persistence is a measure of continuity of cell orientation over time.  It is 
calculated by the cosine of an angle between directions in consecutive frames and is 
expressed on a scale of 0 to 1.  This determines how frequently and rapidly the cells 
change direction during migration.  The closer the cell’s direction is to a straight line the 
higher the persistence.   
Chemotactic index is a measure of accuracy of a cell’s directional orientation.  It is 
calculated by the cosine of the angle between the cell’s direction and the orientation of 
the chemoattractant gradient.  It is expressed on a scale of -1 to 1.  It is an overall 
measure of how accurate and how rapid a cells is in migrating towards a chemoattractant 




2.11 Chemotaxis of neutrophils incubated with PI3K inhibitors 
To investigate the effect of PI3K inhibition on neutrophil migration neutrophils were 
incubated with selective inhibitors of PI3K isoforms α, β, γ and δ.  Stock solutions were 
prepared using dimethyl sulfoxide (DMSO, Sigma Aldrich) further dilutions to achieve the 
half maximal inhibitory concentration (enzymatic IC50) were completed with RPMI.   
Neutrophils isolated at 2x106 were incubated with the different PI3K inhibitors for 40 
minutes (20 minutes in eppendorf and 20 minutes on coverslip).  (Table 2.8)  DMSO was 
also included in the chemotaxis assay as an appropriate vehicle control.  Neutrophils 
incubated with PI3K inhibitors or DMSO were then migrated towards 100nM IL-8 as 
described above.     
Table 2.8 – Concentration, names and manufacturer of PI3K inhibitors 
 
Isoform Inhibitor Name Concentration/IC50 
P110α PIK-75 (Chemie Tek; CT-PIK750) 7.8nM 
P110β TGX-221 (Selleck Chemicals; S1169) 10nM 
P110γ AS-252424 (Selleck Chemicals; 
S2671) 
33nM 






Inhibitor names, manufacturers and concentrations used in experiments for the 




2.12 Chemotaxis of primed neutrophils over a time-course of increasing rest period 
Neutrophils were isolated at the concentration of 1x106 and split between two 50ml 
Falcon tubes: primed neutrophils and vehicle control.  TNFα (Sigma Aldrich) at 1.15nM 
concentration was added to the neutrophils in the ‘primed neutrophils’ falcon tube.  The 
primed neutrophils were then incubated for 15 minutes on a rollator.  During the 
incubation of the primed neutrophils the vehicle control neutrophils were washed (350g 
for 10 mins at 20oc).  Once the vehicle control neutrophils had been washed they were re-
suspended in RPMI-1640 media (Sigma Aldrich) at a concentration of 2x106 and 
chemotaxis continued as described above towards 10nM fMLP.  Following the 15 minute 
incubation the primed neutrophils were washed (350g for 10 mins at 20oc) and then re-
suspended in RPMI-1640 media (Sigma Aldrich) at a concentration of 2x106.  The primed 
neutrophils were then migrated towards 10nM fMLP following a time-course of 
increasing rest period (see table 2.9 for time-points).  The 50ml falcon with the primed 
neutrophils remained on the rollator during the rest period.  Figure 2.7 describes the 
process in pictorial form.         
Table 2.9 - Timings for the time-course of primed neutrophils 
Neutrophils Wash Timing Time neutrophils 
applied to coverslip 
Time neutrophils 
applied to slide 
VC 0-10 15 35 
15 15-25 30 50 
15+15 15-25 45 65 
15+30 15-25 60 80 
15+45 15-25 75 95 
        
 
 
Timings for the timecourse of neutrophils primed with TNFα prior to migration towards 









2.13 Chemotaxis of healthy young adult’s neutrophils towards pooled plasma 
Healthy young adult’s neutrophils were bathed in either RPMI-1640 (Sigma Aldrich), 
pooled plasma from healthy older adults or pooled plasma from a frail older adults to 
assess migration following incubation with pooled plasma.  Plasma samples from 18 
healthy older adults were combined to create pooled plasma of healthy older adults and 
plasma samples from 18 frail older adults were combined to create pooled plasma of frail 
older adults.  Isolated neutrophils at the concentration 4x106 were incubated with either 
Diagram explaining the timecourse of neutrophils primed with TNFα prior to migration 




RPMI-1640, pooled plasma from healthy older adults or pooled plasma from a frail older 
adult for a period of 40 minutes.  The neutrophils were then pelleted in a centrifuge 
(400g for 10 minutes at 20oc) and resuspended in RPMI-1640 at 2 x106.  Chemotaxis was 
performed as described above towards RPMI and IL-8.    
2.14 Neutrophil phenotyping 
To determine whether neutrophils from frail older participants display a different 
phenotype to healthy older participants and healthy younger participants the expression 
of different surface markers was quantified by flow cytometry.  To reduce the risk of 
activation during the process neutrophils were not isolated from whole blood and instead 
whole blood was used and the neutrophil population gated for analysis.  For each set of 
antibodies a stimulated and un-stimulated test was performed.  IgG1 and IgG2 isotype 
matched irrelevant antibodies were also used at the same concentration to control for 
non-specific binding.         
Whole blood was collected in a lithium heparin vacutainer and pelleted by centrifuge at 
250g for 10 minutes.  The plasma layer was removed from the centrifuged blood by 
Pasteur pipette.  2mls of the autologous plasma (AP) was added to 2% phosphate buffer 
solution (PBS)(Gibco)/bovine serum albumin (BSA)(Fisher Scientific) to make 2% PBS/BSA 
+ 5% AP.  The pellet of erythrocytes was re-suspended and the plasma volume initially 
removed was replaced with the same volume of 2%PBS/BSA + 5%AP.  100μl of red blood 
cells re-suspended in 2% PBS/BSA + 5% AP was pipetted into each FACS tube. 
10nM fMLP (Sigma Aldrich) diluted in 2% PBS/BSA + 5% AP was added to the stimulated 




incubation all FACS tubes were placed on ice and the antibodies added as follows.  For 
each group a stimulated and unstimulated test were performed.  Following the addition 
of antibodies all FACS tubes were then incubated for 20 minutes, on ice, in the dark to 
















Stimulated and Unstimulated Tests Isotype Tests 
Group Antibody Manufacturer Concentr
ation 
(µg/μl) 





CD16 – PE-Cy7 ebioscience, San Diego, Ca 0.03/5 Group 
1 
mIgG1 - PE-Cy7 Biolegend, San Diego, Ca 0.03/5 
CD49F - FITC Biolegend, San Diego, Ca 1/5 rIgG2a - FITC Biolegend, San Diego, Ca 1/5 
PE anti-human 
Integrin α9β1 
Biolegend, San Diego, Ca 1/5 mIgG1 - PE Biolegend, San Diego, Ca 1/5 
APC anti-human 
CD29 
Biolegend, San Diego, Ca 1/5 mIgG1 - APC Biolegend, San Diego, Ca 1/5 
Group 
2  
CD16 - PE-Cy7 ebioscience, San Diego, Ca 0.03/5 Group 
2 
mIgG1 - PE-Cy7 Biolegend, San Diego, Ca 0.03/5 
CD11b - PE R+D, Mineapolis, Mn 0.5/20 mIgG1 - APC Biolegend, San Diego, Ca 1/5 
CD11a -  FITC R+D, Mineapolis, Mn 1.2/40 mIgG2b - PE Southern Biotech, 
Birmingham, Al 
0.5/20 





CD16 - PE-Cy7 ebioscience, San Diego, Ca 0.03/5 Group 
3 
mIgG1-PE - Cy7 Biolegend, San Diego, Ca 0.03/5 










CD16 - PE-Cy7 ebioscience, San Diego, Ca 0.03/5 Group 
4  
mIgG1 - PE-Cy7 Biolegend, San Diego, Ca 0.03/5 
APC anti-human 
CD26L 
ebioscience, San Diego, Ca 0.3/3 mIgG1 - PE Biolegend, San Diego, Ca 1/5 
CD63 - PE Invitrogen, Frederick, Md 0.5/5 mIgG1 - APC Biolegend, San Diego, Ca 1/5 









Stimulated and Unstimulated Tests Isotype Tests 
Group Antibody Manufacturer Concentr
ation 
(µg/μl) 





CD16 PE-Cy7 ebioscience, San Diego, Ca 0.03/5 Group 
5 
mIgG1 - PE-Cy7 Biolegend, San Diego, Ca 0.03/5 
CD184 – APC ebioscience, San Diego, Ca 0.25/5 mIgG2a - APC Biolegend, San Diego, Ca 1.25 
CD182 – PE ebioscience, San Diego, Ca 0.25/5 mIgG1 - PE Biolegend, San Diego, Ca 1.25 
CD66b - FITC ebioscience, San Diego, Ca 0.3/3 mIgM - FITC Biolegend, San Diego, Ca 1.5 




The cells were then washed at 250g, 4oc for 5 minutes in 2% PBS/BSA + 5% AP using a 
centrifuge (Jouan C3i Centrifuge, DJB Labcare).  The supernatant was carefully removed 
from each FACS tube with a Pasteur pipette.  2mls of lysis solution, 1 FACS lyse (BD 
Biosciences, Oxford UK): 9 ddH2O, was added to each FACS tube to remove the 
erythrocytes.  The cells with lysis solution were incubated for 10 minutes at room 
temperature.  The cells were then washed twice at 250g, 4oc for 5 minutes; the second 
time with 2% PBS/BSA + 5% AP and then re-suspended in 100μl of 2% PBS/BSA + 5% AP.  
The samples were immediately analysed on a BD Accuri C6 Flow Cytometer (BD 
Biosciences).  10,000 cells were analysed in each sample and the neutrophil population 
was identified by assessing forward and sideways light scattering.  Forward scatter 
equates to cell size and side scatter to cell granularity. Gating was used to ensure only 
signals from the neutrophil population were analysed. Neutrophil fluorescence from 
those labelled with specific receptor antibodies were determined relative to those 
labelled with the analogous non-specific antibody by subtraction of the isotype Median 
Fluorescence Intensity (MFI) value from that of the receptor antibody.   
2.15 Neutrophil Phenotyping by CD16 and CD62L 
To consider the effect of cell maturity samples subject to condition 4 which included 
exposure to both the antibodies, CD16 and CD62L, were gated using the isotypes as a 
negative control.   The baseline sample without exposure to stimulation was used as a 






2.16 Western Blots 
To determine whether the expression of pAKT is reduced and delayed in frail older adults 
Western blots were performed.   
2.16.1 Preparation of Western lysates 
1 ml of isolated neutrophils at a concentration of 5x106 were incubated at 37oc in a petri 
dish (35mm diameter) for 20 minutes.  The supernatant was carefully removed and 
100nM IL-8 added for a period of stimulation: 20 sec, 40 sec or 60 sec.  For baseline 
comparison this step was omitted.  Following stimulation the supernatant was removed 
and the petri dish placed on ice.  150μl radioimmunoprecipitation assay (RIPA) buffer (see 
table 2.11 for reagents, concentrations and suppliers) was immediately added to 
terminate all reactions; the process of dissociation was enhanced with a cell scraper.  The 
supernatant containing the intracellular protein was removed into an Eppendorf, 
vortexed and kept on ice throughout the experiment.  Before storing the lysates at -80oc 
the protein concentration was determined with a Bicinchoninic acid (BCA) assay.       
Table 2.11 - RIPA buffer 
Reagent Concentration Supplier 
PhosStop Diluted 1 tablet: 10mls 
RIPA buffer (Sigma Aldrich) 
Roche 
Protein Inhibitor Cocktail Diluted 1:10 Sigma Aldrich 
Phenylmethanesulfonylfluoride 50mM Sigma Aldrich  
Sodium Fluoride 10mM Sigma Aldrich 
Β-glycerophosphate 500mM Sigma Aldrich 
Sodium Vanadate 10mM Sigma Aldrich 
  
    
2.16.2 BCA Assay 
A commercially available BCA assay (Thermo-fisher) was used to perform protein 
concentration determination.  Albumin Standard was diluted in accordance with 




instructions to provide a range of BCA concentrations from 0 to 2000μg/ml.  12.5μl of 
each BSA concentration standards and 12.5μl of each sample were pipetted into separate 
wells in a flat bottomed 96 well plate.  87.5μl of BCA working reagent (50 parts BCA 
reagent B: 1 part BCA reagent A) was added to each well.  Standards and samples were 
completed in duplicate to improve accuracy.  The 96 well plate was incubated in the dark 
at 37oc for 30 minutes and immediately analysed using a plate reader and corresponding 
Gen 5 software (BioTek).  The data was exported to Microsoft excel for determination of 
protein concentration.  
2.16.3 Western Blot 
The protein concentration of lysates was adjusted to enable loading of 40μg protein per 
lane.  SDS sample treatment buffer (containing 0.05M Trizma, 2% SDS, glycerl and 10% β-
mercaptoethanol) was added.  Proteins were separated using a 10% acrylamide gel and 
then transferred onto a nitrocellulose membrane using wet transfer.  Blots were blocked 
with 5% BSA before probing overnight at 4oC with 1:750 pAKT Thr308 ((D25E6) XP® 
Rabbit mAB #13038, Cell Signalling Technologies), 1:2000 pAKT Ser473 ((D9E) XP® Rabbit 
mAB #4060, Cell Signalling Technologies) or 1:4000 β-Actin (mouse mAb, clone AC-15, 
Sigma UK) primary antibodies and appropriate horseradish peroxidase conjugated 
secondary antibodies.  Western blots were visualised using enhanced chemiluminescence 
(Amersham ECL-Prime, GE heathcare) and ChemidocTM MP (BioRad, UK).  Density of the 
protein was assessed using Image Lab 5.2.1 software (BioRad, UK).           
2.17 Oxidative burst 
The oxidative burst protocol was devised to investigate whether neutrophils primed for 




described above at the concentration of 2x106 and 500μl of isolated neutrophils were 
pipetted into individual eppendorfs.   
1.15nM (10ng/ml) TNFα was added to the isolated neutrophils primed conditions and 
vortexed.  Following a 15 minutes period of priming the neutrophils were washed at 
250g, 4oc for 5 minutes in a centrifuge (Jouan C3i Centrifuge, DJB Labcare) and then 
resuspended in RPMI.  The neutrophils were then stimulated with 5μl of 1μM fMLP for 25 
minutes.  Following 10 minutes of stimulation with fMLP 2.8μl of 30mM 
dihydrorhodamine-123 (DHR) or 2.8μl DMSO was added to the Eppendorf and were 
incubated for 15 minutes.  On completion of 25 minutes of stimulation and the 
simultaneous 15 minutes of incubation with DHR all reactions were terminated with 
incubation on ice for 10 minutes.  The neutrophils were then washed twice at 250g, 4oc 
for 5 minutes using a centrifuge (Jouan C3i Centrifuge, DJB Labcare) and re-suspended in 
50μ of FACS fixing solution.      
 The samples were then immediately analysed on a BD Accuri C6 Flow Cytometer (BD 
Biosciences).  10,000 cells were analysed in each sample and the neutrophil population 
was identified by assessing forward and sideways light scattering.  Forward scatter 
equates to cell size and side scatter to cell granularity. Gating was used to ensure only 
signals from the neutrophil population were analysed. Neutrophil fluorescence from 
those labelled with DHR was determined relative to those labelled with DMSO.  The 
Median Fluorescence Intensity (MFI) value was quoted.           
2.18 Collection and storage of serum and plasma samples  
Blood was collected using the BD vacutainer system, green vacutainers for plasma and 




a centrifuge at room temperature (plasma 438g for 8 minutes, serum 1539g for 10 
minutes).  The serum and plasma were then removed using a pipette and stored at -800c.     
2.19 Determination of inflammatory profile 
To determine the inflammatory profile cytokine concentrations were measured using 
multiplex technology and hsCRP was measured using ELISA technology; both protocols 
were completed according to the manufacturer’s instructions (Bio-Plex Pro Human 
Cytokine Standard 27-Plex, Bio-Rad; hsCRP kit, IBL International).  Table 2.12 displays the 
cytokines measured with the Human Cytokine Standard 27-Plex. 
Table 2.12 – Human Cytokine Standard 27-Plex 
IL-1β IL-10 IFN-γ 
IL-1ra IL-12p IP-10 
IL-2 IL-13 MCP-1 
IL-4 IL-15 MIP-1α 
IL-5 IL-17A MIP-1β 
IL-6 Eotaxin PDGF-BB 
IL-7 Basic FGF RANTES 
IL-8 G-CSF TNFα 
IL-9 GM-CSF VEGF 
    
 
Briefly, wells within a 96 well plate were pre-wet with wash solution.  50μl of a 1X 
antibody bead stock for the aforementioned cytokines was added to each well of the 
assay plate.  Following a 30 second incubation at room temperature the plate was 




washed twice with 100μl of wash solution.   50μl of each serum sample, prepared to a 1 
in 4 dilution (25μl serum sample: 75μl of Bio-Plex sample diluent), or standard solution 
was added to the relevant wells and the plate incubated in the dark for 30 minutes at 
room temperature on an orbital shaker (speed 800-900 rpm; Grant Instruments Limited, 
Cambridge, UK).  Post incubation, the plate was washed three times with 100μl wash 
buffer and 25μl of 1x detection antibodies was added to all the wells.  The plate was then 
incubated in the dark for 30 minutes at room temperature on an orbital shaker (speed 
800-900 rpm).  The plate was then washed three times with 100μl of wash buffer and 
50μl of 1X streptavidin-RPE was added to all the wells.  This was followed by a 10 minute 
incubation at room temperature on an orbital shaker (speed 800-900 rpm) and three 
further washes with 100μl wash buffer.  The antibody beads were resuspended in 125μl 
of assay buffer.  Cytokine concentrations were then analysed using a Luminex® 100TM 
instrument (Luminex® Corporation, Austin, Texas, USA). 
To determine the hs-CRP concentration of the samples the serum samples were first 
diluted to 1 in 1000 with the supplied sample diluent.  100µl of diluted serum sample or 
standard solution was added to the relevant wells in a 96 well plate and the plate was 
then incubated in the dark for 30 minutes at room temperature on an orbital shaker 
(speed 800-900 rpm; Grant Instruments Limited, Cambridge, UK).  Post incubation, the 
plate was washed three times with 100μl wash buffer.  Following the wash step 100µl of 
conjugate solution was added to each well and the incubation and wash step repeated as 
described above.  100µ of chromogen solution was then added to each well and the plate 
was then incubated in the dark for 10 minutes at room temperature on an orbital shaker 




each well and immediately analysed using a plate reader and corresponding Gen 5 
software (BioTek). 
2.20 Determination of neutrophil elastase activity 
Neutrophil elastase activity was determined by quantification of the amount of elastase-
specific fibrinogen fibrinogen breakdown product, AαVal360 within the previously stored 
serum samples (see section 3.8) using a competition ELISA as previously described (212).  
Neutrophil elastase activity was determined on the 18 frailest older individuals and 18 
healthiest older individuals as determined by frailty index.      
Briefly, rabbit ant-sera raised against free carboxyl group of AαVal360 was incubated with 
plasma samples at 1:2500 dilution overnight at 4oC.  The samples were pipetted into a 96 
well tissue culture plate pre-coated with neutrophil elastase cleaved fibrinogen.  Free 
AαVal360 within the samples binds to the degraded fibrinogen and this is detected and 
subsequently quantified with a europin-conjugated anti-rabbit IgG secondary antibody.  
All samples were completed in duplicate and an average of the two readings used in 
further analysis.          
2.21 Statistics 
Statistical analyses were performed using the SPSS statistical program (version 22.0 
Chicago, USA).  Data were tested for normality using the Shapiro-Wilk or Kolmogorov 
Smirnov test and the appropriate parametric (ANOVA, t-test – independent or paired) or 
non-parametric test (Kruskal-Wallis, Mann-Whitney) was used to compare the groups.  
Relationships between variables were examined with a Pearson rank correlation test 
(normally distributed data) or Spearman’s correlation test (non-normally distributed 
data).  A p value < 0.05 was considered to be statistically significant where appropriate 




tested with the intraclass-correlation coffecient and interpreted using the Koo and Li 
criteria (<05 = poor reliability, 0.5-0.75 = moderate reliability, 075-0.9 = good reliability, 

















3. Ultrasound as a diagnostic 
tool for the identification of 
low muscle mass and poor 


















Sarcopenia is an under recognised condition which is rarely diagnosed in clinical practice 
despite poor associated outcomes and evidence of available treatment with benefit (11).  
A barrier to recognition in clinical practice is the diagnosis of low muscle mass (an 
absolute criterion of sarcopenia).  Traditional methods such as DXA and CT or MRI are 
both expensive and impractical in a frail community based population.  Ultrasound is a 
portable diagnostic tool that could be utilised to diagnose low muscle mass.  However, 
there are no standardised diagnostic criteria for low muscle mass measured by 
ultrasound and criteria quoted for more traditional diagnostic tools, for example dual-
energy x-ray absorptiometry (DXA), are not translatable to ultrasound measurements.  
Guidance from the international working groups on sarcopenia suggest that low muscle 
mass in older adults should be defined as less than two standard deviations from the 
mean of a healthy younger population, similar to diagnostic criteria for osteoporosis (11). 
The quality of muscle is increasingly recognised as important to physical function as 
quantity (256).  Recent advances suggest that increased volumes of intramuscular 
adipose tissue correlates with poor physical function (257).  The current gold standard 
diagnostic method of measuring low muscle mass DXA does not provide an assessment of 
muscle quality.  Ultrasound echogenicity expressed as echo intensity has been previously 
utilised in the diagnosis of muscular dystrophy and assessment of muscle quality in 
sarcopenia (257-259).  Analysis of muscle biopsies has demonstrated that increased 
ultrasound echogenicity is due to intramuscular adipose tissue rather than fibrosis within 





This chapter aims to:  
 Present a simple scanning protocol that can be utilised in a clinical setting.   
 Determine whether ultrasound is an accurate diagnostic technique in the 
identification of sarcopenia considering inter-rater, intra-user, inter-instrument 
reliability. 
 Provide the criteria for the diagnosis of low muscle mass in sarcopenia using the 
suggested simple scanning protocol   




















3.2 Participant Characteristics 
3.2.1 Reference population 
113 young adult participants, 59 male and 54 female, were assessed by ultrasound to 
form the reference population. Demographic data are displayed in Table 3.1.  The 
calculated criteria for identification of low muscle mass derived from the appendicular 
lean muscle mass/ht2 (two standard deviations below the mean of a healthy young 
population) measured by BIA in the reference population are 5.6 kg/m2 for women and 
7.39 kg/m2 for men.  These values are almost identical to criteria previously quoted in the 
literature (5.5, 5.67 and 5.67 kg/m2 in women and 7.26, 7.25 and 7.23 kg/m2 in men) from 
much larger sample sizes and utilising a variety of assessment methods (two standard 
deviations below the mean of a healthy young population and lowest gender specific 20% 
in older adults as the benchmarks) (11).  This suggests that the sample is representative 
of a healthy young adult population and the proposed criterion for the diagnosis of low 
muscle mass in older adults, bilateral anterior thigh thickness (BATT), has been created 
from an appropriate reference population.    
 3.2.2 Healthy older adult and frail older adult populations 
40 healthy older adults and 31 frail older adults were scanned to form the comparison 
populations; demographic data are displayed in Table 3.1.  The two groups were 
anthropologically similar with no significant difference in age, height, weight or BMI 
(median data shown for all data).  The healthy older and frail older men were very similar 
in age, but the frail older women were older than the healthy older women.  This was a 
non-significant difference, p=0.174.  There was very little difference in the height of the 




was a trend of the frail older women being shorter than their healthy older counterparts, 
HO 1.60m and FO 1.54m.  Again this was not significant, p=0.062.  The frail older men and 
women were lighter than the healthy older adults: HO men 73.1kg, FO men 69.5kg, 
p=0.220, HO women 62.0kg, FO women 59.0kg, p=0.624.  Despite differences in weight 
there was no difference in BMI between the healthy older and frail older adults: HO men 
23.3, FO men 23.1, p=0.621, HO women 24.3, FO women 25.5, p=1.00.  As expected there 
was a significant difference in frailty index: HO men 0.03, FO men 0.40, p<0.001, HO 




Table 3.1 – Demographics of healthy younger adult reference population and the comparison populations: healthy older adults and frail 
older adults 
 Healthy Young Adults Healthy Older 
Adults 
Frail Older Adults Groups HO and FO 
 Male Female Male Female Male Female Male Female Male Female 
Proportion (N) (%) 52.2% 
(59) 








    












p<0.001 p<0.001 P=1.00 P=0.174 












p=0.081 p<0.001  P=0.062 












p=0.220 p=0.624   


























N/A N/A N/A N/A     
Frailty Index 0.02 +/- 
0.02 





















38.3% (13) N/A N/A N/A N/A     












Data sets: Healthy Young (HY) – 113, Healthy Old (HO) -40, Frail Old (FO) – 31.  
Median +/- IQR given except appendicular lean muscle mass where mean and CI are 
given.  Categorical data given as percentage of total population with raw number in 
brackets.  Appendicular lean muscle mass - data shown from smaller subset of 45 
men and 37 women.  Exercise (adheres to government recommendations for exercise 
and physical activity) - data shown from smaller subset of 41 men and 34 women.  
N/A – data not available.  Statistical difference analysed with Kruskal-Wallis with 
post-hoc pairwise analysis with Bonferroni correction.   
Female – Age: HY and HO not ND, FO ND, Height: HY, HO and FO all ND, Weight: HY, 
HO and FO all ND, BMI: HY and HO not ND, FO ND, Appendicular leam muscle mass: 
HY ND, FI: HY and HO not ND, FO ND. 
Male – Age: HY not ND, HO and FO ND, Height: HY, HO ND, FO not ND, Weight: HY 
and HO ND, FO not ND, BMI: HY ND, HO and FO not ND, Appendicular lean muscle 
mass: HY ND, FI: HY and HO not ND, FO ND.   




3.3 Ultrasound as a diagnostic tool 
3.3.1 Ultrasound is a reproducible diagnostic tool for the measurement of muscle 
thickness 
Lay sonographers were able to reliably reproduce the same measurements on the same 
individuals. The intra-class correlation coefficient of 304 muscle thicknesses in 38 healthy 
young individuals (eight muscle thicknesses each individual) measured by both 
sonographer one and sonographer two was 0.972 (0.966-0.978).  The intra-class 
correlation coefficient of 210 muscle thickness in 35 different healthy young individuals 
(six muscle thicknesses each individual) measured by sonographer two and sonographer 
three was 0.992 (0.989-0.995).  The muscle thicknesses considered here are averages of 
three replicates.    
 
There was also excellent agreement (using Koo and Li’s criteria for interpreting ICC) 
between measurements taken on two different instruments.  The intra-class correlation 
coefficient of 312 muscle thicknesses in 39 healthy young individuals measured by one 
sonographer on two different ultrasound machines was 0.989 (0.986-0.991).   
 
The bilateral variability and intra-rater variability are not strictly measures of repeatability 
because of both the short period of time between the image replicates and the natural or 
pathological variations in muscle size bilaterally.  However, the excellent agreement for 
all the sonographers for both bilateral variability and intra-rater variability suggests that 
ultrasound imaging is repeatable.  The intra-class correlation coefficient of: 312 replicates 
of muscle thicknesses measured in 39 individuals by sonographer one was 0.992, 210 




0.982 and 210 replicates of muscle thicknesses measured in 35 individuals by 
sonographer three was 0.997.  The intra-class correlation coefficient of: 308 muscle 
thicknesses in 77 individuals was 0.992, 105 muscle thicknesses in 35 individuals was 
0.981 and 105 muscle thicknesses in 35 individuals was 0.982.  The muscle thicknesses 
considered in bilateral variability are averages of three replicates and the muscle 
thicknesses considered in intra-rater variability are the replicates before averaging. (Table 
3.2.)  
 
Considering the repeatability of ultrasound as a diagnostic tool for healthy and frail older 
adults bilateral variability is less useful because of possible pathological differences such 
as a previous fractured hip.  However, there is excellent agreement in intra-rater 
variability in frail older adults and good agreement in intra-rater variability in healthy 
older adults.  The intra-class correlation coefficient of: 160 muscle thicknesses in 80 
healthy older individuals was 0.867 and 124 muscle thicknesses in 31 frail older 
individuals was 0.928.  (Table 3.3.)    
 
These data suggest that ultrasound determination of muscle thickness is repeatable in a 
healthy young, healthy older and frail older adult population.  It is also reproducible by 
lay sonographers with minimal training in healthy young adults.  Ultrasound as a 
diagnostic tool could be used for the identification of sarcopenia in both research and 





3.3.2 Ultrasound could be used as a research tool for measurement of echogenicity 
Lay sonographers were unable to reproduce the same echogenicity values in the same 
individuals with consistency.   The intra-class correlation coefficient of measurements of 
echogenicity from 74 individuals analysed by one analyser from images performed by 
sonographer one and sonographer two was 0.559 (0.179-0.924).  The intra-class 
correlation coefficient of measurements of echogenicity from 70 individuals analysed by 
one analyser from images performed by sonographer two and sonographer three was 
0.794 (0.180-0.847).  This was also the case when comparing one sonographer taking 
images on different ultrasound machines.  The intra-class correlation coefficient of 
measurements of echogenicity from 74 individuals analysed by one analyser from images 
performed by one sonographer on two different machines was 0.305 (-0.085-0.597).  The 
low levels of reproducibility suggest using the current protocol for the identification of 
high ultrasound echogenicity would not be accurate enough to use as a diagnostic tool in 
clinical practice.    
 
However, different analysers analysing the same exported image showed excellent 
agreement.  The intra-class correlation coefficient of measurements of echogenicity on 
the same 160 images analysed by different analysers was 0.924 (0.843-0.957).  There was 
also good agreement between bilateral measurements and intra-rater variability 
suggesting higher levels of repeatability than reproducibility.  The intra-class correlation 
coefficient of intra-rater variability: 262 replicates of muscle echogenicity measured by 
sonographer one was 0.895, 70 replicates of muscle echogenicity measured by 




sonographer three was 0.768.  The intra-class correlation coefficient of bilateral 
variability: 142 images of muscle echogencity measured by sonographer one was 0.891, 
35 images of muscle echogencity measured by sonographer two was 0.862 and 35 images 
of muscle echogenicity measured by sonographer three was 0.820.  The muscle 
echogenicity considered in bilateral variability are averages of three replicates and the 
muscle echogenicity considered in intra-rater variability are the replicates before 
averaging.  (Table 3.2) 
 
Strasser et al commented on the large variability in ultrasound echogenicity 
measurements witnessed in older adults when considering inter-subject variance in a 
young and old population (250).  However, the variability between replicates of 
echogenicity in healthy older adults and frail older adults in this study was as good, or 
even better than healthy younger adults; intra-class correlation coefficients: sonographer 
one for healthy young was 0.895, for healthy old was 0.912 and for frail old was 0.889. 
 
These data suggest that whilst ultrasound determination of muscle echogenicity using the 
described protocol would not be useful in a clinical setting, in a research setting where 
the sonographer and machine can be standardised this could be an adequate method of 
determining muscle quality which is both easier and cheaper than the current gold 







Table 3.2 – Inter-rater, intra-rater, inter-instrument, inter-analyser and bilateral 
variability for muscle depths and ultrasound echogenicity using ultrasound for 




 Sonographer 1 v 
Sonographer 2 
Sonographer 2 v 
Sonographer 3 









Inter-instrument Variability  
 
 Machine 1 v Machine 2 
Muscle Depth 0.992* 
(0.990-0.993) 





 Analyser 1 v Analyser 2 





 Sonographer 1 Sonographer 2 Sonographer 3 
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Table shows the variability in measurements between different: sonographers, 
instruments, analysers and the variability within measurements from different 
sonographers and comparing measurements from the right to the left leg.  
Measurements for inter-rater, inter-instrument, inter-analyser and bilateral variability 
are the mean of three to four replicates.  Intra-rater measurements are variability 
within the three to four replicates.  Numbers given are intra-class coefficient, 2-way 
mixed, absolute agreement and single measures.  Interpreting ICC using Koo and Li 
criteria:>0.9 = excellent reliability, 0.75-0.9 = good reliability, 0.5-0.75 = moderate 
reliability and <0.5 = poor reliability.  Values starred indicate those of excellent 
reliability.  Below are the number of measurements included in ICC statistical test for 
each criteria.  
Inter-rater variability.  The variability between one sonographer and another when 
taking measurements from the same individual.  Sonographer 1 v Sonographer 2: 
muscle depth – 304, ultrasound echogenicity - 74.  Sonographer 2 v Sonographer 3: 
muscle depth - 210, ultrasound echogenicity - 70. Inter-instrument variability.  The 
variability between accuson static machine and voluson portable machine when 
measuring the same individual.  Machine 1 v Machine 2: muscle depth - 312, 
ultrasound echogenicity -74 .  Inter-analyser variability.  The variability in calculated 
ultrasound echogenicity values from analyser 1 and analyser 2 when calculating 
ultrasound echogenicity using Image J on images created by one sonographer.  
Analyser 1 v Analyser 2 = 160.  Intra-rater variability.  The variability in replicates for 
one individual by one sonographer.  Sonographer 1: muscle depth – 312,  ultrasound 
echogenicity – 261, Sonographer 2: muscle depth – 210, ultrasound echogenicity – 68, 
Sonographer 3: muscle depth – 210, ultrasound echogenicity – 70.  Bilateral variability.  
The variability between right and left measurements.   Sonographer 1: muscle depth – 
308,  ultrasound echogenicity – 142, Sonographer 2: muscle depth – 105, ultrasound 
echogenicity – 35, Sonographer 3: muscle depth – 105, ultrasound echogenicity – 35.   




Table 3.3 - Intra-rater variability for anterior thigh muscle depths and ultrasound 




 Healthy Older Adult Frail Older Adult 



































Table shows the variability when comparing measurements from the right to the left 
and variability within the replicates.  Measurements for bilateral variability are mean of 
three replicates.  Numbers given are intra-class coefficient, 2-way mixed, absolute 
agreement and single measures.  Interpreting ICC using Koo and Li criteria: >0.9 = 
excellent reliability, 0.75-0.9 = good reliability, 0.5-0.75 = moderate reliability and <0.5 = 
poor reliability.  Values starred indicate those of excellent reliability.  Below are the 
number of measurements included in ICC statistical test for each criteria.  
Bilateral variability.  The variability between right and left thigh measurements.   Healthy 
Older Adult: muscle depth – 80,  ultrasound echogenicity – 31, Frail Older Adult: muscle 
depth – 58, ultrasound echogenicity – 17.   
Intra-rater variability.  The variability within replicates:  Healthy Older Adult: muscle 
depth – 160,  ultrasound echogenicity – 44, Frail Older Adult: muscle depth – 124, 
ultrasound echogenicity – 31.   




3.4 Identification of low muscle mass in older adults    
3.4.1 Bilateral Anterior Thigh Thickness 
The mean bilateral anterior thigh thickness (BATT) for healthy young women was 60.64 
mm and for healthy young men was 75.78 mm.  Both datasets were normally distributed 
(male dataset 3 outliers excluded).  The standard deviation was 11.1 mm and 10.71 mm 
for women and men respectively.  Therefore, the cut off using the BATT for low muscle 
mass identification in older adults was 38.53 mm in women and 54.36 mm in men in this 
population.  (Table 3.4)   
 
In a community based healthy older adult population using the EWGSOP classification of 
sarcopenia (11) with the BATT criteria for identification of low muscle mass: 51.3% 
(20/39) were identified as having low muscle mass but only 2.6% (1/39) were diagnosed 
as having sarcopenia. (Figure 3.1)   
 
In a frail older adult population using the EWGSOP classification of sarcopenia with the 
BATT criteria for identification of low muscle mass: 93.5% (29/31) were identified as 
having low muscle mass, 80.6% (25/31) were then further classified as having severe 
sarcopenia and 9.7% (3/31) were classified as having sarcopenia.  (Figure 3.1)  For further 
discussion on sarcopenia prevalence and the relationship with frailty please see chapter 
six.   
 
The BATT correlated with physical markers of performance, namely both grip strength 




grip and BATT for men, R=0.619, p<0.001, both assessed by Spearman’s correlation 
coefficient two-tailed test.  Walk time and BATT for women, R=-0.599, p<0.001.  Walk 
time and BATT for men, R=-0.324, p=0.003.  (Figure 3.2).  The regression line was 
different for men and women, there was an increased gradient of the regression line for 
the male population; the same increase in muscle size for both genders resulted in 
smaller gains to muscle strength for women. 
3.4.2 Forearm thickness  
Forearm thickness was measured in a subset of the healthy younger adult population 
(N=77).  The mean forearm thickness of the right arm was 34.54 mm for HY women 
(N=35) and 43.52 mm for men (N=42).  Both datasets were normally distributed.  The 
standard deviation was 2.87 mm and 3.06 mm for women and men respectively.  
Therefore, the criteria for low muscle mass using forearm thickness for low muscle mass 
identification in sarcopenia in older adults is 28.8 mm in women and 37.4 mm in men.  









































Prevalence of sarcopenia within each cohort expressed as percentage of total number of 
individuals within the cohort.  Low muscle mass defined as BATT less than 38.55mm for 
women and 54.36 for men.  Sarcopenia defined as BATT less than 38.55mm for women 
and 54.36 for men and either gait speed of less than 0.8 m/sec or grip strength in highest 
performing hand less than the cut off for lowest 20% for gender and BMI in over 65s.  
Severe sarcopenia defined as BATT less than 38.55mm for women and 54.36 for men and 
gait speed of less than 0.8m/sec and grip strength in highest performing hand less than 
the cut off for lowest 20% for gender and BMI  in over 65 population.   














Table 3.4 - Identification of low muscle mass criteria using ultrasound  
 
Women BATT < 38.55 
Forearm Thickness < 28.8 
Men BATT < 54.36 











Adjusted Hand Grip Adjusted Hand Grip 
Correlation of grip strength with BATT in A – women and B – men.  Hand grip 
adjusted for gender and BMI (fold change of cut-off low lowest 20% for gender 
and BMI in over 65) plotted against BATT (sum of rectus femoris depth right and 
left and vastus intermedius right and left).   BATT is given in mm.  BATT was 
normally distributed in women, all other data sets not normally distributed.    
A – N=95.  Spearman’s correlation coefficient. 2-tailed.  R=0.750. P<0.001  















Table displays low muscle mass criteria for women and men.  Low muscle mass criteria 
derived from two standard deviations below the mean in a healthy younger 





3.5 Reliability of BATT as a measure of low muscle mass identification 
To determine the effect of height on muscle thickness in our populations the BATT was 
correlated with muscle thickness.  There was no association between height and muscle 
thickness in any of the three cohorts which suggests differences in height do not result in 
differences in muscle thickness.  (Table 3.5) A height adjusted BATT (BATT (mm) /ht (m)) 
showed weaker correlation with muscle strength than a non-adjusted value.  All data 
included (HY, HO and FO) for Spearman’s correlation coefficient. BATT with grip strength: 
R=0.812, p<0.001.  Height adjusted BATT with grip strength: R=0.737, p<0.001.       
 
Table 3.5 – Correlation of BATT with height for the three separate groups 
 
 Male Female 
Healthy Young Adults R = -0.74 
P = 0.578 
R = 0.190 
P= 0.098 
Healthy Older Adults R = 0.109 
P = 0.735 
R = 0.064 
P = 0.777 
Frail Older Adults R = -0.193 
P = 0.509 
R = 0.330 









Correlation of height measured in metres with BATT measured in mm.  Data sets are all 
normally distributed except HY Male BATT, FO Female BATT and FO Male BATT.  Data 
given are Spearman’s correlation coefficient.   





3.6 Ultrasound echogenicity 
 ‘Muscle quality’ (muscle strength or power per unit of muscle mass) (261) is considered 
to be as, or more, important as muscle mass in the development of sarcopenia and 
frailty.  Ultrasound echogenicity has been suggested as a tool to assess muscle quality 
(262) but its utility in frail older adults has not been investigated.  
Visual interpretation of ultrasound scans suggested that there was increased ultrasound 
echogenicity in scans from frail older adults.  The method of determination of ultrasound 
echogenicity is discussed in chapter two and is adapted from the method suggested by 
Harris-Love (257).   Figure 3.3 depicts representative ultrasound images from a healthy 
older and frail older individual. 
Ultrasound echogenicity increased with both age and frailty.  Ultrasound echogenicity 
(values adjusted to HY population: median +/- IQR) - HY: 0.95+/-0.31, HO: 1.48+/-0.55, 
FO: 1.80+/-0.88.  (Figure 3.4.)  Ultrasound echogenicity was not related to BMI, 
ultrasound echogenicity and BMI:  R = 0.061, p = 0.465 by Spearman’s correlation 
coefficient.  Ultrasound echogenicity was also unrelated to subcutaneous tissue depth, 
ultrasound echogenicity and subcutaneous tissue depth:  R = -0.060, p = 0.475.  However 
it was correlated with the physical parameters of sarcopenia, muscle strength and 
physical performance (Figure 3.5).  Ultrasound echogenicity and adjusted hand grip 
strength:  R = -0.529, p<0.001 by Spearman’s correlation coefficient.  Ultrasound 
echogenicity and walk time:  R = -0.302, p<0.001 by Spearman’s correlation coefficient.  
This effect was independent of muscle size.  Ultrasound echogenicity and adjusted hand 




Ultrasound echogenicity and walk time controlling for BATT:  R = -0.306, p<0.001 by 
Partial correlation coefficient.   
Linear regression suggests that ultrasound echogenicity has a larger effect on muscle 
strength than muscle size.  Every increase in the fold change of ultrasound echogenicity 
by 0.46 resulted in a decrease in the adjusted hand grip by 0.17.  (Table 3.6)      
 
Figure 3.3 – Representative ultrasound scans of anterior thigh in a healthy young adult 













Ultrasound scans from A – healthy younger adult B – frail older adult.  Anatomical 
structures from top of scan to bottom – skin, subcutaneous tissue (marked by first 
yellow measuring line), rectus femoris (marked by second yellow measuring line), 
vastus intermedius (marked by third yellow measuring line), femur.  It is possible 
to see increased ultrasound echogenicity in both rectus femoris and vastus 
intermedius in frail older adults compared to the healthy younger adult.  Increased 












































Ultrasound echogenicity of healthy young adults (HY), healthy older adults (HO) and 
frail older adults (FO).  Ultrasound echogenicity is expressed as fold change of healthy 
younger adults to allow data from two different instruments to be analysed together.  
HY and HO not normally distributed.  Data shown are median +/- IQR. HY – 99, HO – 
33, FO – 16  
HY – 0.95+/- 0.31, HO – 1.48 +/- 0.55, FO – 1.80 +/- 0.88. 
Kruskal-Wallis test: p<0.001, post-hoc pairwise comparisons with Bonferroni 












Table 3.6 - Multiple linear regression of model 1 – BATT and model 2 – BATT and 
ultrasound echogenicity 






























































Ultrasound echogenicity and adjusted hand grip strength.  Ultrasound echogenicity is 
expressed as fold change of healthy younger adults to allow data from two different 
instruments to be analysed together.  Hand grip adjusted for gender and BMI (fold 
change of cut-off low lowest 20% for gender and BMI in over 65).  N=148.  Neither 
data set was normally distributed. 
Ultrasound echogenicity and adjusted hand grip.  R= -0.529, p<0.001.  Spearman’s 
correlation coefficient. 





This chapter has reviewed ultrasound as a diagnostic technique in the identification of 
sarcopenia using a simple scanning protocol to produce the BATT that can be utilised in 
both a clinical and research setting to diagnose low muscle mass.  It has also measured 
the BATT in a reference population, 113 in total, and proposed criteria for the 
identification of low muscle mass in older adults based on this reference population. It 
provides evidence for routinely reviewing muscle quality in sarcopenia and suggests that 
ultrasound echogenicity can act as an appropriate surrogate marker for muscle quality in 
research (where the sonographer can be standardised) but not clinical practice.     
To consider the use of ultrasound as a diagnostic tool in both clinical and research 
settings a number of factors, such as accuracy, reliability and bias, need to be considered; 
most of these have been addressed in this chapter but there are flaws in the study 
methodology which mean the results presented in this chapter need to be interpreted 
with caution.  The most significant limitation is the absence of a comparison of 
ultrasound both as a diagnostic tool and also the proposed BATT criteria to a gold 
standard technique.  It is also important to consider the two potential roles for 
ultrasound, identification of low muscle mass and identification of poor muscle quality, 
separately due to the reported differences in reliability.   
Current gold standard diagnostic methods for the identification of low muscle mass are 
neither easily accessible nor suitable for assessing frail older adults particularly those 
within the community setting.  Assessment of muscle mass using MRI, CT and DXA 
scanners is expensive and multiple physical and cognitive barriers exist preventing a frail 




utilising these methods in a frail population is non-attendance; 12% of all NHS outpatient 
clinic appointments are not attended; the most frequent reasons for not attending are: 
forgetting (33%), not well enough to attend (15.2%), caring responsibilities (12.1%) and 
lack of transport (6.1%) (263, 264).  These studies were not completed in an older adult 
population but the declared reasons for non-attendance are particularly generalisable to 
an older adult population.  CT, MRI and to a lesser extent DXA all require comprehension 
and adherence to instructions and this can preclude their use in older adults with 
cognitive impairment.  The most clinically important difference between ultrasound and 
the gold standard techniques is the portability of the machine allowing an immediate 
diagnosis and management plan to be made.  This is essential in an older adult 
population where timely intervention is fundamental to good care and the intervention 
can be carefully explained to all those involved in an individual’s care.  In a frail older 
adult population those most vulnerable to the consequences of sarcopenia are those 
most likely to be lost to follow up due to poor mobility, difficulty accessing transport, 
inability to read and understand appointment letters, memory impairment and increased 
risk of inter-current illness.  A portable method of identification of low muscle mass is 
particularly important in this subsection of the older adult population.       
An alternative portable diagnostic technique to ultrasound is BIA but this can be 
unsuitable in a population with a high prevalence of co-morbidities that affect fluid 
balance.  There has been limited validation of BIA as a technique to determine muscle 
mass in healthy older adults and none in frail older adults (265-268).  Original BIA 
machines were able to diagnose fat free mass or proportion of fat within the body; newer 




(269).  A recent study has demonstrated that current protocols in use are not accurate in 
older adults with functional impairment, over-estimating muscle mass (270).  BIA does 
not provide information on muscle quality but the technique is simpler and quicker than 
ultrasound.  The role of BIA in the diagnosis of low muscle mass in a frail older adult 
population needs to be further investigated particularly in comparison with both 
ultrasound and a gold-standard method.   
In section 3.2 data are presented that support the repeatability, reproducibility and 
accuracy of ultrasound as a diagnostic tool in the measurement of muscle depth by lay 
sonographers.  It demonstrates that three sonographers with no prior experience in the 
practical application of ultrasound following a period of minimal training were able to 
reproduce measurements on healthy young individuals with excellent consistency.  It also 
shows excellent consistency between measurements taken on different ultrasound 
instruments, namely a static and portable instrument in healthy young adults.  There was 
also excellent consistency between the replicates from each sonographer in the healthy 
young and frail older adults and good consistency between the replicates from healthy 
older adults suggesting acceptable repeatability within all the populations.   
One of the concerns of applying techniques originally investigated and refined in healthy 
younger adults to healthy older and frail older adults is that the degree of variability 
within the older population renders these techniques inaccurate (250).  However, the 
data presented in this chapter demonstrate that the variability witnessed in the healthy 
older and frail older population was comparable to the variability witnessed in the 




these data.  The accuracy of the data, the degree to which the measurement of muscle 
thickness represents muscle mass, is not possible to calculate without comparison to a 
gold standard which is absent in this study.  However, there is a significant correlation 
between muscle thickness and physical parameters indicative of muscle health such as 
grip strength and walk speed which suggests ultrasound determination of muscle 
thickness is an accurate method of measuring muscle mass.  The accuracy of ultrasound 
in the estimation of muscle quality is discussed later in this chapter.     
This chapter also proposes the BATT as a novel method for the identification of low 
muscle mass.  The BATT is a composite measure of muscle thickness from four different 
muscles in the anterior thigh incorporating bilateral measurements.  A composite 
measure including both right and left legs was considered to be more accurate than a 
single measure because of the degree of bilateral variability demonstrated in both the 
healthy and frail older adults.  Lower limb measurements were included rather than 
upper limb measurements for two reasons: one, it has been demonstrated that older 
adults lose muscle preferentially from the lower limbs (271); two, loss of independence in 
the basic activities of daily living is primarily dependent on lower limb rather than upper 
limb performance (272).  The raw muscle thicknesses were included in the BATT rather 
than a muscle thickness adjusted for height.  This is similar to other ultrasound studies 
(249, 273) though there are a variety of methods within the literature including those 
which do adjust for height (274).  Abe and colleagues demonstrated that adjustment for 
height did not improve their correlations of muscle thickness with muscle strength or 
physical performance, or improve the accuracy of their predictive models (275).  




between muscle thickness and height (276).  The data presented in this chapter also 
demonstrate no relationship between muscle thickness and height for all three groups 
and adjustment for height weakened the correlation with physical parameters.  It could 
be argued that the BATT is a simplistic approach to determination of muscle mass as it 
measures a thickness, one dimension, rather than area, two dimensions or volume or 
weight, three dimensions.  However, a recent study has demonstrated that ultrasound 
determination of mid-femur vastus lateralis muscle thickness was significantly correlated 
with both volume and cross-sectional area of the muscle measured by MRI (277).       
The proposed BATT criteria for low muscle mass were derived from the healthy young 
reference population; gender specific, two standard deviations below the mean of the 
reference population.  This criterion has been suggested by EWGSOP and is identical to 
criteria used to identify osteoporosis (11).  Although the reference population is not 
extensive, 113 in total, 59 men and 54 women, appendicular lean muscle mass measured 
by BIA in our reference population is almost identical to values quoted in multiple studies 
with much larger sample sizes and calculated using a variety of methods (two standard 
deviations below the mean of a healthy young population and lowest gender specific 20% 
in older adults) (11).  This suggests that the sample is representative of a healthy young 
adult population and the proposed criterion for the diagnosis of low muscle mass in older 
adults (BATT) has been created from an appropriate reference population.  Three outliers 
were excluded from the male population to ensure a normal distribution of the data; 
calculation of low muscle mass criteria using two standard deviations below the mean 




data may have introduced bias into the results; increasing the reference population size 
would hopefully ameliorate the effect of outliers on the quoted BATT criteria.   
It could be suggested that the reference population is not representative of an average 
UK younger adult population.  The BMI for the reference population for men was 24.3 
and for women was 21.7, whereas national averages in these age groups are 25.1 for men 
and 25.3 for women (278).  73% of the men and 70.4% of the women in the reference 
population met government recommendations for physical activity whereas the national 
average is only 67% of men and 55% of women (279).  The increased amounts of physical 
activity in the reference population could result in an increased muscle mass which may 
not be representative of an average UK younger adult population.  However, considering 
the term ‘healthy’ in the truest sense, the absence of chronic disease plus meeting target 
recommendations for exercise and activity, the reference population could be argued to 
be a more appropriate comparison population than the national average.   
A further limitation of the study is that the healthy young reference population included 
individuals from a variety of ethnicities.  The majority of the healthy young reference 
population was white (British, Irish, Brazilian and other European countries), 85.8%.  The 
remainder of the healthy young reference population was Asian (9.7%), Arab (1.8%), 
Black African (1.8%) and Chinese (0.6%).  The healthy older and frail older adults were all 
white either British or Irish.  There are ethnic differences in skeletal muscle mass with 
African Americans having increased skeletal muscle mass and Asian Americans having 
decreased skeletal muscle mass compared to white Americans (280).  Whilst the 




frail older adults described in this study it cannot be extrapolated to be used in other 
non-white ethnic groups.         
The female healthy older and frail groups were significantly shorter and heavier than the 
healthy young adult group whereas the male healthy older and frail older groups were 
comparable to the healthy young adult group.  This is likely secondary to both the effect 
of osteoporosis and osteopenia on vertebral height and nutritional deficiencies during 
the war and post-war rationing in childhood and young adulthood.  Women are more 
likely to suffer from malnutrition due to the double burden of increased requirements 
secondary to menstruation and motherhood, and gender inequality (281). However, as 
discussed before height does not appear to have an effect on muscle thickness, so the 
BATT criteria can be appropriately applied to the female healthy older and frail older 
populations.      
This chapter also presents the data for forearm thickness in a smaller subset of healthy 
young adults.  Whilst this chapter does not present the rigorous comparison data for 
healthy older and frail older adults, the forearm thickness data was included for two 
reasons: one, others have demonstrated its relationship with physical performance and 
muscle strength (273); two, the clinical utility of the technique particularly in a 
community based frail population.  It is recognised that the relatively small data set limits 
these data’s use but it was included because it is hoped that further research will 
acknowledge the potential of forearm thickness in sarcopenia diagnosis and add to this 




The hierarchical nature of sarcopenia diagnosis, with low muscle mass an obligatory 
component but not the sole criteria, suggests that the identification of low muscle mass 
could be considered as a screening step in the diagnosis of the syndrome.  As a screening 
tool the sensitivity should be high and this may be achieved at the detriment of the 
specificity.  The current lack of evidence for any management of low muscle mass but 
conservative management would ensure that the potential negative impacts of false 
positives would be limited.  However, this would need to be reconsidered if a 
pharmacological management was proven to be of benefit.     
In the era of personalised medicine a diagnostic criterion for sarcopenia that includes a 
blanket definition of low muscle mass regardless of height, weight or body composition 
seems rather inelegant and potentially inaccurate.  Particularly as research suggests that 
muscle loss with ageing occurs differently with gender and ethnicity (280) and there are 
generational differences in diet, lifestyle and body composition.  I propose that further 
research should be conducted to inform criteria for diagnosis that closely mimic loss of 
function.  Further longitudinal work is required to consider the relationship of muscle 
strength, muscle size and physical performance with outcomes of independence and 
well-being over an extended period of time.         
The chapter provides evidence for routinely reviewing muscle quality in sarcopenia and 
furthermore suggests that ultrasound echogenicity can act as an appropriate surrogate 
marker for muscle quality.  There was a significant difference between the echogenicity 
of the three groups and there appears to be a difference in echogenicity of healthy older 




be confirmed with statistical tests.  This difference is independent of age.  Modelling the 
data suggests that ultrasound echogenicity is of the same if not of more importance than 
muscle size in the determination of muscle strength.  Whilst the groups are not large 
enough to draw complete conclusions there is significant evidence that ultrasound 
echogenicity is an excellent surrogate marker or component of muscle quality and should 
be included in further research studies.  Higher ultrasound echogenicity values have been 
previously demonstrated to be associated with sarcopenia in older adults (250, 257).    
Section 3.2 highlights the difficulties in measuring ultrasound echogenicity with the 
currently available equipment; there are limitations with the method, and measurements 
from different sonographers and instruments are not reproducible.  However, there was 
good to excellent repeatability suggesting data from one sonographer on one machine 
can be considered reliable.  While it would not be possible to standardise both the 
sonographer and machine in a clinical environment it is feasible that both could be 
standardised for research purposes.  As presented here an alternative to using a single 
instrument is that measurements on different instruments by one sonographer can be 
standardised to the healthy young adult mean value.  The witnessed differences in 
measurements between the different sonographers is hypothesised to be secondary to 
different scanning techniques probably related to the pressure applied with the probe, 
angle of incidence (the angle at which ultrasound waves encounter the anatomical 
structure) and volume of contact gel.  Following analysis of sonographer one and 
sonographer two and considering differences in technique to be the probable cause for 
witnessed differences in ultrasound echogenicity the scanning technique for sonographer 




between the two sonographers the confidence intervals remained very large suggesting 
an unacceptable degree of variability.  The difference between the two machines is likely 
to be due to discrepancies in clarity secondary to both hardware and software.  The 
difference witnessed between the two machines is unlikely to follow an entirely linear 
relationship because whilst re-running the ICC analysing consistency rather than absolute 
agreement does improve the agreement it is still not of acceptable agreement 
(ICC=0.521. 0.333-0.669).  A previous study has suggested a method of calibrating a form 
of ultrasound echogenicity which allows comparisons from different machines with both 
different software and hardware to be made (282).  A further limitation of the method 
that cannot be currently standardised is the effect of different depths of overlying 
subcutaneous tissue on muscle echogenicity measures.  Subjective assessment of the 
images suggested that there was increased echogenicity of the rectus femoris compared 
to the vastus intermedius and this was confirmed with objective assessment in a small 
subset of the complete sample.  Echogenicity is a measure of acoustic reflectance but 
deep structures may appear hypoechoic because the incident ultrasound beam is weak 
from attenuation resulting in diminished returning echoes.  Interestingly this has not 
been previously discussed in the literature in the context of sarcopenia or sarcopenic 
obesity.    
It is however possible to conceptualise an ultrasound instrument that could standardise 
both the pressure applied through the probe and the angle of incidence plus be able to 
run algorithms that could standardise the effect of the overlying tissue.  This could 
improve the accuracy of the technique and ensure that values taken by different 




This evidence all supports the use of ultrasound as a method to identify low muscle mass 
in sarcopenia diagnoses.  Sarcopenia is rarely formally diagnosed in clinical practice with 
the most significant barriers to diagnosis being availability and accessibility of DXA or 
other gold standard diagnostic methods for identification of low muscle mass.  The 
relative ease of measuring the other two criteria, low muscle strength and poor physical 
performance, suggests that if low muscle mass could be easily identified sarcopenia 
would be more likely to be diagnosed.  Ultrasound provides a pragmatic diagnostic tool 
that is: non-invasive, with no radiation exposure, and can be used within both community 
and hospital settings.  The proposed BATT criteria are a simple method of identification of 
low muscle mass which have excellent correlation with physical parameters of muscle 
health.  However, the absence of a gold standard comparison in this study precludes 
widespread adoption of this protocol.  In addition whilst this chapter has demonstrated 
the importance of ultrasound echogenicity in sarcopenia and physical function it has not 
established an accurate or reproducible approach to its measurement.  Further research 
on the comparison of the BATT protocol with gold standard techniques of low muscle 












4. Muscle biopsy is not a 
feasible tool in a 















Sarcopenia, the loss of muscle mass and physical function in older adults, and frailty, a 
syndrome of diminished strength, endurance, and reduced physiological function that 
increases the risk of adverse outcomes, are both common conditions affecting older 
adults (4, 11).  The pathophysiology of both syndromes is complex and incompletely 
characterised however, muscle health is central to both conditions (283).  ‘Muscle 
quality’ (muscle strength or power per unit of muscle mass) (261) is considered to be as, 
or more, important as muscle mass in the development of sarcopenia and frailty. In 
Chapter 3 the association of ultrasound echogenicity, a marker of muscle quality, with 
physical parameters was demonstrated. Factors affecting the quality of the muscle 
include: morphological characteristics of the muscle, aerobic capacity, intramuscular 
adipose tissue, fibrous tissue and motor units (256).       
Investigators with research interests that include sarcopenia and frailty require muscle 
tissue to investigate factors contributing to muscle quality; due to the complexities of 
both syndromes animal models are unlikely to provide an adequate model for 
investigation although they do exist (284).  Animal models which utilise the manipulation 
of a single gene, such as the IL-10 knock out mouse, are often considered too 
pathophysiologically simplistic to represent a multi-system human syndrome.  The IL-10 
knock out mouse models do not fully express the frailty phenotype, no decrease in 
physical activity or weight loss in the mouse models, so cannot be considered a complete 
representation of frailty.  Animal models of premature ageing are more complex but 
whether the ageing witnessed in these models occurs by the same pathophysiological 




Muscle tissue from humans can be obtained from either a percutaneous muscle biopsy or 
as a by-product of surgery.  Percutaneous muscle biopsy is preferred for most research 
because muscle tissue acquired as a by-product of surgery will be by definition not from 
healthy older adults and it can be difficult to separate the effects of inflammatory 
conditions such as arthritis from the effects of sarcopenia and frailty.  Percutaneous 
muscle biopsy encompasses both the conchotome forceps technique and needle biopsy 
techniques (286).  Percutaneous muscle biopsy has been used with success on multiple 
occasions in individuals with sarcopenia (287-289) and on fewer occasions in frailty (290).  
A recent study in the UK reported on both the acceptability and feasibility of muscle 
biopsy in an older community dwelling male population and highlighted the importance 
of completing this type of study in a frail population (289).  Anecdotal evidence has 
described difficulties in obtaining good muscle samples (reasonable weight sample sizes 
with minimal attached subcutaneous tissue) from muscle biopsy in older community 
dwelling women (291).  
This chapter reports on the difficulties of obtaining muscle samples using a Bergstrom 
needle technique in a frail older adult population (292) and potential problems in 
obtaining reasonable muscle sample sizes in both healthy older adults and frail older 
adults.  The chapter discusses participant factors resulting in contra-indications to muscle 
biopsy; these have been categorised as: safety of biopsy, ability to attend for biopsy, 
ability to care for wound post biopsy and anticipated high risk for complications.  
Examples for each category are described in table 4.1 and are specific to this sample; the 




Table 4.1 – Participant factors both absolute and relative contraindications.      




Safety of biopsy  Anti-coagulation (293) 
 Anti-platelet (293) 
 Anticipated difficulties 
with positioning for 
biopsy  
 
Ability to attend for a biopsy  Disengagement with 
services/research study 
 Death  
 Started on palliative 
treatment 
 New diagnosis of cancer 
 Loss of capacity 
 Frequent attendances 
at hospital  
 
Ability to care for wound 
post-biopsy 
  Unable to complete 
personal care  
 Visual impairment 
Anticipated high risk for 
complications 






Anti-coagulation and anti-platelet therapy are considered an absolute contraindication to 
muscle biopsy; clinical guidelines suggest a wash out period prior to biopsy (293).  For this 
study all individuals on anti-coagulation or anti-platelet therapy were excluded from 
consideration for a muscle biopsy however, a previous study which judged individuals to 
be taking anti-platelets for primary prevention and low risk for cardiovascular 
complications paused aspirin for a period of four to seven days prior to muscle biopsy for 
research (294).  The other contraindications are proposed on pragmatic grounds.  All the 
Participant factors present in the frail older adult population that are contra-indications 
to muscle biopsy.  Absolute contra-indications cannot be ameliorated.  Relative contra-




proposed contraindications occurred in the frail older individuals and were considered by 
two experienced geriatricians prior to the individual’s exclusion from the muscle biopsy 
sub-study.   
Muscle biopsies, particularly from the vastus intermedius, are considered an extremely 
safe procedure.  The most common complications are intra-procedure pain and 
numbness of the leg post-procedure (289).  The pain is frequently described as 
discomfort and was reported to not deter participants considering a further biopsy (289).  
Serious wound infections or disability have not been reported in the literature.  The 
aftercare of a muscle biopsy site is relatively simple and most individuals are able to care 
for their own wound; dressing change at four days and removal of steri-strips at seven 
days plus avoidance of vigorous activity for 72 hours and immersion in water for 48-72 
hours (293).  Individuals unable to complete their own personal care due to physical 
disability were excluded from the study as it was considered they would be unable to 
adequately care for their wound site.  Individuals with significant visual impairment were 
also excluded as ability to review the wound for signs of infection was considered 
essential.  Although beyond the scope of this study these contraindications could be 
potentially ameliorated in future studies with the appropriate resources, for example 
daily nursing care to care for the incision post-operatively.  These contra-indications 
which could be potentially mitigated are therefore considered relative rather than 
absolute.   
Anticipated difficulties with positioning for the biopsy describes a number of individuals 




Parkinson’s Disease that would preclude adequate positioning, severe chronic back pain 
that would prevent an individual from remaining in a semi-recumbent position for thirty 
minutes and an individual with morbid obesity where following ultrasound assessment of 
the thigh it was judged the Bergstrom needle window would not reach the muscle due to 
the increased depth of the subcutaneous tissue.   
Disengagement with services describes both those individuals who became 
uncontactable after the first or second contact or those who were unwilling to return to 
the hospital for the purpose of the study.  Frequent attendances at hospital describes a 
number of individuals who following their recruitment to the study were admitted to 
hospital a number of times during the subsequent year; these individuals were judged to 
never be well enough for muscle biopsy.  Death and starting on palliative treatment 
within the year following recruitment were considered to be an absolute contra-
indication.  An individual with a new diagnosis of cancer was excluded because of the 
effect of cancer cachexia on muscle.  There was no provision in the study ethics for 
inclusion of individuals who did not have capacity.  All participants at the time of 
recruitment had capacity but a number lost their ability to consent before a muscle 
biopsy could be organised.                    
Multiple falls (more than one a month) was considered an anticipated high risk for 
complications due to the potential for damage of the healing biopsy site on falling and 




Contraindications that have been previously reported in muscle biopsy studies in 
sarcopenic individuals but did not occur in this sample (therefore not listed) are 
medications that impair healing such as steroids and methotrexate (11). 
 
 
This chapter aims to: 
 Consider the prevalence of contraindications to muscle biopsy in both a healthy and 
frail older adult population 
 Consider the impact of muscle thickness on the success of muscle biopsy in both 
healthy and frail older adults  













40 HO and 37 FO adults were recruited to the study; their demographic data is described 
below.  (Table 4.2)   
Table 4.2 – Demographic data of recruited participants  
 Healthy Older 
Adults 
Frail Older Adults MW 
Gender 67.5% (27) Female 
32.5% (13) Male 
54.1% (20) Female 
45.9% (17) Male 
 
Age 71.9 +/- 9.0 84.0 +/- 15.0 p<0.000 
BMI 23.4 +/- 4.0 24.9 +/- 7.0 p=0.782 
FI 0.03 +/-0.07 0.41 +/- 0.17 p<0.000 
    
 
 
 4.3 Contraindications to muscle biopsy    
Seven (17.5%) healthy older adults had a recognised contraindication to muscle biopsy.  
All seven participants were precluded from undergoing a muscle biopsy due to the safety 
of biopsy; this was secondary to anti-platelet or anti-coagulant use.  One of the healthy 
older adults in addition to taking an anti-coagulant subsequently became chronically 
unwell which would have prevented them from attending for a muscle biopsy within the 
follow up period (one year).  In stark comparison only two (5.4%) of the frail older adults 
did not have a contraindication to muscle biopsy.  (Table 4.3).  
 
The majority of frail older adults had more than one contraindication to muscle biopsy; 
12 (32.4%) had a single contraindication, 15 (40.5%) had two, 5 (13.5%) had three, 2 
(5.4%) had four and 1 (2.7%) had five contraindications.  The contra-indications were 
Data sets: HO – 40, FO – 37.  Median +/- IQR given.  Categorical data is given as 
percentage of total population with raw number in brackets.  All data not normally 
distributed except FO Age and FO FI.  Statistical difference analysed with Independent 




grouped in to four categories: safety of muscle biopsy, inability to attend for muscle 
biopsy, inability to complete own personal care and anticipated high complication rates 
post-biopsy.  Inability to attend and safety of the biopsy were the most frequent contra-
indications.  (Table 4.4)  Figure 4.1 demonstrates both the frequency of each contra-
indication and the number of participants with multiple contraindications illustrating the 
complexities of the individuals.      
 
Considering the contraindications to muscle biopsy as either absolute, cannot be 
ameliorated, for example anti-coagulation, or relative, modifiable with appropriate 
resources, the number of frail older adults who could potentially undergo a muscle 
biopsy increased to 4 (10.8%).  (Table 4.5)      
 
Table 4.3 – Prevalence of contra-indications to muscle biopsy in healthy older and frail 
older populations 
 
 No contraindications Contraindications 
Healthy Older 
Adults 
82.5% (33) 17.5% (7) 






Prevalence of contra-indications to muscle biopsy in healthy older and frail older 
groups.  Percentage of total number in group given with raw number in brackets.   




Table 4.4 – Prevalence of the categorised contra-indications in healthy older and frail 
older population 
 
 Safety Attendance Personal Care Complications 
Healthy Older 
Adults 
17.5% (7) 2.5% (1) 0% (0) 0% (0) 
Frail Older 
Adults 
51.3% (19) 54.1% (20) 35.1% (13) 13.5% (5) 
  
 
   
 
Table 4.5 – Prevalence of absolute and relative contra-indications to muscle biopsy in 
















Prevalence of categorised  contra-indications to muscle biopsy in healthy older and frail 
older groups.  Percentage of individuals with a contraindication in each category given 
with raw number in brackets.   HO – 40, FO – 37.   
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4.4 Muscle thickness 
As described in the methods section, to obtain an adequate muscle sample total muscle 
thickness of the vastus lateralis and underlying vastus intermedius at the site of sampling 
should be thicker than the needle point and window; the total depth of needle point and 
window of a Bergstrom needle is 17.5mm.  Therefore, at a muscle thickness greater than 
17.5mm a muscle sample between 25 and 140mg should be obtained which is an 
adequate size for most laboratory based experiments including Westerns (293).  As 
illustrated in figure 4.2C at a muscle thickness between 9.5mm and 17.5mm a muscle 
sample will be obtained but it may not be of adequate size for experiments and will 
contain subcutaneous tissue.  At a muscle thickness less than 9.5mm no muscle will be 
obtained using a Bergstrom needle biopsy within the biopsy sample.  (Figure 4.2D.)  
Whilst there are no reports in the literature of directly measured muscle depths linked to 
failed Bergstrom needle muscle biopsies there are multiple reports of failed needle 






Frequency of contraindications to muscle biopsy.  Each row represents a single frail 
older individual.  Each column represents the contraindication.  Coloured block 











Research has demonstrated that the combined muscle thickness of rectus femoris and 
vastus intermedius at 50% of the femur length is the same as the muscle thickness of 
vastus lateralis and vastus intermedius at maximum cross-sectional area of vastus 
Illustration of Bergstrom needle muscle biopsy.  Figure A – Bergstrom needle muscle 
biopsy with dimensions.  Figure B – successful Bergstrom needle muscle biopsy with 
labelled anatomical structures.  Figure C – unsuccessful Bergstrom needle muscle 
biopsy in individual with inadequate muscle thickness.  Figure D - unsuccessful 
Bergstrom needle muscle biopsy in individual with inadequate muscle thickness 




intermedius, the location of muscle biopsy site (297).  Therefore, it is possible to take the 
sum total muscle thickness of rectus femoris and vastus intermedius measured at 50% 
femur length as a surrogate measure of muscle thickness at the muscle biopsy site.   
Analysing the entire samples (including those with a contraindication to muscle biopsy) 
there is no risk of a failed biopsy in of healthy older males but there is a risk in 40.7% of 
the healthy older females.  The risk to the individual is that multiple passes may be 
required to obtain an adequately sized muscle biopsy which increases the probability of 
trauma and pain or an inadequate sized muscle sample is obtained which is too small for 
analysis and the procedure was therefore unnecessary.  In the frail older adults only 
18.7% of females and 21.4% of males had adequate muscle depth to ensure a successful 
biopsy.  It would be possible in 68.8% of females and 57.1% of males to obtain some 
muscle from a biopsy but the sample may not be of adequate size or multiple passes 
might be required to obtain an adequate sample.  (Table 4.6)  Figure 4.3 demonstrates 
the spread of the data.  It shows that although there is a risk of an inadequate sized 
muscle biopsy in 41% of healthy older females the muscle samples obtained in these 
individuals are likely to be of sufficient size for analysis because most of the healthy older 
females had muscle thicknesses closer to 17.5mm than 9.5mm.  Conversely in the at risk 
frail older individuals the proportion of muscle thickness between 9.5 mm and 13.5 mm is 
much higher suggesting a real possibility of a failed muscle biopsy: 50% of the at risk 
females and 60% of the at risk males.      
Combining the data on muscle thickness with the data presented on absolute 




research tool in both healthy and frail older adults demonstrates real problems with the 
Bergstrom needle muscle biopsy technique in frail older adults. 
There were 33 healthy older adults who have no contraindications to muscle biopsy, 25 
females and 8 males.  All eight males had adequate muscle thickness for a Bergstrom 
needle biopsy.  20% (5 individuals) of the healthy older females had inadequate muscle 
thickness bilaterally and 20% (5 individuals) of the healthy older females had inadequate 
muscle thickness on a single side.  Therefore, in the total sample size of 40: 82.5% (33) 
had no contraindications to muscle biopsy, 12.5% (5) were at risk of multiple passes or 
failed attempts at muscle biopsy, consequently 70% (28) of the original healthy older 
adult sample had no contraindications and would have sufficient muscle thickness for a 
successful muscle biopsy.        
There are four frail older adults who have either relative or no contraindications to 
muscle biopsy: one male had sufficient muscle thickness for a successful muscle biopsy 
(muscle thickness right leg 22.8 mm and left leg 25.0 mm), two individuals were at risk of 
a failed muscle biopsy (100 year old male muscle thickness right leg 13.65 mm and left leg 
12.7 mm and 85 year old female muscle thickness right leg 10.1 mm and no muscle 
thickness measurements for left leg due to poor image quality), one female was lost to 
follow up prior to ultrasound measurements (not categorised as disengagement as 
reasonable effort was not made by the research team to contact the patient).           





Table 4.6 – Prevalence of muscle depths less than 17.5mm and 13.5mm in healthy older 
adult and frail older adult population 
 




>17.5mm 59.3% (16) 100% (13) 
9.5 - 17.5mm 40.7% (11) 0% (0) 
<9.5mm 0% (0) 0% (0) 
Frail Older 
Adults 
>17.5mm 18.7% (3) 21.4% (3) 
9.5 - 17.5mm 68.8% (11) 57.1% (8) 













Prevalence of muscle depths in healthy older adults and frail older adults.  Numbers 
are percentage of total individuals within group: HO F -27, HO M – 13, FO F – 16, FO 
M – 14.   Raw numbers in brackets.  Risk of failed biopsy – muscle depth less than 
17.5 or 9.5 in right and/or left leg.  17.5 mm is the depth of needle point and window 
and this corresponds to a complete muscle biopsy sample.  9.5 mm is the depth of 
needle point.  Muscle depths between 9.5 and 17.5 mm correspond to an incomplete 














































































































































































































Distribution of muscle thickness. A – healthy older women. B – healthy older men. 
C – frail older women. D – frail older men.  X axis is muscle thickness measured in 
mm.  Y axis is frequency of individuals.  Left of the red line are individuals in who 
no muscle would be obtained using a Bergstrom needle biopsy technique.  Left of 
the green line are individuals who are at risk of inadequate muscle samples using 




4.5 Discussion  
This chapter has reviewed the feasibility of muscle biopsy in both a healthy older adult 
and frail older adult population.  It reports on the difficulties in obtaining muscle samples 
in a frail older adult population and the potential difficulties with obtaining adequately 
sized muscle samples in a healthy older women and frail older adult population.   
Section 4.2.1 describes the numerous contraindications to percutaneous muscle biopsy in 
frail older adults.  It demonstrates that 94.6% of frail older adults had a contraindication 
either absolute or relative to muscle biopsy and that the majority (62.1%) had multiple 
contraindications.  It also established that the majority of these contraindications (89.2%) 
were absolute with no capacity for amelioration.  Whilst this data relates to muscle 
biopsies performed using the Bergstrom technique it is also applicable to the other 
percutaneous muscle biopsy techniques, conchotome forceps and microbiopsy needle 
techniques (286, 298).  The contraindications are the same for all the techniques, 
although it could be argued that the incision with the microbiopsy needle technique is so 
small that the individual being able to perform adequate post-biopsy care would be 
unnecessary.  Nevertheless, even if this was the case only 10.8% of the sample population 
would have no contraindications to muscle biopsy.  These data interpreted together 
suggests that percutaneous muscle biopsy performed on a subset of a relatively small 
sample of frail older adults is not feasible.       
Section 4.2.2 reviews the potential difficulties in obtaining muscle samples of a 
reasonable size in both healthy older adults and frail older adults using a Bergstrom 
needle technique.  There is a risk of an inadequately sized muscle sample of 40.7% in a 




an ‘unnecessary’ procedure this is an unacceptable risk.  In this population the risk can be 
easily ameliorated with ultrasound assessment of muscle depth at the biopsy site.  This 
would raise the success rate of adequate muscle biopsy sample size from 59.3% 
(individuals with adequate muscle depth bilaterally) to 81.5% (individuals with adequate 
muscle depth on at least one side) and would also prevent individuals undergoing an 
unsuccessful procedures.  In the healthy older male population there was no risk of a 
failed muscle biopsy and therefore muscle biopsies could be undertaken without prior 
ultrasound assessment.  There is a considerable risk of a failed muscle biopsy in frail older 
adults, 81.3% in female and 78.5% in male populations.  This risk can be ameliorated to 
some extent by ultrasound assessment of muscle depth at the biopsy site.  This would 
raise the success rate of adequate muscle biopsy sample size from 18.8% in females and 
21.4% in males (individuals with adequate muscle depth bilaterally) to 43.7% in females 
and 50% in males (individuals with adequate muscle depth on at least one side).   
The data presented on the difficulties in obtaining adequate muscle samples in this 
chapter relates to muscle biopsies obtained using a Bergstrom needle technique.  
However it is possible to apply the same rationale to muscle biopsies obtained using 
other percutaneous muscle biopsy techniques, namely conchotome forceps and 
microbiopsy needle technique.  The advantage of using a microbiopsy needle technique is 
the small gauge of the needle causing less trauma to both the muscle and overlying 
tissues.  However, due to the narrowness of the gauge to ensure an adequate sized 
muscle biopsy sample the window is longer.  The tip of the needle to window is 9mm 
which is comparable to the Bergstrom needle but the window length is 19mm over 




inadequately sized muscle sample in individuals with a muscle thickness of less than 
28mm; in this sample population only adequate muscle biopsy samples would be 
obtained in 3.7% (1) of healthy older women, 23.1% (3) of healthy older men and none of 
the frail older adults.  The conchotome forceps are an alternative to a needle biopsy 
technique with the advantage of the researcher being able to operate at shallower 
depths of muscle (293).  However, this is at the expense of increased trauma to the area 
with an incision 5-10mm in length required to access the muscle.  An alternatively 
proposed method for needle biopsy in individuals with low muscle mass is penetrating 
the muscle at a much shallower angle.  The majority of needle biopsy protocols describe 
the needle entering the muscle perpendicularly however it has been suggested that a 
shallower angle will be more successful in individuals with a small muscle thickness (293, 
296).  However, this will disrupt more of the muscle architecture and may therefore not 
be appropriate technique in a research study.     
The data presented in this chapter is contrary to current literature which suggests that 
muscle biopsy is feasible in older adults with frailty and/or sarcopenia.  The paucity of 
negative results in published literature means that whilst muscle biopsy has been 
possible on occasions in these populations it is unclear whether the data presented here 
is an anomaly or a real threat to successful research.  Appropriate study design is 
fundamental to the success of muscle biopsy within these populations and by exploring 
the differences in study design between this sample population and the successful 




The Hertfordshire sarcopenia study reported on the feasibility and acceptability of muscle 
biopsy using the conchotome forceps method in a community dwelling male population.  
The study was able to perform 105 successful muscle biopsies in men of an average age 
of 72.4.  However, 1086 men were screened and only 105 underwent a muscle biopsy.  
Therefore only 9.7% were either eligible or willing to have a muscle biopsy.  Of these 105 
men only 6% had sarcopenia as defined by EWGSOP criteria (289, 299).  This study whilst 
successful in performing muscle biopsies on older males employed a broad screening 
process and included only a small percentage of individuals with sarcopenia.  Alternative 
studies that have specifically performed muscle biopsies on sarcopenic populations 
employ diagnostic criteria of sarcopenia that do not include measures of muscle strength 
or physical performance and could therefore be considered to be criteria of low muscle 
mass rather than sarcopenia (287, 288).  The methods utilised for defining sarcopenia 
included the FNIH criteria (ALM/BMI) in this sample the BMI was high (34.0) and 
therefore sarcopenia could be falsely reported due to high BMI (287).  Muscle biopsies 
were obtained from 43 pre-frail and frail individuals of an average age 78. To obtain a 
total sample population of 62 (of which 43 received a muscle biopsy) 686 individuals 
were originally invited and 233 screened again employing a broad screening process 
before individuals were recruited to the study (290).  
The chapter provides evidence that ultrasound assessment of the biopsy site prior to 
needle insertion should be mandatory in all frail populations and female community 
dwelling older adults.  As part of best practice it could also be performed on male 
community dwelling older adults.  Whilst potentially causing more trauma to the tissue 




more reliable method of obtaining adequate muscle samples.  The data presented in the 
chapter also demonstrates that performing muscle biopsies on a subset of a relatively 
small sample of frail older adults is not possible.  Reviewing the study design of successful 
muscle biopsy studies highlights the importance of a large number of invitees (289, 290).  
In the UK this could be relatively easily achieved with access to general practice 
databases that routinely calculate the electronic frailty index (eFI) along with routine data 
on the use of anti-coagulants, anti-platelets and diagnosis of cognitive impairment.  This 



















5. Neutrophil dysfunction in 




















Frailty is the increased vulnerability of an individual to stressors (4, 300); its 
pathophysiology is uncharacterised but it is postulated that the immune system is central 
to both its development and propagation.  There are known associations with 
inflammation and a dysregulated immune system which are thought to pre-date the 
physical manifestations of frailty (301).  A raised white cell and neutrophil count have 
been associated with frailty along with an increase in the pro-inflammatory cytokines, IL-
6 and TNFα, and the acute phase protein CRP (169-171, 178).  Research has also 
demonstrated that baseline IL-6 and CRP are predictive of muscle strength loss at three 
years (302).  Recent work has shown for the first time that neutrophils from frail older 
adults are functionally compromised; stimulated neutrophils from frail older adults 
produce less chemokine than neutrophils from healthy older adults (208).   
Previous work by has demonstrated dysregulation in the function of neutrophils with an 
individual’s increasing age (163).  To reach interstitial pathogens neutrophils must 
migrate through tissue but as neutrophils migrate they cause obligate tissue damage 
through the release of proteinases and reactive oxygen species(303, 304); therefore it has 
been hypothesised that inaccurate neutrophils will cause an increased amount of tissue 
damage and the associated release of pro-inflammatory cytokines propagating an 
environment of chronic inflammation (233).  The PI3K signalling pathway is central to 
neutrophil motility, and previous work has implicated dysregulation of this pathway in 
the inaccurate neutrophil migration associated with ageing.  Importantly, in vitro 
neutrophil migratory inaccuracy can be corrected with selective PI3K inhibitors, and this 




Previous investigation of immunesenescence and inflammageing has been very limited in 
frailty.  This chapter investigates the functional ability of neutrophils from frail older 
adults, in particular focusing on neutrophil migration, and describes an environment of 
chronic inflammation.     
This chapter aims to  
 Investigate neutrophil migratory dynamics in healthy older and frail older adults 
 Describe the difference in neutrophils from healthy older and frail older adults 
using cell surface markers thought to be fundamental to neutrophil adhesion, 
activation and senescence 
 Investigate the role of PI3 kinase in migratory dynamics in neutrophils from frail 
older adults 













Experiments were conducted on three extensively characterised groups: healthy younger 
adults, healthy older adults and frail older adults.  Not all individuals were included in 
every experiment and therefore slight variations in characteristics are present.  Table 5.1 
describes some of the characteristics in the groups as a whole.  More in depth analysis of 
the three groups is described in Chapter 6. 
Throughout Chapter 5 the data is displayed as either:  
1 – Parametric data.  Mean (Confidence Intervals) 













Table 5.1 – Demographics of healthy young adult, healthy older adults and frail older 
adults.   
 HY HO FO I K-W Pairwise 
comparison 
Number 40 40 37   
Gender % 
(F:M) 
51:49 67:33 54:46   
Age 26.0 +/- 9.8 71.0 +/- 9.0 84.0 +/- 14.8 p<0.001 HY-HO p<0.001 
HY-FO p<0.001 
HO-FO p<0.019 
















1.62 +/- 0.00 1.26 +/- 0.00 0.33 +/- 0.00 p<0.001 HY-HO p<0.007 
HY-FO p<0.001 
HO-FO p<0.001 











Demographics of the three different groups: HY - healthy young adults, HO - healthy 
older adults and FO - frail older adults.  N = HY – 40, HO – 40, FO – 37.  Categorical data 
presented as proportion of total.  Age, frailty index, walk speed and short physical 
performance battery (SPPB) are not distributed normally.  Data given as median +/- IQR.  
Statistical tests are Independent Kruskal-Wallis (I K-W) with pairwise comparison with 
Bonferroni correction.  Adjusted grip strength normally distributed and data given as 
mean with confidence intervals.  Statistical test is ANOVA with post-hoc Tukey’s for 




Migration was assessed using 3 parameters: Average cell speed of movement 
(µm/minute) was measured from the distance travelled between frames, in any direction, 
over time (termed chemokinesis). Average cell velocity (speed in a consistent direction 
towards the chemo-attractant, termed chemotaxis) was measured in µm/minute. Only 
distance travelled in the y-direction over time was included in calculations of chemotaxis.   
Accuracy (termed chemotactic index) was calculated by the cosine of the angle between 
the cell’s direction and the orientation of the chemoattractant gradient at each time 
frame forming a vector analysis of movement, expressed in a comparative scale (cs) 
ranging from −1 to 1, where 1 represents movement directly toward the 
chemoattractant, and −1 represents movement directly away from the chemoattractant 
source in all frames. 
5.3 Neutrophils from healthy and frail older adults do not have a reduction in 
chemokinesis. 
Migratory pathways from individual cells suggested that neutrophils from frail subjects 
migrated more slowly and with less accuracy than those from younger subjects.  Figure 
5.1 shows representative neutrophil migratory pathways as tracked in one healthy young 
subject and one frail older subject.   
There were no significant differences between the chemokinesis of isolated neutrophils 
to either IL-8 and fMLP for the three groups.  However, there was a non-significant 
reduction in chemokinesis towards fMLP across healthy older adults and frail older adults.  
(Figure 5.2.)  Chemokinesis to fMLP (μm/min): HY 4.26 +/- 2.08, HO 3.62 +/- 1.71 and FO 
3.24 +/- 1.13.  Independent Kruskal-Wallis p=0.131.  Chemokinesis to IL-8 (μm/min): HY 




5.4 Neutrophils exhibit an age related decline in chemotaxis to a bacterial 
chemoattractant but a frailty related decline to an endogenous chemoattractant  
Neutrophils from frail older adults showed a reduction in chemotaxis to both a bacterial 
chemoattractant, fMLP, and an endogenous chemoattractant, IL-8.  Neutrophils from 
healthy older adults only showed a significant decline in migratory accuracy to the 
bacterial chemoattractant fMLP; there was preserved chemotaxis to IL-8.  (Figure 5.3.)  
Chemotaxis to fMLP (μm/min): HY 1.68 (1.40-1.95), HO 0.78 (0.49-1.08) and FO 0.92 
(0.48-1.36).  ANOVA p<0.001.  Chemotaxis to IL-8 (μm/min): HY 1.07 (0.72-1.41), HO 0.90 















Figure 5.1 – Representative migratory pathways of neutrophils towards fMLP  
 
 















A - HY B - HO 
Representative migratory pathways of neutrophils to fMLP in A – healthy young adult, B – 
healthy older adult and C – frail older adult.  Migratory pathways of neutrophils over a 12 
minute period standardised to start within the centre of the circular grid.  Chemoattractant 
(fMLP) is at the top of the circle and control (RPMI) at the bottom of the page establishing a 
gradient over the region of the circular grid.   Each line represents one neutrophil with the 
black circle marking the position of the neutrophil following 12 minutes of tracking.  Ten 
neutrophils were tracked for each sample.  The red triangle represents the average position 
of the tracked neutrophils.  The circular lines on the grid are 20μm apart. A – HY: 33M, FI 
0.00.  B – HO: 84M, FI 0.00, C-FO:95F, FI 0.38.           




Figure 5.2 - Chemokinesis of neutrophils  
 





















































Chemokinesis of neutrophils toward A – fMLP and B – IL-8.  Isolated neutrophils from 
healthy young adults (HY), healthy older adults (HO) and frail older adults (FO) migrated 
towards  A -10nM fMLP and B- 100nM IL-8.  Chemokinesis has been calculated and 
expressed as µm/min.  Data sets are median+/-IQR.  Chemokinesis to IL-8 not normally 
distributed.  Chemokinesis to fMLP normally distributed.      
A – N = HY-30, HO-25, FO-22.  .   HY - 22.9, FI 0.01.  HO - 75.6, FI  0.05.  FO - 84.1, FI 0.41.   
Independent Kruskal-Wallis  p=0.131, Post-hoc Dunn’s test all non-significant.   
B - N = HY-30, HO-21, FO-17.  HY – 22.3, FI 0.01.  HO – 76.4, FI-0.06.  FO – 84.1, FI 0.41.  
Independent Kruskal-Wallis  p=0.219, Post-hoc Dunn’s test all non-significant.   
.   
 















































A - fMLP B – IL-8 
Chemotaxis of neutrophils migrating toward A – fMLP and B – IL-8.  Isolated neutrophils from healthy 
young adults (HY),  healthy older adults (HO) and frail older adults (FO) migrated towards;  A -10nM 
fMLP and B- 100nM IL-8.  Each dot represents one participant. Chemotaxis calculated and expressed 
as µm/min.  The line and error bars represent the mean+/-SEM; both normally distributed.     
A: Numbers in each group are as follows: HY-30, HO-25, FO-22. Age and frailty index as follows: HY - 
22.9, FI 0.01.  HO - 75.6, FI  0.05.  FO - 84.1, FI 0.41.  ANOVA p<0.001, Post-hoc Tukey’s – HY-HO 
p<0.001, HY-FO p=0.004, HO-FO p=0.831 
B: Numbers in each group are as follows: HY-30, HO-21, FO-17.   Age and frailty index as follows: HY – 
22.3, FI 0.01.  HO – 76.4, FI-0.06.  FO – 84.1, FI 0.41.  ANOVA p=0.042, Post-hoc Tukey’s – HY-HO 


















5.5 Neutrophil chemotaxis correlates with both physical markers of frailty and 
sarcopenia, and cognitive parameters; this is independent of age.   
To determine whether increasing frailty was associated with decreasing chemotaxis both 
physical markers of frailty, namely grip strength adjusted for gender and BMI (fold change 
of cut-off for lowest 20% for gender and BMI in over 65) and cognitive parameters, 
Stroop score, were correlated with chemotaxis towards fMLP.  There was a linear 
relationship between the markers of frailty and chemotaxis; increasing frailty in an 
individual was associated with decreasing migratory accuracy of their neutrophils.  
Chemotaxis to fMLP (µm/min) and adjusted hand grip. R=0.492. p<0.001.  Chemotaxis to 
fMLP (µm/min) and Stroop score. R=0.430. p=0.002. (Figure 5.4.)  Chemotaxis to fMLP 
(µm/min) and walk time.  R=-0.381. p=0.005.  (Pearson’s correlation coefficient for all.)   
This relationship was independent of age and a partial correlation adjusted for age 
demonstrated significant correlation between both physical and cognitive markers of 
frailty.  Chemotaxis to fMLP (µm/min) and adjusted hand grip and adjusted for age.  
R=0.305.  p=0.005.  Chemotaxis to fMLP (µm/min) and Stroop Score adjusted for age.  
R=0.255. p=0.037.   
Chemotaxis was also associated with indicators of muscle health, ultrasound echogenicity 
and BATT.  Chemotaxis to fMLP (µm/min) and ultrasound echogenicity.  R= -0.371, 
p=0.012.  Chemotaxis to fMLP (µm/min) and adjusted BATT.  R=0.394, p=0.004, 







Figure 5.4 – Correlation of neutrophil chemotaxis to fMLP with adjusted hand grip and 














































A – Hand Grip B - Stroop 
Correlation of neutrophil chemotaxis to fMLP with A – adjusted hand grip strength and B – 
Stroop interference score.  Isolated neutrophils from healthy young adults, healthy older 
adults and frail older adults migrated towards 10nM fMLP; chemotaxis has been calculated 
expressed as µm/min.  Figure 5.4A demonstrates the correlation of chemotaxis to fMLP 
with adjusted hand grip strength and figure 5.4B the correlation of chemotaxis to fMLP with 
Stroop interference score.  Each individual also had grip strength adjusted for gender and 
BMI (fold change of cut-off for lowest 20% for gender and BMI in over 65) calculated and 
Stroop score obtained. All data sets are normally distributed.    
A – N=73.  Pearson’s correlation coefficient. 2-tailed.  R=0.492.  P<0.001  
B – N=51.  Pearson’s correlation coefficient.  2-tailed.  R=0.430.  P=0.002 
 




5.6 Neutrophils exhibit an age related decline in chemotactic index to a bacterial 
chemoattractant but a frailty related decline to an endogenous chemoattractant  
A neutrophil’s ability to migrate efficiently towards a target is dependent on both 
migratory accuracy and speed.  To assess the overall migratory function of neutrophils in 
frailty and old age chemotactic index was compared across the three groups.  The 
chemotactic index of the three groups demonstrated an identical pattern to that 
witnessed with chemotaxis.   
 
There was a significant difference between the chemotactic index to fMLP for the three 
groups but not IL-8. Chemotactic index towards fMLP: HY 0.38cs (0.32-0.44), HO 0.15cs 
(0.09-0.21) and FO 0.21cs (0.13-0.28).  ANOVA p<0.001.  Post-hoc Tukey’s: HY-HO 
p<0.001, HY-FO p<0.001, HO-FO p=0.481.  Chemotactic index towards IL-8: HY 0.24cs 
(0.17-0.31), HO 0.24cs (0.17-0.30) and FO 0.13cs (0.06-0.20).  ANOVA p=0.057.  Post-hoc 
Tukey’s: HY-HO p=0.994, HY-FO p=0.063, HO-FO. p=0.109.   
 
5.7 CXCR1 and CXCR2 expression cannot explain the differences witnessed between the 
migration of neutrophils from healthy older and frail older adults  
The experiments described in this chapter demonstrate preserved migratory accuracy to 
IL-8 in healthy older adults whereas neutrophils from both healthy older and frail older 
adults demonstrate reduced migratory accuracy to fMLP.  To investigate these 
differences the expression of CXCR1 and CXCR2 on the neutrophil cell surface was 





There was no difference in expression of CXCR1 or CXCR2 on the neutrophil cell surface at 
baseline or on stimulation in frail older adults and healthy older adults when compared 
with healthy young adults.  (Figure 5.5.)  CXCR1 US MFI: HY 17512.0 +/-2804.5, HO 
18092.5 +/- 4424.5, FO 15905.8 +/- 4447.0.  Independent Kruskal-Wallis p=0.160.  CXCR1 
S MFI: HY 14954.0 +/- 3227.0, HO 15426.8 +/- 4556.6, FO 14930.3 +/- 3936.3 .  
Independent Kruskal-Wallis p=0.710.  CXCR2 US HY 10856.5 +/- 10035.0, HO 12232.0 +/- 
7181.0, FO 12931.0 +/- 3662.1.  Independent Kruskal-Wallis p=0.788. CXCR2 S HY 8400.5 
+/- 10151.6, HO 9517.0 +/- 4052.3, FO 10576.0 +/- 4151.5.  Independent Kruskal-Wallis  


























































































The MFI of A - CXCR1 and B - CXCR2 expression on neutrophil cell surface in unstimulated cells 
(US) and cells stimulated with 10nM fMLP (S) in healthy young adults (HY), healthy older adults 
(HO) and frail older adults (FO).  Data sets are median +/- IQR.  Data not normally distributed. 
CXCR1 – N for US = HY-13, HO-9, FO-10, N for S = HY-13, HO-10, FO-12.  CXCR1 US MFI: HY 
17812.0 +/-2805.0, HO 28092.5 +/- 4424.5, FO 15905.8 +/- 4447.0, CXCR1 S MFI: HY 14954.0 
+/- 3227.0, HO 15426.8 +/- 4556.6, FO 14930.3 +/- 3936.3 Independent Kruskal-Wallis test US 
p=0.160, S p=0.710  
CXCR2 - N for US = HY-16, HO-9, FO-11, N for S = HY-18, HO-9, FO-15. CXCR2 US HY 10856.5 +/- 
10035.0, HO 12232.0 +/- 7181.0, FO 12931.0 +/- 3662.1, CXCR2 S HY 8400.5 +/- 10151.6, HO 
9517.0 +/- 4052.3, FO 10576.0 +/- 4151.5.  Independent Kruskal-Wallis test US p=0.788, S 











5.8 Neutrophils from frail older adults have reduced expression of the adhesion 
markers CD11a and CD11b whereas neutrophils from healthy older adults have reduced 
expression of CD11b. 
To consider whether differences in neutrophil expression of the β2 integrins Mac-1 and 
LFA-1 (which bind to ICAM-1 during cell-cell adhesion) could explain the reduction in 
chemotaxis witnessed in both frail and healthy older adults the MFI of CD11a, CD11b, 
CD18 and activated 11b expressed on the neutrophil cell surface was measured using 
flow cytometry in unstimulated, time-matched controls (denoted baseline in following 
text) and following stimulation with fMLP.   
There was no difference in the expression of CD18 at baseline or on stimulation but there 
were differences in the expression of CD11a, CD11b and activated CD11b.  MFI of CD18 
US: HY 34431 +/- 10014, HO 30542 +/- 8825, FO 29205.5 +/- 15525.  Independent 
Kruskal-Wallis p=0.514.  CD18 S: HY 57389 +/- 12419, HO 57452.5 +/- 15462, FO 51621 
+/- 19523.  Independent Kruskal-Wallis p=0.278.  CD18 fold change ((Stimulated – 
Baseline)/Baseline) baseline and stimulated: HY 0.8 +/-0.38, HO 0.7 +/- 0.3, FO 0.7 +/- 0.5.  
Independent Kruskal-Wallis p=0.787. 
Neutrophil cell surface expression of CD11a was reduced in frail older adults but not in 
healthy older adults at both baseline and at stimulation.    MFI of CD11a US: HY 1296 +/- 
318, HO 1186 +/- 332, FO 1054 +/- 174.  Independent Kruskal-Wallis p=0.004.  Bonferroni 
corrected pairwise comparisons HY-HO p=1.000, HY-FO p=0.003, HO-FO p=0.028.  CD11a 
S: HY 1270 +/- 454, HO 1242.5 +/- 464, FO 1081 +/- 211.  Independent Kruskal-Wallis 
p=0.005.  Bonferroni corrected pairwise comparisons HY-HO p=1.000, HY-FO p=0.006, 
HO-FO p=0.031.  There was no difference in response to stimulation throughout the three 




stimulated: HY 0.0 +/-0.1, HO 0.0 +/- 0.1, FO 0.1 +/- 0.1.  Independent Kruskal-Wallis 
p=0.951.   
Neutrophil cell surface expression of CD11b was significantly reduced in healthy older 
adults at baseline and on stimulation and there was a trend to reduction in frail older 
adults.  However, the response to stimulation, upregulation, was similar throughout the 
three groups.  MFI of CD11b US: HY 2015.8 +/- 884, HO 1665 +/- 880, FO 1649 +/- 1629.  
Independent Kruskal-Wallis p=0.018.  Bonferroni corrected pairwise comparisons HY-HO 
p=0.039, HY-FO p=0.053, HO-FO p=1.000.  CD11b S: HY 3997.3 +/- 1495, HO 3195.5 +/- 
1241, FO 3180.7 +/- 1673.  Independent Kruskal-Wallis p=0.002.  Bonferroni corrected 
pairwise comparisons HY-HO p=0.002, HY-FO p=0.074, HO-FO p=1.000.  CD11b fold 
change ((Stimulated – Baseline)/Baseline) between baseline and stimulated: HY 0.8 +/- 
0.5, HO 0.7 +/- 0.4, FO 0.75 +/- 1.33.  Independent Kruskal-Wallis p=0.937.    
There was reduced expression of activated CD11b at baseline in healthy older adults and 
on stimulation in both healthy older and frail older adults.  There was a significant 
reduction in the ability of neutrophils from healthy and frail older adults to upregulate 
activated CD11b with stimulation.  MFI of Act11b US: HY 3149 +/- 2944, HO 2992 +/- 955, 
FO 2301 +/- 2260.  Independent Kruskal-Wallis p=0.038.  Bonferroni corrected pairwise 
comparisons HY-HO p=0.037, HY-FO p=0.409, HO-FO p=1.000.  Act11b S: HY 11323 +/- 
7118, HO 5239 +/- 5446, FO 6410 +/- 6393.  Independent Kruskal-Wallis p=0.001.  
Bonferroni corrected pairwise comparisons HY-HO p=0.003, HY-FO p=0.021, HO-FO 
p=1.000.  ActCD11b fold change ((Stimulated – Baseline)/Baseline) between baseline and 




Wallis p=0.002.  Bonferroni corrected pairwise comparisons HY-HO p=0.005, HY-FO 
p=0.021, HO-FO p=1.000.   (Figure 5.6.)     
The reduction in expression of CD11b and ActCD11b correlated with reduced chemotaxis 
to fMLP illustrating the role of Mac-1 in neutrophil migration towards fMLP.  The 
correlation, whilst significant, was not very strong, suggesting this was not the only 
process important in neutrophil migration towards fMLP.  Chemotaxis to fMLP (µm/min) 
and expression of CD11b at baseline (MFI).  R=0.413.  p=0.029.  Pearson’s correlation 
coefficient.  Chemotaxis to fMLP (µm/min) and expression of activated 11b at baseline 
(MFI).  R=0.364.  p=0.038.  (Figure 5.7.)           





































Figure 5.6 – Neutrophil cell surface expression of CD18 at baseline, CD18 on 
stimulation, CD11a at baseline, CD11a on stimulation, CD11b at baseline and Act11b 























































































A – CD18 Baseline B – CD18 Stimulation 
C – CD11a Baseline D – CD11a Stimulation 




























The MFI of A - CD18 baseline, B – CD18 on stimulation, C - CD11a baseline, D – CD11a 
on stimulation, E – CD11b at baseline and F - Act11b response to 10nM fMLP 
stimulation in healthy young adults (HY), healthy older adults (HO) and frail older 
adults (FO).  Stimulation is 10nM fMLP.  Data sets are median +/- IQR; data not 
normally distributed. 
A – CD18US: HY – 28, HO – 27, FO - 13.  HY 34431 +/- 10014, HO 30542 +/- 8825, FO 
29205.5 +/- 15525.  Independent Kruskal Wallis – p=0.514. B - CD18 S: HY – 29, HO – 
26, FO – 15. HY 57389 +/- 12419, HO 57452.5 +/- 15462, FO 51621 +/- 19523. 
Independent Kruskal Wallis – p=0.278.   
C - CD11a US: HY – 28, HO – 27, FO – 16.  HY 1296 +/- 318, HO 1186 +/- 332, FO 1054 
+/- 174. Independent Kruskal Wallis – p=0.004.  Post-hoc pairwise comparison with 
Bonferroni correction: HY-HO p=1.000, HY-FO p=0.003, HO-FO p=0.028.  D - CD11a S: 
HY – 29, HO – 26, FO – 19.  HY 1270 +/- 454, HO 1242.5 +/- 464, FO 1081 +/- 211.  
Independent Kruskal Wallis – p=0.005.  Post-hoc pairwise comparison with Bonferroni 
correction: HY-HO p=1.000, HY-FO p=0.006, HO-FO p=0.031.   
E - CD11b US: HY – 24, HO - 25, FO – 18.  HY 2015.8 +/- 884, HO 1665 +/- 880, FO 1649 
+/- 1629.  Independent Kruskal Wallis – p=0.018.  Post-hoc pairwise comparison with 
Bonferroni correction: HY-HO p=0.039, HY-FO p=0.053, HO-FO p=1.000.  F - Act11b fold 
change: HY – 28, HO – 27, FO – 14.  HY 78.4 +/- 50.5, HO 31.0 +/- 48.5, FO 36.8 +/- 
45.6. Independent Kruskal Wallis – p=0.002.  Post-hoc pairwise comparison with 








































The correlation of cell surface expression of CD11b at baseline expressed in 
MFI and chemotaxis to fMLP (µm/min).  Data sets are normally distributed.  




5.9 Neutrophils from healthy and frail older adults have a poorer response to 
stimulation. 
The expression of β2 intergrins Mac-1 and LFA-1 are in part regulated by the activation 
molecules and selectins CD62L, CD63 and CD66b which are expressed on the neutrophil 
cell surface.  To explore the effect of frailty on these activation molecules, the MFI was 
measured on neutrophils using flow cytometry both at baseline and following stimulation 
with fMLP. 
At baseline there was no difference in the expression of all three cell surface markers.  
(Table 5.2.)  However, there were significant differences in how all three cell surface 
markers were expressed on stimulation (with upregulated CD63 and CD66b and shedding 
of CD62L) and the neutrophil’s response to stimulation, Independent Kruskal-Wallis 
P=0.001, with neutrophils from healthy older and frail older adults less able to upregulate 











Table 5.2 – Median fluorescence intensity (MFI) of CD62L, CD63 and CD66b in healthy 
younger, older and frail older adults at baseline and on stimulation  



















-0.7 +/- 0.3 -0.5 +/- 0.2 -0.4 +/- 0.5 p<0.001 HY-HO p=0.004 
HY-FO p=0.001 
HO-FO p=0.961 
CD63 US 653.5 +/- 269 578 +/- 325.5 571.5 +/- 403 p=0.638  






































MFI at baseline and on stimulation with 10nM fMLP, and fold change with stimulation in 
CD62L, CD63 and CD66b in healthy younger adults (HY), healthy older adults (HO) and 
frail older adults (FO). Data sets are median +/- IQR; data not normally distributed.  
Independent Kruskal-Wallis(I K-W) test with post-hoc pairwise comparison with 
Bonferroni correction.  
CD62L US: HY – 27, HO – 27, FO -17, CD62L S: HY – 29. HO -28, FO -16, CD62L fold 
change: HY – 27, HO – 27, FO – 15.         
CD63 US: HY – 27, HO – 29, FO – 14, CD63 S: HY – 29, HO – 29, FO – 17, CD63 fold 
change: HY – 27, HO – 29, FO – 14.   
CD66b US: HY – 16, HO – 11, FO – 12, CD66b S: HY – 17, HO – 11, FO – 13, CD66b fold 




















































The fold change in MFI on stimulation with 10nM fMLP of A – CD62L, B – CD63 and C – CD66b.  Data sets 
are median +/- IQR; data not normally distributed.  A - CD62L fold change: HY – 27, HO – 27, FO – 15.  HY - 
-0.7 +/- 0.3, HO - -0.5 +/- 0.2, FO - -0.4 +/- 0.5. Independent Kruskal-Wallis test p<0.001.  Post-hoc pairwise 
comparison with Bonferroni correction.  HY-HO p=0.004, HY-FO p=0.001, HO-FO p=0.961.      B - CD63 fold 
change: HY – 27, HO – 29, FO – 14.  HY – 0.4 +/- 0.4, HO – 0.2 +/- 0.4, FO – 0.1 +/- 0.3. Independent 
Kruskal-Wallis test p=0.001.  Post-hoc pairwise comparison with Bonferroni correction.  HY-HO p=0.014, 
HY-FO p=0.041, HO-FO p=1.000.      C - CD66b fold change: HY – 16, HO – 11, FO – 12.  HY – 1.61 +/- 1.0, HO 
– 0.83 +/- 1.0, FO – 0.92 +/- 1.0. Independent Kruskal-Wallis test p<0.001.  Post-hoc pairwise 
comparison with Bonferroni correction.  HY-HO p=0.001, HY-FO p=0.002, HO-FO p=1.000.      
A – CD62L B - CD63 

























5.10 Poor migratory accuracy in neutrophils from frail older adults can be rescued by 
incubation with selective PI3kinase inhibitors  
Previous work has demonstrated that decline in chemotaxis of neutrophils with ageing is 
due to dysregulated intracellular mechanisms and in particular the PI3kinase-Akt 
pathway; poor chemotaxis could be rescued in vitro in the neutrophils from healthy older 
adults by incubation with PI3kinase inhibitors (163).  The data shown already in this 
chapter demonstrates that migratory accuracy to IL-8 is frailty dependent and 
independent of age.  To consider whether frailty related decline in migratory accuracy to 
IL-8 was a consequence of dysregulated PI3kinase activity and could be rescued with 
PI3kinase inhibitors neutrophils from the three groups were incubated with PI3kinase 
inhibitors, α,β,δ and γ, or vehicle control and migrated towards 100nM IL-8.           
 
Poor migratory accuracy towards IL-8 was seen again in neutrophils from frail older adults 
(Chemotaxis (µm/min): FO 0.57+/-0.64) which could be restored with PI3kinase inhibitors 
δ (Chemotaxis (µm/min): FO δ 1.05+/-0.66, Mann-Whitney Test p=0.03) and γ 
(Chemotaxis (µm/min): FO γ 0.99+/-0.94, Mann-Whitney Test p=0.04 ).  Incubation with 
PI3 kinase inhibitor α and β did not alter migratory accuracy: chemotaxis (µm/min) FO α 
0.19+/-1.17, Mann-Whitney Test p=0.62), FO β 0.70+/-1.61, Mann-Whitney Test p=0.31).  



















































Chemotaxis to IL-8 at baseline in healthy young, healthy older and frail older adults and 
following incubation with PI3kinase inhibitors in frail older adults.  HY – isolated neutrophils 
from healthy younger adults incubated with DMSO (vehicle control) migrated towards 100nM 
IL-8 (N=20). HO – isolated neutrophils from healthy older adults incubated with DMSO (vehicle 
control) migrated towards 100nM IL-8 (N=21). FO – isolated neutrophils from frail older adults 
incubated with DMSO (vehicle control) migrated towards 100nM IL-8 (N=13).  Isolated 
neutrophils from frail older adults incubated with: FO Alpha – PI3K α (N=8), FO Beta - PI3K β 
(N=7), FO Delta – PI3K δ (N=8) and FO Gamma – PI3K γ (N=8), and migrated towards 100nM IL-
8.  Chemotaxis expressed as µm/min. Red line represents median chemotaxis in healthy older 
adults.  Data sets all normally distributed except HY, FO and FO Alpha.  Data sets are median+/-
IQR.   
HY – 24.3, FI 0.01.  HO – 76.4, FI 0.06, FO – 81.1, FI 0.42.   
Mann-Whitney test.  HY-FO p=0.08. FO-FO Alpha p=0.49. FO-FO Beta p=0.23. FO-FO Delta 











Response to all four PI3kinase inhibitors was variable in healthy older adults; some 
individuals demonstrated an improvement, others a decline in migratory accuracy and 
some individuals demonstrated no response.  There was no discernible pattern to the 
response when considering the individual inhibitor or baseline chemotaxis to the 
response.  (Figure 5.10.)   
 
Response to PI3kinase α in frail older adults was variable with no discernible pattern to 
the changes in chemotaxis.  PI3kinase inhibitor δ produced the most consistent response 
with a similar improvement in chemotaxis in five individuals but a decrease in migratory 
accuracy in two individuals.  One of these individuals had a baseline chemotaxis which 
was comparable to healthy young adults.  PI3kinase inhibitor γ produced an 
improvement in chemotaxis in all the individuals except one but the response was less 
consistent between the individuals and a marginal response was present in three 
individuals. (Figure 5.11.)        
 
Improvement of chemotaxis in neutrophils incubated with PI3kinase inhibitors could be 
predicted by adjusted hand grip strength; individuals with low grip strength (adjusted for 
gender and BMI) had larger improvements in chemotaxis from baseline folllowing 
incubation of their neutrophils with PI3kinase inhibitors.  Pearson’s correlation between 
the fold change in chemotaxis, vehicle control to PI3kinase δ and adjusted hand grip.  R= -
0.577.  P=0.031.  (Figure 5.12.)     
 




Figure 5.10 – Chemotaxis to IL-8 following incubation with PI3kinase inhibitors in 















































A - Alpha B - Beta 

































Chemotaxis to IL-8 at baseline and following incubation with PI3kinase inhibitors in healthy 
older individuals.  Isolated neutrophils from healthy older adults incubated with DMSO (vehicle 
control) and migrated towards 100nM IL-8 (N=9). Isolated neutrophils from healthy older adults 
incubated with: A - Alpha – PI3K α (N=8), B - Beta - PI3K β (N=10), C - Delta – PI3K δ (N=9) and 
FO Gamma – PI3K γ (N=10), and migrated towards 100nM IL-8.  Chemotaxis expressed as 
µm/min.  Each circle represents one individual and slope represents change in chemotaxis 
























































A - Alpha B - Beta 

































VC Inhibitor VC Inhibitor 
VC Inhibitor VC Inhibitor 
Chemotaxis to IL-8 at baseline and following incubation with PI3kinase inhibitors in healthy 
older individuals.  Isolated neutrophils from healthy older adults incubated with DMSO (vehicle 
control) and migrated towards 100nM IL-8 (N=9). Isolated neutrophils from healthy older adults 
incubated with: A - Alpha – PI3K α (N=8), B - Beta - PI3K β (N=7), C - Delta – PI3K δ (N=8) and FO 
Gamma – PI3K γ (N=8), and migrated towards 100nM IL-8.  Chemotaxis expressed as µm/min.  
Each circle represents one individual and slope represents change in chemotaxis following 





Figure 5.12 – Correlation of adjusted hand grip with fold change in chemotaxis 













Chemokinesis towards IL-8 in neutrophils from frail older adults did not change following 
PI3kinase β,γ and δ inhibition compared to the vehicle control.   (Chemokinesis (µm/min): 
FO 3.12+/- 1.14, FO α 2.92+/-1.43, p=0.606, FO β 3.53 +/- 1.47, p=0.408, FO δ 3.61+/- 
0.83, p=0.200, FO γ 3.87 +/- 0.94, p=0.114.  All Mann-Whitney Test.)   




















Adjusted hand grip 
Correlation of adjusted hand grip with fold change in chemotaxis following PI3kinase δ 
inhibition.  Isolated neutrophils from healthy and frail older adults migrated towards 
100nM IL-8 following incubation with vehicle control (DMSO) or PI3kinase δ inhibitor.  
Fold change in chemotaxis is the change in chemotaxis from vehicle control to following 
incubation with PI3 kinase δ inhibitor.   Plotted against hand grip strength adjusted for 
gender and BMI (fold change of cut-off for lowest 20% for gender and BMI in over 65).  
Data normally distributed.   
HO – 78.7, FI 0.06.  FO – 84.0, FI 0.31.   





In contrast, incubation with PI3kinase inhibitors resulted in no effect on chemotaxis in 
healthy younger adults. (Chemotaxis (µm/min): HY 0.85+/- 1.24, HY α 0.19+/-0.49, 
p=0.133, HY β 0.32 +/- 1.27, p=0.393, HY δ 0.76+/- 1.59, p=0.796, HY γ 0.47 +/- 0.64, 
p=0.393.)   Chemokinesis was no different following incubation with PI3kinaseinhibitors.  
(Chemokinesis (µm/min): HY 3.16+/- 1.25, HY α 2.71+/-1.07, p=0.182, HY β 2.75 +/- 1.01, 
p=0.190, HY δ 3.09+/- 1.47, p=0.631, HY γ 3.25 +/- 1.80, p=0.971.)  All statistical tests 
quoted are Mann-Whitney test. 
 
There was a reduction in chemotaxis in neutrophils from healthy older adults incubated 
with PI3kinase α and β and no effect when the neutrophils were incubated with the 
PI3kinase δ and γ inhibitors.  (Chemotaxis (µm/min): HO 0.97+/- 0.79, HO α 0.34+/-0.85, 
p=0.004, HO β 0.49 +/- 1.12, p=0.035, HO δ 1.11+/- 0.98, p=0.095, HO γ 0.36 +/- 1.42, 
p=0.863.)  Chemokinesis was significantly reduced following incubation with the 
PI3kinase γ and there was a trend to reduction with PI3kinase β inhibitors.  There was no 
difference in chemokinesis following incubation with PI3kinase α and δ inhibitor.  
(Chemotaxis (µm/min): HO 3.14+/- 0.66, HO α 2.41+/-1.34, p=0.161, HO β 2.89 +/- 1.20, 
p=0.095, HO δ 4.03+/- 1.62, p=0.136, HO γ 2.61 +/- 1.10, p=0.035.) All statistical tests 








Table 5.3 – Chemotaxis, chemokinesis and chemotactic index of the three groups for 
vehicle control and all four inhibitors  
  HY HO FO 
VC Chemotaxis 0.85 +/- 1.24 0.97 +/- 0.79 0.39 +/- 0.45 
Chemokinesis 3.16 +/- 1.25 3.14 +/- 0.66 3.12 +/- 1.14 
Chemotactic 
Index 
0.21 +/- 0.19 0.27 +/- 0.17 0.09 +/- 0.12 
PI3k α Chemotaxis 0.19 +/-0.49 0.34 +/-0.85 0.19 +/- 1.07 
Chemokinesis 2.71 +/- 1.07 2.41 +/- 1.34 2.92 +/- 1.43 
Chemotactic 
Index 
0.09 +/- 0.1 0.14 +/-0.27 0.09 +/- 0.36 
PI3k β Chemotaxis 0.32 +/- 1.27 0.49 +/- 1.12 0.70 +/-1.61 
Chemokinesis 2.75 +/-1.01 2.89 +/- 1.20 3.53 +/-1.47 
Chemotactic 
Index 
0.13 +/- 0.34 0.13  +/-0.35 0.14 +/-0.39 
PI3k δ Chemotaxis 0.76 +/-1.59 1.11 +/- 0.98 1.05 +/- 0.66 
Chemokinesis 3.09 +/-1.47 4.03 +/-1.62 3.61 +/- 0.83 
Chemotactic 
Index 
0.19 +/- 0.37 0.19 +/- 0.22 0.23 +/- 0.11 
PI3k γ Chemotaxis 0.47 +/-0.64 0.36 +/-1.42 0.99 +/-0.94 
Chemokinesis 3.25 +/-1.80 2.61 +/-1.10 3.87 +/-0.94 
Chemotactic 
Index 
0.08 +/- 0.28 0.12 +/- 0.32 0.21 +/- 0.21 











VC – neutrophils incubated with DMSO (vehicle control) migrated towards 100nM IL-8 
(N- HY=20, HO=20, FO=13).  PI3K α – neutrophils incubated with PI3k α and migrated 
towards 100nM IL-8 (N- HY=9, HO=9, FO=8). PI3K β – neutrophils incubated with PI3k β 
and migrated towards 100nM IL-8 (N- HY=10, HO=10, FO=7). PI3K δ – neutrophils 
incubated with PI3k δ and migrated towards 100nM IL-8 (N- HY=10, HO=9, FO=8). PI3K γ 
– neutrophils incubated with PI3k γ and migrated towards IL-8 (N- HY=10, HO=10, FO=7).  
Chemotaxis and chemokinesis expressed as µm/min.  
Data sets all normally distributed except chemotaxis HY, chemotaxis FO and chemotaxis 
FO Alpha.  Data sets are median+/-IQR.  Numbers in bold represent values that are 
significantly different to vehicle control values. FO PI3kδ p=0.03. FO PI3k γ p=0.04.    







5.11 Akt signalling in neutrophils following stimulation with IL-8.   
The presented data suggest that PI3kinase is involved in the control of directional 
migration and its dysregulation results in poor neutrophil migratory accuracy.  The data 
have demonstrated that PI3kinase dysregulation can be corrected in frail older adults 
with PI3kinase inhibitors, suggesting increased expression or activity.  Akt is downstream 
of PI3kinase and plays a central role in a number of cellular responses (see Figure 1.6 in 
the introduction for a description of its role within myocytes).  To determine the extent of 
the effect of dysregulated PI3kinase on downstream intracellular activity the 
phosphorylation of AktThr308 was measured using β-actin as a control.  
 
Phosphorylated Thr 308 increased in response to stimulation with IL-8 in all three groups 
with a maximal response at 40 seconds of stimulation.  (Figure 5.13.)  Healthy older and 
frail older adults had a trend towards the greatest increase in phosphorylation of Thr 308 
but this was not significant (Area under the curve HY: 38.17, HO: 82.25 and FO: 66.71, 
Independent Kruskal-Wallis p=0.066).  There was significant variability in responses 











Figure 5.13 – Phosphorylation of AktThr 308 in response to IL-8. Representative Western 














60kDa HY – 0             HY -20              HY – 40               HY – 60              HO – 0                HO – 20              HO – 40                HO - 60 
60kDa  HY – 0               HY -20              HY – 40          HY – 60              FO – 0             FO – 20             FO – 40               FO - 60 
Phosphorylation of Thr 308 in response to increasing periods of stimulation with 100nM 
IL-8.  Isolated neutrophils stimulated with 100nM IL-8 for increasing periods of time, 0 to 
60 seconds.  Figure A shows a representative western blot of a healthy young adult (HY) 
and healthy older adult (HO).  Top western blot is phosphorylated Thr 308 and below is 
the beta actin.  Figure B shows a representative western blot of a healthy young adult 
(HY) and healthy older adult (HO).  Top western blot is phosphorylated Thr 308 and below 
is the corresponding beta actin western blot.  Columns from left to right are: protein 
ladder (60kDa), unstimulated neutrophils, neutrophils stimulated with 100nM IL-8 for 20 
seconds, neutrophils stimulated with 100nM IL-8 for 40 seconds, neutrophils stimulated 




Figure 5.14 - Densitometry of phosphorylated Thr 308 in neutrophils from healthy older 









































Phosphorylation of Thr 308 in response to increasing periods of stimulation with 
100nM IL-8.  Isolated neutrophils stimulated with 100nM IL-8 for increasing 
periods of time, 0 to 60 secondsLevels of phosphorylated Thr 308 were quantified 
using densitometry and expressed as a ratio of β-actin.  X axis - time for 
stimulation expressed in seconds.  Y axis – ratio of phosphorylated Thr 308 to β-
actin.  Number within each group =3.  Plotted median with range.  Area under the 
curve  calculated: HY- 38.17, HO – 82.25, FO – 66.71.  p=0.066.  (Independent 




5.12 Changes in neutrophil function following exposure to pooled plasma from healthy 
and frail older adults 
 
Poor migratory accuracy has been demonstrated to be the result of dysregulated 
intracellular mechanisms (163).  However, in frailty it is not known whether this 
dysregulation occurs due to an acute response to an inflammatory environment or an 
intrinsic defect, present even in immature cells.  To assess this, neutrophils from healthy 
younger adults were incubated with pooled plasma from healthy older and frail older 
adults.   
 
There was a trend to reduction in chemotaxis of neutrophils from healthy younger adults 
following incubation with pooled plasma (PP) from frail older adults.  In contrast, 
incubation with pooled plasma from healthy older adults did not change the migratory 
accuracy of neutrophils from healthy younger adults.  Chemotaxis towards IL-8 (μm/min): 
VC (neutrophils from healthy younger adults) 1.08 (0.62-1.55), HO PP (neutrophils from 
healthy younger adults incubated with pooled plasma from healthy older adults) 1.12 
(0.81-1.43) and FO PP (neutrophils from healthy younger adults incubated with pooled 
plasma from frail older adults) 0.45 (0.06-0.84).  Independent samples T-test between VC 
and FO PP p = 0.053.  (Figure 5.15)   
 
There was no difference in chemokinesis when neutrophils from healthy younger adults 
were incubated with pooled plasma from healthy older adults. Similarly, there was no 
change in chemokinesis following neutrophil incubation with pooled plasma from frail 




3.81) and FO 2.42 (1.88-2.96).  Independent samples T-test between VC and HO PP 
p=0.209 and between VC and FO PP p = 0.140.  (Figure 5.15)  
 
Figure 5.15 – Chemotaxis and chemokinesis of neutrophils from healthy younger adults 


































Chemotaxis and chemokinesis of neutrophils from healthy younger adults incubated with 
pooled plasma and migrated towards IL-8.  Isolated neutrophils from healthy younger adults 
incubated with either: VC – RPMI, HO PP – pooled plasma from 18 healthy older adults (Mean 
Frailty Index – 0.04), FO PP – pooled plasma from 18 frail older adults (Mean Frailty Index – 
0.41).  Neutrophils migrated towards 100 nM IL-8.  Data sets are mean+/-SEM; data sets are 
normally distributed.  Chemotaxis and chemokinesis expressed as µm/min.  N= VC-15, HO PP-
9, FO PP-9.   
Independent samples t-test for chemotaxis. VC-HO PP p=0.904  VC-FO PP p=0.053 
Independent samples t-test for chemokinesis VC-HO PP p=0.209. VC-FO PP p=0.140 





































5.13 Frail older adults exist in a state of chronic inflammation    
To describe the systemic environment in frail older adults and explore its effect on 
neutrophils in vivo, a commercially available human cytokine multiplex and the acute 
phase protein hs-CRP ELISA were used to calculate cytokine and hs-CRP concentration in 
healthy younger and older adults, and frail older adults.   
 
The concentrations of hs-CRP in healthy younger adults and healthy older adults were 
comparable but there was significantly increased concentrations of hs-CRP in the serum 
from frail older adults.  Concentration of hs-CRP (µg/ml): HY 1.39 +/- 1.86, HO 1.34 +/- 
1.65 and FO 8.87 +/- 7.97.  (Figure 5.16.) 
 
For the commercially available human cytokine kit, only IL-1ra, IL-4, IL-7, IL-8, IL-9, IL-17, 
Eotaxin, FGF, G-CSF, IP-10, MCP-1, MIP1a, PDGF, MIP1b, RANTES and TNFα provided 
results where more than 50% of values were within the measured range.  Values below 
the detectable range were recorded as half the lowest detectable standard. Table 5.4 
describes the cytokines with greater than 50% of values within the detectable range and 
table 5.5 describes the cytokines with fewer than 50% of cytokines with the detectable 
range.  Only these cytokines were included for further analysis.  
 
There was no significant difference in the concentration of TNFα throughout the three 
groups and the concentrations of IL-6 and IL-10 were mostly undetectable throughout the 





However, there were significantly increased concentrations in both the healthy older 
adults and the frail older adults compared to healthy younger adults for IL-1ra, IL-8 and 
Eotaxin with no difference between the healthy older adult and frail older adult 
concentrations.   
 
There were significantly increased concentrations of IL-4, IL-17 and IL1β in healthy but 
not frail older adults.  There were significantly decreased concentrations of MCP 1a in 
frail older adults compared to healthy older adults and significantly increased 
concentrations of MIP1a, resulting in a stepwise increase in MIP1a with age and frailty.  







































100.0 49.6 +/- 
42.3 
100.0 64.7 +/- 
69.0 




85.7 5.71 +/- 
3.32 
97.4 10.4 +/- 
4.54 




92.9 12.0 +/- 
7.65 
89.5 16.0 +/- 
6.26 




46.4 4.82 +/- 
0.69 
94.7 7.37 +/- 
3.60 




89.3 52.9 +/- 
10.5 
76.3 47.0 +/- 
38.5 




39.3 4.56 +/- 
11.5 
81.6 19.8 +/- 
12.7 




100.0 877.7 +/- 
592.2 
100.0 1440.2 +/- 
1005.4 




100.0 102.8 +/- 
68.9 
100.0 167.3 +/- 
83.0 




78.6 17.2 +/- 
2.93 
81.6 20.5 +/- 
6.28 




100.0 25.8 +/- 
12.9 
100.0 30.7 +/- 
24.0 
93.9 19.8 +/- 
23.4 
MIP1a 0.53-517.8 100.0 0.97 +/- 
0.62 
92.1 1.41 +/- 
1.35 




100.0 82.5 +/- 
13.0 
100.0 82.3 +/- 
74.0 
























100.0 36.9 +/- 
8.22 
100.0 41.0 +/- 
88.5 






Cytokines with greater than 50% of total sample within detectable range in healthy younger adults 
(HY), healthy older adults (HO) and frail older adults (FO).   Cytokines in horizontal rows.  Vertical 
rows from left to right: measureable range in pg/ml (individuals with cytokine concentrations 
below the measurable range ascribed a value of half the lowest detectable value), proportion of 
individuals in the group within the measurable range (%) and median concentration of cytokine 



























14.3 0.83 +/- 
0.27 
 
55.3 1.09 +/- 
0.68 




0 3.08 +/- 
0.00 
2.6 3.08 +/- 
0.00  












0 1.41 +/- 
0.00 
10.5 1.41 +/- 
0.00 




0 3.41 +/- 
0.00 
5.3  3.41 +/- 
0.00 




0 3.68 +/- 
0.00 
5.3 3.68 +/- 
0.00 




7.1 1.28 +/- 
0.00 
5.3  1.28 +/- 
0.00 




0 21.9 +/- 
0.00 
2.6 21.9 +/- 
0.00 




7.1 20.7 +/- 
0.00 
81.6 41.4 +/- 
0.00 






7.1 6.31 +/- 
0.00 
10.5 14.52 +/- 
0.00 




3.6 1.17 +/- 
0.00 
2.6 1.17 +/- 
0.00 




0 17.8 +/- 
0.00 
13.2  17.8 +/- 
0.00 







Cytokines with fewer than 50% of total sample within detectable range in healthy younger 
adults (HY), healthy older adults (HO) and frail older adults (FO).   Cytokines in horizontal 
rows.  Vertical rows from left to right: measureable range in pg/ml (individuals with 
cytokine concentrations below the measurable range ascribed a value of half the lowest 
detectable value), proportion of individuals in the group within the measurable range (%) 
and median concentration of cytokine (pg/ml) within the group plus IQR. Numbers = HY: 28, 
HO: 38, FO: 33.       




Table 5.6 – Statistical comparisons of cytokines with greater than 50% of total sample 
within detectable range and IL-1β 
 
 Independent Kruskal-Wallis Pairwise Comparisons 
IL-1ra p=0.001 HY-HO p=0.003, HY-FO p=0.002, HO-FO 
p=1.000 
IL-4 p=0.001 HY-HO p=0.001, HY-FO p=0.06, HO-FO 
p=0.493 
IL-7 p=0.116  
IL-8 p<0.001 HY-HO p=0.015, HY-FO p=0.001, HO-FO 
p=0.537 
IL-9 p=0.266  
IL-17 p=0.001 HY-HO p=0.001, HY-FO p=0.126, HO-FO 
p=0.284 
Eotaxin p=0.001 HY-HO p=0.001, HY-FO p=0.023, HO-FO 
p=1.000 
FGF p=0.087  
G-CSF p=0.401  
MCP-1 p=0.042 HY-HO p=0.356, HY-FO p=1.000, HO-FO 
p=0.041 
MIP1a p<0.001 HY-HO p=0.043, HY-FO p<0.001, HO-FO 
p=0.005 
PDGF p=0.949  
MIP1b p=0.432  
RANTES p=0.256  
TNFα p=0.305  
IL-1β p=0.029 HY-HO p=0.025, HY-FO p=0.705, HO-FO 
p=0.415 
  
Statistical comparison of cytokines with greater than 50% of total sample within 
detectable range and IL-1β.  All cytokines not normally distributed.  Statistical tests are 
Independent Kruskal-Wallis test with post-hoc Bonferroni corrected pairwise 








































































































A – IL-1ra B – IL-4 
C – IL-8 D – IL-17 










































































5.14 Neutrophils from frail older adults primed with TNFα demonstrate improved 
chemotaxis but the response is delayed. 
A chronic inflammatory environment has been demonstrated with increased 
concentrations of systemic hs-CRP, IL-1ra, IL-4, IL-8 and IL-17 in frail older adults.   To 
determine the effect of this chronic inflammatory environment on migration of 
neutrophils; neutrophils were primed with of TNFα (1.15 nM) and migrated towards the 
bacterial end chemoattractant fMLP.   
Neutrophils from healthy young and older adults, and frail older adults showed an initial 
reduction in chemotaxis with priming which improved with an increasing period of rest.  
This reduction was significant in healthy younger and frail older adults.  Chemotaxis; 
mean (confidence intervals) (µm/min): HY without priming 1.68 (1.40-1.95), HY following 
15 minutes of priming 0.22 (0.08-0.36), independent t-test p<0.001, HO without priming 
0.78 (0.49-1.08), HO following 15 minutes of priming 0.30 (0.16-0.46), independent t-test 
A-IL-1ra, B-IL-4, C-IL-8, D-IL-17. E-TNFα and F-hsCRP 
Concentration of IL-1ra, IL-4, IL-8, IL-17, TNFα (pg/ml) and hs-CRP (µg/ml) measured 
using a multiplex or commercially available ELISA.  N = HY-28, HO-38, FO-33.  Values 
below the detectable range were recorded as half the lowest detectable standard.  
Values above the detectable range were recorded as highest detectable value.  Not 
normally distributed.  Values are median +/- IQR.  Independent  Kruskal-Wallis with 
pairwise analysis with Bonferroni correction. 
IL-1ra: p<0.001.  HY-HO p=0..003, HY-FO p=0.002, HO-FO p=1.000.   IL-4: p<0.001. HY-
HO p=0..001, HY-FO p=0.062, HO-FO p=0.471. IL-8: p<0.001.  HY-HO p=0..001, HY-FO 
p<0.001, HO-FO p=1.000.   IL-17: p=0.004.  HY-HO p=0..003, HY-FO p=0.244, HO-FO 
p=0.328.  TNFα: p=0.305. hs-CRP: p<0.001.  HY-HO p=1.00, HY-FO p<0.001, HO-FO 




p=0.079, FO without priming 0.92 (0.48-1.36), FO following 15 minutes of priming 0.13 
(0.04-0.22), independent t-test p=0.001.  (Figure 5.17.)   
 
The maximal response to priming (the time-point chemotaxis reached the highest value 
following the initial priming) occurred at 15 minutes of priming and 30 minutes of rest for 
healthy younger and older adults but was delayed at 15 minutes of priming and 45 
minutes of rest for frail older adults.  At maximal response to priming,  chemotaxis was: 
no different to chemotaxis without priming in healthy younger adults ((Chemotaxis; mean 
(confidence intervals) (µm/min): HY without priming 1.68 (1.40-1.95), HY with 15+30 
priming 0.83 (0.36-1.31) p=0.081) healthy older adults ((Chemotaxis; mean (confidence 
intervals) (µm/min): HO 0.78 (0.49-1.08), HO with 15+30 priming 0.93 (0.22-1.64) 
p=0.866), and frail older adults ((Chemotaxis; mean (confidence intervals) (µm/min): FO 
0.92 (0.48-1.36), FO with 15+45 priming 1.35 (0.35-2.34)p=0.474).  Not significantly 
different using independent t-test between vehicle control and maximal response to 








Neutrophils primed with 1.15nM TNFα for 15 minutes, washed to remove stimulus  and then undergoing increasing periods of 
rest following priming (eg. VC – vehicle control 15+15 – 15 minutes of priming with TNFα, wash to remove priming agent and 15 
minutes of rest before migration) and then migrated towards 10nM fMLP. Data sets are all normally distributed and data shown 
is adjusted to vehicle control (chemotaxis without priming).  Vehicle control data not shown.  Chemotaxis is expressed as µ/min.  
Data shown is mean +/- SEM.  P values are derived from independent t-tests.   
N – HY – VC = 11, 15 = 10, 15+15 = 7, 15+30 = 7, 15+45 = 8. HO – VC = 6, 15=7, 15+15 = 7, 15+30 = 6, 15+45 = 10. FO – VC = 6, 15 
= 6, 15+15 = 6, 15+30 = 6, 15+45 = 7.    
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5.15 Neutrophils from frail older adults do not produce a reduced amount of superoxide 
on stimulation or with priming 
To confirm that the experiments described above provided a sufficient stimulus to prime 
neutrophils from each participant group, the effect of the same concentration of TNFα 
(1.15nM) on neutrophil superoxide production was assessed compared to a vehicle control, 
and subsequent stimulation with fMLP.  The oxidative burst of the neutrophils was 
measured using DHR-123 and flow cytometry.  There was no difference witnessed 
throughout the time-course and all primed data were analysed together.   
The data suggests that the concentration of 1.15nM TNFα was sufficient to prime 
neutrophils from healthy younger, healthy older and frail older adults.  There was increased 
superoxide release from neutrophils from all three groups after fMLP exposure following 
priming with 1.15nM TNFα compared to the superoxide production in the neutrophils with 
no prior priming (vehicle control).  Furthermore, there was no difference in oxidative burst 
production between the three groups either on stimulation or with priming preceding 
stimulation.  Stimulation: HY 586157.0 +/- 457040.3, HO 952060.7 +/- 567821.4, FO 
727388.8 +/- 892021.8.  Primed and stimulated: HY 5.34 +/- 3.06, HO 2.04 +/- 3.63, FO 4.99 









Figure 5.18 – Superoxide production in healthy younger, healthy older and frail older 





















Superoxide production in healthy younger, healthy older and frail older adults on stimulation 
with fMLP and following priming with TNFα and subsequent stimulation with fMLP. 
A – MFI of isolated neutrophils stimulated with 10nM fMLP in healthy younger (HY), healthy 
older (HO) and frail older (FO) adults.  B – Fold change in MFI with priming isolated neutrophils 
with 1.15nM TNFα prior to stimulation with 10nM fMLP.  Data sets are not all normally 
distributed and data shown mean +/- SEM.  N: HY – 9, HO – 9, FO – 8.   
A - HY 586157.0 +/- 457040.3, HO 952060.7 +/- 567821.4, FO 727388.8 +/- 892021.8.  
Independent Kruskal-Wallis test. P=0.602.  

















5.16 Functional differences in neutrophils from frail older adults cannot be explained by 
either differences in neutrophil subpopulations or activation and senescence status.   
As described in section 5.11 frail and healthy older adults exist in a state of chronic 
inflammation but the effect this systemic state has on neutrophils is uncharacterised.  To 
investigate both subpopulations and the activation status of neutrophils in frail older 
adults the expression of cell surface receptors were measured using flow cytometry.   
There was a small but significant difference in some neutrophil subpopulations between 
the three groups.   
1. There was no difference in the proportion of immature granulocytes (CD16 dim CD62L 
bright).  Proportion of immature granulocytes of total number of neutrophils: healthy 
younger adults 3.18 +/- 2.73, healthy older adults 2.33 +/- 2.22, frail older adults 2.87 +/- 
3.83, Independent Kruskal-Wallis p=0.177.   
2. There was a significant increase in the proportion of neutrophils which had surface 
markers which have been described as being consistent with reverse transmigration 
(CD16 bright CD62L dim) in frail older adults; with frail older adults having double the 
proportion of neutrophils expressing the ‘reverse transmigration’ phenotype in 
comparison to healthy younger and older adults.  Proportion of neutrophils expressing 
the ‘reverse transmigration’ phenotype: healthy younger adults: 0.45 +/- 0.56, healthy 
older adults 0.40 +/- 0.33, frail older adults 0.86 +/- 1.60, Independent Kruskal-Wallis p = 






Table 5.7 – Proportion of neutrophils within the CD16 CD62L defined subpopulations     
 























































Neutrophils stained with anti CD16 and anti CD62L antibodies and gated on these 
populations.  Data shown for healthy younger adults (HY) healthy older adults (HO) 
and frail older adults (FO).  Data sets all not normally distributed.  Data shown is 
median +/- interquartile range of proportion of the subpopulation of total number to 
total number of neutrophils.  CD16 bright CD62L bright = phenotypically normal, CD16 
dim CD62L bright = immature granulocytes, CD16 bright CD62L dim = older phenotype.  
Data set numbers as follows: HY – 29, HO – 27, FO - 18.  P values in bold represent 
statistically significant values.  
CD16 bright CD62L bright: HY – 96.17 +/- 3.56, HO – 97.25 +/- 2.2.6, FO 95.79 +/- 5.55.  
Independent Kruskal-Wallis. P=0.029.  Post-hoc pairwise analysis with Bonferroni 
correction HY-HO p=0.121, HY-FO p=1.000, HO-FO p=0.044. 
CD16 dim CD62L bright: HY – 3.18 +/- 2.73, HO – 2.33 +/- 2.22, FO – 2.87 +/- 3.38.  
Independent Kruskal-Wallis. P=0.177. 
CD16 bright CD62L dim: HY 0.45 +/- 0.56, HO – 0.40 +/- 0.33, FO 0.86 +/- 1.60.  
Independent Kruskal-Wallis. P=0.004. Post-hoc pairwise analysis with Bonferroni 





Utilising a method developed in chronic inflammatory conditions to describe neutrophils 
as activated or senescent using neutrophil surface marker expression, there was no 
difference in activation or senescence throughout the three groups (305-307).   
As described in section 1.7.4 of the introduction, in senescence it is hypothesised that 
CXCR2 is downregulated and CXCR4 is upregulated.  There was no significant difference in 
the expression of CXCR2 in frail older adults.  There was a significant reduction in the 
expression of CXCR4 in healthy older adults when compared to healthy younger adults.  
(Table 5.8 and Figure 5.19.)  However, analysed together these data suggest there was no 
difference in the proportion of senescent neutrophils throughout the three groups.   
 
Table 5.8 – Median fluorescence intensity (MFI) of CXCR2 and CXCR4 markers of 
senescence in healthy younger, older and frail older adults at baseline  
 






















Median fluorescence intensity (MFI) of CXCR2 and CXCR4 in healthy younger (HY), older 
(HO) and frail older (FO) adults at baseline a.  Data sets are median +/- IQR; data not 
normally distributed.  Independent Kruskal-Wallis test with post-hoc pairwise 
comparison with Bonferroni correction.  P values in bold represent statistically significant 
values.  
CXCR2: HY – 17, HO – 9. FO – 11. 




In activation, it has been described that CD18, CD11b, CD63 and CD66b are upregulated 
and CXCR1, CXCR2 and CD62L are downregulated (306-308). There was no difference in 
how these cell surface markers were expressed throughout the three groups suggesting 
neutrophils from healthy and frail older adults are not activated.  (Table 5.9, figure 5.20, 
figure 5.21)     
Table 5.9 - Median fluorescence intensity (MFI) of CD18, CD11, CD63, CD66b, 
CXCR1,CXCR2 and CD62L markers of activation in healthy younger, older and frail older 
adults at baseline  
 
 HY HO FO I K-W Pairwise 







CD11b 2105.8 +/- 
884 
1665 +/-880 1649 +/-
1629 
p=0.018 HY-HO p=0.039 
HY-FO p=0.053 
HO-FO p=1.000 








































Median fluorescence intensity (MFI) of CD18, CD11, CD63, CD66b, CXCR1, CXCR2 and 
CD62L markers of activation in healthy younger, older and frail older adults at baseline.  
Data sets are median +/- IQR; data not normally distributed.  Independent Kruskal-Wallis 
test with post-hoc pairwise comparison with Bonferroni correction.  
Numbers included in each set of experiments are given below: 
CD18: HY – 28, HO – 27, FO – 13, CD11b: HY – 24. HO – 25, FO – 18, CD63: HY – 27, HO – 
29, FO – 14, CD66b: HY – 16, HO – 11, FO – 12, CXCR1: HY – 13, HO – 9, FO – 10, CXCR2: 




Figure 5.19 – Neutrophil cell surface markers associated with senescence 















   
 
Neutrophil cell surface markers downregulated (CXCR2) and upregulated (CXCR4) in 
senescence. MFI of A - CXCR2 and B - CXCR4 on neutrophils at baseline from healthy 
younger adults (HY), healthy older adults (HO) and frail older adults (FO).  Data sets are not 
normally distributed.  Data shown are median with IQR.  with.   
A - CXCR2. Numbers in each group: HY-17, HO-16, FO-14.  HY 10856.5 +/- 10035.0, HO 
12232.0 +/- 7181.0, FO 12931.0 +/- 3662.1. Independent Kruskal-Wallis test. P=0.788.   
B - CXCR4.  Numbers in each group HY-17, HO-14, FO-16. HY-539+/-68.5, HO-415+/-53.5, FO-
467.5+/-145.3. Independent Kruskal-Wallis test.  P=0.002.  Post-hoc test with Bonferroni 
















































































MFI of A – CD18, B – CD11b, C – CD63 and D - CD66b on neutrophils at baseline from healthy 
younger adults (HY), healthy older adults (HO) and frail older adults (FO).MFI.  Data sets are not 
normally distributed.  Data shown are median with IQR.  CD18.  Numbers in each group: HY-28, 
HO-27, FO-13.  HY-34431 +/- 10014, HO –30542 +/- 8825, FO –29205.2 +/- 15525.  Independent 
Kruskal-Wallis test.  p=0.514   CD11b.  Numbers in each group: HY-23, HO-25, FO-16.  HY -2105.8 
+/- 884, HO- 1665 +/-880, FO -1649 +/-1629.  Independent Kruskal-Wallis test.  P=0.018.  Post-
hoc pairwise comparison with Bonferroni correction.  HY-HO p=0.039, HY-FO p=0.053, HO-FO 
p=1.000.  CD63.  Numbers in each group HY-27, HO-29, FO-14. HY - 653.5 +/- 209, HO – 578 +/- 
325.5, FO – 571.5 +/- 403.  Independent Kruskal-Wallis test.  p=0.638.  CD66b.  Numbers in each 
group; HY-16, HO-11, FO-12. HY – 9093.5 +/- 2601, HO – 9075.5 +/- 2058, FO – 9937 +/- 6444. 

































A – CD18 B – CD11b 


























MFI of A – CXCR1, B – CXCR2 and C-CD62L on neutrophils at baseline from healthy younger 
adults (HY), healthy older adults (HO) and frail older adults (FO).  Data sets are not normally 
distributed.  Data shown are median with IQR.  Data sets are not normally distributed.   
CXCR1;  Numbers; HY-14, HO-14, FO-13.  MFI: HY 17812.0 +/-2805.0, HO 28092.5 +/- 4424.5, FO 
15905.8 +/- 4447.0.  Independent Kruskal-Wallis test. p=0.160 
CXCR2.  Numbers; HY-17, HO-16, FO-14.  MFI HY 10856.5 +/- 10035.0, HO 12232.0 +/- 7181.0, 
FO 12931.0 +/- 3662.1.  Independent Kruskal-Wallis test. p=0.751 
CD62L; Numbers; HY-27, HO-27, FO-17. HY-27510 +/- 11358.5, HO-32110.0 +/- 10115.5, FO-































B – CXCR2 A – CXCR1 




CD16 expression on the neutrophil cell surface increases with stimulation.  CD16 
expression was significantly increased in frail older adults both at baseline and on 
stimulation when compared to both healthy younger and older adults.  There was also a 
significant reduction in upregulation with stimulation in the frail older adults.  (Table 5.10 
and Figure 5.22.)   
 
Table 5.10 - Median fluorescence intensity (MFI) of CD16 at baseline, on stimulation 
and the fold change in expression with stimulation in healthy younger, healthy older 
and frail older adults  
 















































Median fluorescence intensity (MFI) of CD16 at baseline, on stimulation and the fold 
change in expression with stimulation in healthy younger (HY), healthy older (HO) and 
frail older adults (FO).  Data given as mean with confidence intervals; data normally 
distributed.  Statistical tests are ANOVA and post-hoc Tukey for pairwise comparison.   
Numbers; CD16US:  HY – 29, HO – 29, FO – 17, CD16S: HY - 29, HO - 29, FO – 19, CD16 
fold change: HY -29, HO - 29, FO - 17 















































MFI of A – CD16 expression at baseline, B – CD 16 expression on neutrophils on 
stimulation from healthy younger adults (HY), healthy older adults (HO) and frail older 
adults (FO).  Data sets are mean+/-SEM.  All normally distributed.   N- US: HY=29, 
HO=29, FO=17.  S: HY=29, HO=29, FO=19.   
CD16 US HY: 26284.2 (21218.6-31349.8), HO: 23833.3 (20363.2-27303.3), FO: 37944.8 
(29102.0-46787.5).  ANOVA p=0.002, Post-hoc Tukey: HY-HO p=0.751, HY-FO p=0.012, 
HO-FO p=0.002.   
CD16 S HY: 34291.6 (27747.2-40836.1), HO: 31726.1 (27279.1-36173.1), FO: 43507.4 
(34820.3-52194.5).  ANOVA p=0.037, Post-hoc Tukey: HY-HO p=0.806, HY-FO p=0.118, 
HO-FO p=0.033 
 










5.17 Neutrophil elastase activity is reduced in the plasma from frail older adults in 
comparison to healthy older adults 
Data generated so far using the expression of neutrophil surface markers suggests that 
systemic neutrophils from healthy older and frail older adults are not activated.  
Activated neutrophils are known to degranulate more readily (212).  To confirm that 
neutrophils from HO or FO participants were not constitutively activated, AαVal360(a 
validated footprint of neutrophil elastase activity) was measured (212).  
Healthy older adults displayed an increase in AαVal360 compared to both healthy young 
adults and frail older adults (Figure 5.23.) AαVal360 HY – 11.13nM (8.91-13.35), HO - 
17.74nM (15.45-20.02), FO – 14.32nM (12.24-16.39).  There was no significant difference 
between the concentration of AαVal360 in healthy younger adults and frail older adults.   
To determine if systemic activation of neutrophils was associated with physical 
parameters of frailty and sarcopenia: walk time, grip strength, BATT, ultrasound 
echogenicity and cognitive function were compared to AαVal360 concentrations.   BATT 
significantly and negatively correlated with AαVal360 concentrations, R= -0.466, p=0.019.  
The correlation with ultrasound echogenicity and adjusted hand grip showed a trend 
towards significance: ultrasound echogencity and AαVal360 R=0.494, p=0.086, adjusted 
grip strength and AαVal360 R= -0.329, p=0.094.  There was no significant correlation 
between time to walk four metres and AαVal360 R=0.112, p=0.593, and Stroop 



































Neutrophil elastase activity in healthy younger (HY), older (HO) and frail older adults 
(FO).  AαVal360 , a marker of neutrophil elastase activity, calculated in serum from 
healthy younger adults (HY), healthy older adults (HO) and frail older adults (FO). Data 
sets are mean+/-SEM; all normally distributed.  AαVal360 expressed as nM. N- HY=11, 






This chapter has investigated both immunesenescence and inflammageing in frailty.  It 
has described altered neutrophil function in healthy older and frail older adults, and 
explored the differences witnessed in the two groups.  It is only the second study to 
explore function in the innate immune system in a defined population of frail older adults 
(208) and links a chronic inflammatory environment with neutrophil functional ability.      
The most important limitation to accurate interpretation of the data quoted throughout 
this chapter is the fundamental differences in the healthy and frail older adults namely 
age and health status.  Table 5.1 describes the basic demographic data of the three 
groups.  It demonstrates that the frail older adults are significantly older than the healthy 
older adults and there is therefore a risk that differences attributed to frailty are actually 
related to ageing.  However, the experiments described within this chapter do not include 
every individual within each cohort and therefore each experiment is a selection of 
individuals from the complete cohort.  Where possible the data has been adjusted for age 
to prove that differences witnessed are due to frailty rather than ageing.  The frail older 
adults had an increased number of chronic inflammatory conditions compared to the 
healthy older adults as chronic inflammatory conditions were an exclusion criteria for the 
healthy older adults but not the frail older adults.  (See Chapter 6 for more in depth 
analysis.)  Chronic inflammatory conditions such as COPD and cardiovascular disease are 
associated with immunesenescence (309).  The differences described with frailty could 
therefore also be attributable to chronic inflammatory conditions rather than frailty itself. 
The method of recruitment could have been improved by age matching each of the frail 




would be the exclusion of chronic inflammatory conditions in the frail older adults.  Both 
of these changes to the method of recruitment would have been possible in this study 
population; 40% (15) of the frail older adults did not have any chronic inflammatory 
conditions and the range of healthy older adults extended to 84.  However, the changes 
may have proved difficult in practice and hindered adequate recruitment and comparing 
frail older adults with and without co-morbidities does not provide sufficient numbers to 
adequately exclude potential differences.   
Sections 2.1 to 2.4 describe the reduction in chemotaxis with both ageing and frailty; 
reduction in chemotaxis to the end target chemoattractant fMLP in both healthy and frail 
older adults, and preserved chemotaxis in healthy older adults to the intermediate 
chemoattractant IL-8.   
This is the first study investigating neutrophil migration in frail older adults but several 
studies have demonstrated reduction in chemotaxis with increasing age to several 
different chemoattractants including fMLP and IL-8 (163, 310, 311).  The SENIEUR 
protocol (protocol outlining the inclusion and exclusion criteria for studies investigating 
the effect of age on the immune system) on which most gerontological studies base their 
inclusion and exclusion criteria does not identify or exclude frail individuals from ageing 
research (312).  Previous studies which have demonstrated reduction in chemotaxis with 
increasing age may have included frail individuals within their study populations and 
therefore, the demonstrated decrease in neutrophil chemotaxis to IL-8 with age may 
actually represent a decrease with frailty, particularly as the prevalence of frailty 




immune studies and either the exclusion of frail individuals or preferentially their 
inclusion as a separate comparator group.  Whilst this is the first study investigating 
chemotaxis in frail older adults a single study investigating chemotaxis in healthy older 
adults with differing levels of daily physical activity had similar results; the most active 
healthy older adults had preserved chemotaxis to IL-8 whereas the least active healthy 
older adults had reduced chemotaxis to IL-8 in comparison to healthy younger adults 
(313).  Section 2.2 demonstrated that neutrophil function correlated with markers of 
both physical and cognitive health and this was independent of age.  Considering the data 
presented in this chapter along with data already reported in the literature suggests 
there are two different patterns of immunesenescence occurring in the neutrophils of 
older adults: the chronological age dependent, chemotaxis to fMLP and biological age or 
frailty dependent, chemotaxis to IL-8.  Appropriate neutrophil response to both 
intermediate (IL-8) and end target (fMLP) chemoattractants are required for organised 
and efficient migration to sites of infection.  The reduction in migratory accuracy towards 
fMLP might in part explain the increased rates of infection in all older adults whereas the 
additional reduction in migratory accuracy to IL-8 in frail older adults can partially explain 
the exponentially increased rates of infection in frail older adults (314).   
An alternative explanation for the apparently preserved chemotaxis to IL-8 in healthy 
older adults is the sample size was too small to determine the actual difference between 
the healthy older and frail older adults and the current study lacked power.  Reviewing 
the data and statistical tests confirms there is a significant difference in the chemotaxis to 
IL-8 in neutrophils from healthy younger and frail older adults.  However, there is no 




younger or frail older adults.  This means it’s true value could lie anywhere between the 
values for chemotaxis for healthy younger adults and frail older adults.  To confirm 
whether there is actually preserved chemotaxis to IL-8 in healthy older adults a statistical 
difference between the chemotaxis of healthy older adults and frail older adults is 
required.  A sample size of 19 in each group has been calculated to be adequate to 
demonstrate a statistical difference between healthy and frail older adults.   
As discussed in brief above differences witnessed in the frail older adults could be due to 
the presence of chronic inflammatory conditions rather than frailty itself.  Statistical 
analysis of the data suggests there is no difference in the chemotaxis to IL-8 in frail older 
adults without chronic inflammatory conditions and those with chronic inflammatory 
conditions.  Chemotaxis to IL-8 (µm/min): frail older adults without chronic inflammatory 
conditions 0.57 (0.03-1.12) and frail older adults with chronic inflammatory conditions 
0.46 (0.15-0.77).  Independent t-tests p=0.658.  However, as the sample populations are 
small (frail older adults without chronic inflammatory conditions – 5 and frail older adults 
with chronic inflammatory conditions – 12) this should be interpreted with caution and 
further investigation is required.       
Similar to other studies investigating migratory function in older adults there was no 
significant differences in chemokinesis (163, 313) although there was a trend towards a 
reduction across the three groups in migration towards fMLP.  This small reduction in 
chemokinesis did not affect the chemotactic index, the overall migratory function.  This 
suggests neutrophils from healthy and frail older adults can move just as effectively as 




The Insall chamber assay is an imperfect technique for the quantification of neutrophil 
migration primarily it is not physiological but it does have some advantages over 
alternative assays.  The direct visualisation of the neutrophils as they migrate allows 
quantification of both chemotaxis and chemokinesis rather than an assessment of their 
overall migratory function as used in the transwell approach (315).  The Insall chamber 
assay is a relatively simple technique for neutrophil migration which does not require 
tissue culture and has been therefore been utilised in multiple labs across the world 
ensuring data is widely applicable.  The assay quantifies neutrophil migration in two-
dimensions not the more physiological three dimensions, the advantages and 
disadvantages of two and three dimensional methods are discussed later.  A further 
criticism of the Insall chamber assay is the presence of subjective bias in the analysis of 
the video microscopy films.  Whilst the analysis protocol was standardised: 
randomisation of neutrophil selection, strict inclusion and exclusion criteria for 
neutrophils, there is still an unacceptable degree of human interpretation.  Automation 
of the process and inclusion of all the neutrophils not just ten randomly selected cells 
would improve the accuracy of the data.  A potential advantage of the transwell assay is 
that neutrophil migration can be measured across an endothelial membrane replicating a 
more physiological environment (27) and migratory transwell assays incorporating flow 
have also been described.  These are reported to be more physiological because laminar 
flow is important in securing the adhesion of neutrophils to the endothelial wall prior to 
the neutrophils initiating their migration through the endothelial walls However, they do 
not allow accurate separate analysis of speed and directionality.  The microfluidic device 




accurately decouple the measurement of speed and directionality (316) but cells have to 
enter the chemotactic viewing well, and thus only a select population of cells which can 
migrate into this narrow chamber are selected for study .  A further advantage of this 
method is it utilises whole blood rather than isolated neutrophils in the assay.  Isolation 
of neutrophils by any method results in a degree of activation, but the percol gradient 
method used in this study was selected as it has been shown to minimise this effect 
(254).  It is possible to review the activation status of the neutrophils by eye under a 
microscope using the morphology and behaviour of the neutrophils as indicators.  This is 
well characterised in healthy younger adults and any neutrophils believed to be activated 
at this point by the process of isolation can be discarded prior to the migratory assay.  
However, the morphology and behaviour of neutrophils from frail older adults is poorly 
understood and therefore the utility of this assessment is not known in this patient 
group. 
Both chemotaxis and chemokinesis is reliant on adhesion molecules which propagate the 
adhesion of neutrophils to the endothelium and their subsequent migration through the 
endothelial cell wall.  In vitro, the albumin coating the coverslips mimics ICAM-1 which 
binds to both LFA-1 and Mac-1 on the neutrophil cell surface.   
Sections 2.6 and 2.7 describe the differences throughout the three groups in adhesion 
molecules expression on the neutrophil cell surface.  Throughout the three groups there 
was no difference in expression of CD18 but differences in the expression of both CD11a 
and CD11b, and differences in the response to stimulation in CD62L, CD66b and CD63 




older adults but CD11b and activated CD11b expression was reduced, by a similar 
amount, in both healthy older and frail older adults.  This is comparable to other studies 
although there is controversy in the literature.  Butcher et al found no significant 
difference in the expression of either CD11a or CD11b on the cell surface of neutrophils 
from healthy older adults (317) and a study investigating the expression of CD11b on the 
surface of neutrophils from nursing home residents demonstrated elevated levels of 
CD11b in the frail cohort (210).  However, similar to the data presented here other 
studies have demonstrated decreased CD11b in low activity older adult cohorts and 
nursing home residents (208, 313).  Investigation into the differing roles of Mac-1 
(CD18/CD11b) and LFA-1 (CD18/CD11a) could potentially explain how the differences in 
CD11a and CD11b expression in healthy and frail older adults are related to the witnessed 
differences in chemotaxis towards different chemoattractants.  Chemotaxis to fMLP has 
been demonstrated to be reliant on the interaction of three adhesion molecules: Mac-1 
which provides traction for movement, LFA-1 and α4 which both provide directional 
signalling for movement.  However, chemotaxis to IL-8 has been demonstrated to be 
mediated by LFA-1 only (318, 319).  Reduction in CD11a and CD11b expression in frail 
older adults is associated with poor chemotaxis towards both IL-8 and fMLP whereas 
preserved CD11a expression in healthy older adults could explain the preserved 
migratory function towards IL-8.  The relationship between CD11b, activated 11b and 
chemotaxis to fMLP was demonstrated in the significant correlation of the adhesion 
markers with chemotaxis to the bacterial chemoattractant.     
CD62L, CD63 and CD66b are all implicated in the upregulation and recruitment of Mac-1.  




cell surface markers at baseline there are significant differences in how these cell surface 
markers are expressed on stimulation in both healthy older and frail older adults.  This 
suggests that an ineffective response to stimulation in healthy older and frail older adults 
may contribute towards poor neutrophil function.    
A further hypothesis that could explain the apparent preserved chemotaxis to IL-8 in 
healthy older adults could be differences in the amount or function of IL-8 receptors, 
CXCR-1 and CXCR-2, expressed on the neutrophil cell surface in healthy and frail older 
adults.  Similar to data reported in this chapter and previous studies have not elicited a 
difference in the cell surface expression of CXCR-1 and CXCR-2 in either healthy older 
adults (compared to healthy younger adults) or healthy older adults with low activity 
levels compared to those with higher activity levels (163, 313, 320).  There is however 
some evidence that CXCR-2 receptor is integral to neutrophil chemotaxis; blocking CXCR-
2 receptor on neutrophils resulted in significantly decreased chemotaxis but not 
chemokinesis (321).Therefore, despite normal cell surface expression of both CXCR-1 and 
CXCR-2 in frail older adults binding of IL-8 to the receptor may not result in either 
appropriate or maximal intracellular signalling and result in reduction in chemotaxis to IL-
8.   
Flow cytometry is considered a simple and reproducible technique that it is utilised for 
diagnostic purposes in clinical medicine in multiple conditions (322).  However, there are 
limitations to its use in research and in particular within this study.  Whilst it is an 
excellent tool to describe the number of cell surface markers both as an absolute 




consider the functional capabilities.  Therefore, the earlier reported ineffective response 
to stimulation due to the failure to upregulate CD62L, CD63 and CD66b in healthy and 
frail older adults could be erroneous.  The neutrophil from the frail older adult may not 
need to upregulate these cell surface markers to the extent of the healthy younger adult 
because the neutrophil cell surface markers in the frail older adult may be able to 
produce a magnified response which is comparable to the response of a greater number 
of cell surface markers expressed on the neutrophil from the healthy younger adult.  In 
brief, number does not necessarily reflect function.  The data presented in this chapter 
obtained from flow cytometry only provides a snapshot of the cell surface of a neutrophil.  
It does not investigate internalised cell surface markers which may be important in the 
consideration of response to varying conditions or provide data on neutrophil response 
over different time-periods.  The data presented in section 12 suggests that responses to 
stimulation may be delayed in frail older adults and therefore reported differences in 
response to stimulation may be incorrect and actually represent a delay in response 
rather than an absolute inability to respond.  The flow cytometry method utilised in 
investigating cell surface markers reported in this chapter also relies on the similarity of 
commercially available antibodies in which there may be functional differences, 
particularly when running experiments over a period of years.                 
PI3kinase is believed to be central to the control of accurate and directional migration in 
the neutrophil; a non-specific inhibitor of PI3 kinase, wortmantin, causes significant 
reduction in neutrophil migration both chemotaxis and chemokinesis (323-326).  Section 
2.8 describes how incubation of neutrophils from frail older adults with PI3 kinase 




expected in neutrophils from healthy younger adults.  This result is similar to data 
published previously which demonstrated that neutrophils from healthy older adults 
incubated with PI3 kinase inhibitors δ and γ had improved chemotactic ability (163).  
However, the data presented in this chapter did not elicit an overall improvement in 
neutrophil chemotaxis in healthy older adults with PI3 kinase inhibition.  Furthermore, 
contrary to previously published data (163) there was no significant reduction in 
neutrophil chemotaxis to IL-8 in the healthy older adult group.  As demonstrated in this 
chapter and elsewhere (163) PI3 kinase has a restorative but not enhancive effect on 
chemotaxis.  It can be hypothesised that previously demonstrated positive responses to 
PI3 kinase inhibition in healthy older adults could be related to the definition of healthy 
older adult which did not take into account the presence of frailty.  This is supported by 
the negative association between the physical parameter grip strength and fold change 
improvement in chemotaxis following PI3 kinase inhibition (figure 5.12).  Not only does 
this ratify the close relationship between frailty, sarcopenia and immunesenescence it 
offers an individualised approach to a potential therapeutic target and could be used to 
identify a suitable target population; PI3 kinase inhibitors prescribed on the basis of grip 
strength.    
The data presented in this chapter demonstrated that both PI3 kinase inhibitors δ and γ 
significantly improved chemotaxis in neutrophils from frail older adults but did not 
significantly affect chemokinesis, although there was a trend towards improvement.  
Figure 5.11 demonstrates further work is required to investigate the effect of each 
inhibitor on individuals.   There is currently conflicting data published on the roles of the 




they are solely related to chemotaxis (163, 327, 328) recent work in three-dimensional 
collagen gels, a reported mimic of peripheral tissue, reports both PI3 kinase δ and γ also 
have an important role in chemokinesis (329).  However, it may not be possible to 
accurately separate chemokinesis from chemotaxis when utilising a three-dimensional 
collagen model; the role of PI3 kinase in aligning the pseudopodia at the leading edge is 
essential in propelling the neutrophil forward in any direction in a confined environment 
such as a collagen model. The data presented in this chapter demonstrates a definite role 
in chemotaxis towards IL-8 but suggests there may also be a role within chemokinesis 
which requires further investigation.       
Pi3kinase inhibitors are reported to be selective: TGX 221 is quoted as being 1000 fold 
more selective for p110β than p110δ, AS 252424 is quoted as being 30 fold more 
selective for PI3 kinase γ than Pi3 kinase α, Cal 101 is quoted as being 40-300 fold more 
selective for p110δ than p110α/β/γ (330).  However, not all possible interactions are 
reported for example TGX 221 selectivity is only quoted in comparison to p110δ not 
p110γ nor p110α.  In addition whilst the PI3kinase inhibitors are reported to be selective 
for the various isoforms specificity is not considered and for these reasons the limitations 
of the inhibitors need to be considered when interpreting these data.   
Akt is an important downstream effector of PI3 kinase and its activation is dependent on 
the generation of PIP2 and PIP3 (the products of PI3 kinase activation).  Threonine 308 is 
situated in the activation loop of Akt and its phosphorylation results in partial activation 
of Akt (331).  Section 2.9 demonstrated there was no significant difference between the 




any certainty due to varied responses from individuals and the small sample. The visual 
interpretation of the data (without statistical analysis) suggests neutrophils from healthy 
older adults and frail older adults may have an exaggerated increase in phosphorylation 
of threonine 308 in response to IL-8 stimulation compared to healthy younger adults.  
The response to IL-8 in the healthy younger adults appears minimal.  However, an 
alternative explanation is a delayed response in the phosphorylation of threonine 308 in 
the neutrophils of healthy older and frail older adults compared to healthy younger 
adults; the phosphorylation of threonine 308 in healthy younger adults occurring almost 
instantaneously on stimulation with IL-8 with a rapid rise and then decline in the 
phosphorylated threonine 308.  This is supported by the representative Western blot 
(figure 5.13A) which shows an increase in density at 20 seconds in the healthy young 
individual and at 60 seconds in the healthy older adult.  Validation work of the 
experiment protocol suggested that there was a rapid rise in phosphorylation of 
threonine 308 in response to IL-8 at twenty seconds in the neutrophils from healthy 
younger adults (332).  It is possible that differences in experimental technique led to an 
absence of signal from the healthy younger adults which suggests a delayed response in 
healthy and frail older adults rather than an exaggerated response.  This section of work 
needs to be repeated in a greater number of samples with a shorter period of initial 
stimulation, for example 10 seconds rather than 20 seconds.     
Sections 2.1 to 2.9 report on the reduction in chemotaxis to IL-8 in neutrophils from frail 
older adults and the reduction in chemotaxis to fMLP in both neutrophils from healthy 
older and frail older adults.  It also reports on the reduction in expression of LFA-1 in frail 




CD63 and CD66b in both healthy and frail older adults to respond to stimulation.  It 
proceeds to report on the dysregulation of PI3 kinase in healthy and frail older adults and 
the potential for individualised therapeutic targets using PI3 kinase inhibitors.  Sections 
2.10 to 2.15 proceed to investigate whether poor migratory function is intrinsic to 
neutrophils from frail older adults due to cellular senescence or whether it can be 
induced by the ‘frail’ environment.    
Studies have demonstrated that chemotaxis is increased in healthy younger adults with 
infection conversely in states of severe sepsis it is reduced suggesting the environment 
can have both an enhancing and detrimental effect on neutrophil migratory accuracy 
(333-335) either by directly altering cellular functions or causing a different subset or 
phenotype of neutrophils to be released systemically.  These effects might be due to 
exposure to priming agents such as TNFα. Previous in vitro studies have demonstrated 
that incubating neutrophils from healthy younger adults with pooled plasma from healthy 
older adults did not induce an “old” migratory phenotype of reduced chemotaxis when 
migrating towards both IL-8 and fMLP (163) and nor did priming the neutrophils with 
1pM TNFα prior to exposure to the chemoattractant  (336).  These experiments were 
repeated in section 2.10 and in concordance with previous results there was no reduction 
in chemokinesis or chemotaxis in neutrophils from healthy younger adults when 
incubated with pooled plasma from healthy older adults.  However, there was a trend 
towards a reduction in chemotaxis in neutrophils from healthy younger adults when 
incubated with pooled plasma from frail older adults; (p=0.053). It is unclear whether 
these studies were under-powered but these data suggest that the ‘frail’ environment 




function.  An important extension of this work would be to increase the number of 
studies and to investigate the effect of pooled plasma from healthy younger adults on the 
neutrophils from frail older adults to consider whether these neutrophils can be rescued 
with plasma from healthy younger adults.  Post-hoc analysis of the data suggests a 
sample size of 14 in each group would be required to demonstrate a significant difference 
in chemotaxis following the incubation of neutrophils with pooled plasma from frail older 
adults.  Previous work using healthy younger and older adults demonstrated that poor 
chemotaxis in healthy older adults was not improved following incubation with pooled 
plasma from healthy younger adults (163). An important consideration when using 
pooled plasma is the effect of one individual on the pool.  It is possible a single individual 
may change the composition of the pool significantly.  This could be negated by selection 
of the individuals to be included in the pool following the multiplex analysis or increasing 
the number of individuals within the pool both of these strategies would not have been 
feasible in this study.         
Immunesenescence is intrinsically linked with inflammageing and it is postulated that 
exposure to chronic inflammation can modulate the immune system and result in 
immunesenescence (150, 337).  Frailty is associated with an increased amount of chronic 
inflammation in comparison to a healthy older population; there is also some evidence 
that inflammation predates frailty (169-171, 206, 302).  Chronological age, rather than 
biological age or frailty, is also considered to be associated with inflammation (150, 230), 
however, the effect of frailty has not been considered in these studies.  Section 2.11 
describes a chronic inflammatory environment in both healthy older and frail older adults 




significantly increased concentrations of IL-4, IL-17 and IL-1β in healthy older adults but 
not frail older adults.  The concentrations of MIP1a increases with frailty; there are 
significantly increased concentrations in frail older adults compared to healthy older 
adults and healthy younger adults.  There are significantly reduced concentrations of 
MCP-1 in frail older adults when compared to healthy older adults but not healthy 
younger adults.  The data presented in this chapter is contrary to previous studies which 
have demonstrated a pro-inflammatory environment in frail older adults; further analysis 
and discussion will be completed in chapter 6.   
 
The investigation of a pro-inflammatory profile in frail older adults has been previously 
limited to IL-6, CRP, TNFα and IL-10.  A number of studies have demonstrated a positive 
association between IL-6, CRP and TNFα, and frailty, sarcopenia or indicators of both 
conditions such as low muscle strength (169, 179-181, 185, 187, 195, 202, 302, 338).  CRP 
was significantly raised in the frail older adults and this is discussed in greater depth, 
below.  Contrary to previous literature TNFα concentrations were not significantly 
different between the three groups and only 3% of the frail older adult group had a 
concentration of IL-6 within detectable range and none had a detectable concentration of 
IL-10.  Reported concentrations of IL-6 in frail older adults range between 3.5-4.4 pg/ml 
(171, 178, 187).  The lowest detectable range of IL-6 in the commercial multiplex used in 
this study was 2.81pg/ml.  An assay with increased sensitivity at the lower end of 
detectable range may have resulted in an increased number of samples in all three 
groups with a concentration within the detectable range ensuring apparent differences 




was a much larger degree of variability within both the healthy older and frail older adult 
suggesting a linear relationship between frailty and TNFα may be too simplistic.  
Furthermore, most cytokines have a short free half-life systemically due to their cognate 
receptors which are present on cells or shed and present in solution (such as TNFsR1 and 
TNFsR2 for TNFα).  The utilised assay does not report if it measures free or receptor 
bound TNFα and measurements taken from plasma and serum would not provide a 
measure of cell bound TNFα, therefore it is unclear how effectively these systemic 
measures reflect cytokine activity.   
         
Similar to previous data there was an increase in CRP concentration in the frail older 
adults.  CRP is primarily produced by hepatocytes and to a lesser extent lymphocytes and 
monocytes; it is unlikely that CRP synthesised by other sources have much of an impact 
on circulating serum concentration.  Pro-inflammatory cytokines, IL-6, IL-1β and TNFα 
induce CRP expression in hepatocytes (339).  CRP exists as two forms both of which have 
significant effects on neutrophil function.  Pentameric CRP circulates in the serum and is 
believed to have mainly anti-inflammatory effects including reduction in neutrophil 
chemotaxis (340).  Monomeric CRP is the tissue bound form and has pro-inflammatory 
effects including delaying neutrophil apoptosis and upregulating Mac-1 (341, 342).  The 
plasma half-life of CRP is approximately 19 hours and is constant under all conditions of 
health and disease therefore the sole determinant of circulating CRP concentration is the 
synthesis rate (300).  The frail older adults could have either a constant stimulus present, 
which is unmeasured in this study, an abnormal exaggerated response to the circulating 




Whilst pentameric CRP is believed to reduce neutrophil chemotaxis the demonstrated 
increase in concentration of CRP in frail older adults is not high enough to explain the 
trend towards a reduction in chemotaxis when pooled plasma from frail older adults was 
added to neutrophils from healthy younger adults.  The concentration of CRP measured 
in the frail older adult population (8.87 µg/ml) is not comparable to concentrations in 
adults with sepsis (48.0-150 µg/ml (343, 344)) and therefore it is unlikely the effect of 
pentameric CRP is having a direct effect on neutrophil migratory ability, but instead might 
be a marker of other serum factors which could induce change in neutrophil function.     
 
The most significant limitation to the data reported in this chapter on CRP is that it is 
unable to fully describe the complete relationship between CRP and frailty.  CRP 
concentration was measured using a hs-CRP ELISA assay which is able to accurately 
measure between 0.4 and 10 µg/ml.  Values greater than 10 µg/ml were recorded as 10 
µg/m and were seen in  3.6% (1 person) of healthy young adults, 2.6% (1 person) of 
healthy older adult and 27.3% (10 people) of frail older adults.  Although this did not 
affect the quoted statistics (not normally distributed therefore median quoted) it does 
prevent full analysis of the relationship between CRP, frailty, immunesenescence and 
inflammageing.     
The data presented in this chapter has so far demonstrated a significant difference in 
migratory accuracy in neutrophils from frail older adults; in vitro this can be corrected 
with a PI3kinase inhibitor suggesting dysregulation of internal cell mechanisms is 




in frail older adults and this can induce a trend towards a detrimental migratory profile in 
neutrophils from healthy younger adults.   
Previous studies suggest that primed neutrophils produce a response to stimulation 
which can be up to ten times larger than a quiescent neutrophil.  This has been shown to 
result in improved chemotaxis along with improvements in other neutrophil functions 
(78, 163, 320). Previous studies have demonstrated: failure to respond to priming in 
neutrophils from healthy older adults (163, 214) and, a reduction in the production of 
NETs following priming with 0.5nM TNFα and subsequent stimulation in healthy older 
adults.  Neutrophils from healthy younger adults primed with 1pM TNFα in experiments 
conducted in an identical manner to the data presented here displayed an improvement 
in chemotaxis (163) whereas in these data priming neutrophils from healthy younger 
adults with 1.15nM TNFα had a detrimental effect.  Subjective review of the videos 
suggested this may be due to increased adhesion of the neutrophils to the albumin.  The 
neutrophils from frail older and healthy older adults primed with 1.15nM TNFα 
demonstrated a non-significant improvement in chemotaxis.  It can be postulated this is 
either an adaptive response to a chronic inflammatory environment or the result of 
neutrophil immunesenescence associated with increasing age and frailty.  Further 
experiments designed to review the effect of the concentration of priming agents on 
neutrophils from the three different groups and the relationship with background 
inflammatory state are necessary to support this hypothesis.  The concentration of TNFα 
in the frail older adults in this study was 2.36pM suggesting the 1.15nM concentration 
used for priming is not physiological.  The concentration of previously reported TNFα in 




concentration rather than the concentration within the tissue or the concentration during 
infection or inflammatory response.  A significant limitation of the data presented 
throughout this chapter is that all the validation work for the concentration of 
chemoattractants, priming and stimulating agents was completed only in healthy younger 
adults.    The data presented in this chapter also suggests a delayed response to priming 
in frail older adults with maximal response at 30 minutes in healthy younger and healthy 
older adults and at 45 minutes in frail older adults.  The effect on the migratory dynamics 
of neutrophils primed over an extending time-period has not been investigated before 
but these data suggests there may be a delay in neutrophil functional response to 
priming in frail older adults.  This supports the hypothesis that there is a lag in 
intracellular signalling which was also suggested by the phosphorylation of threonine 308 
data.  However, this does need to be interpreted with caution as the data is mostly not 
significant.         
The number of circulating neutrophils is raised in the frailty state (210, 215) but the 
mechanisms and characteristics of this relative neutrophilia are unknown. Increased 
release of neutrophils from the bone marrow in response to an acute inflammation state 
would result in increased proportion of immature neutrophils but a functional deficit in 
the clearing mechanism of aged neutrophils would result in a shift in the neutrophil 
population towards senescent neutrophils.  An alternative explanation is the 
inflammatory environment associated with frailty results in decreased apoptosis of 
neutrophils and extends their lifespan.  The differences demonstrated in the functionality 
in neutrophils from frail older adults could be explained by the relative neutrophilia and 




investigating the characteristics of neutrophils from nursing home residents 
demonstrated both an increased proportion of immature band neutrophils in frail older 
adults and an increased frequency of HLA-DR expression in neutrophils from frail older 
adults, which is associated with tissue infiltrating neutrophils, and the authors suggest 
this represents an increased proportion of neutrophils undergoing reverse trans-
endothelial migration (210).     
Section 2.14 demonstrates an increased proportion of CD16 bright CD62L dim 
neutrophils, reportedly aged neutrophils, in frail older adults compared to both healthy 
younger and healthy older adults.  Three different neutrophil subsets, CD16 bright CD62L 
bright, CD16 bright CD62L dim and CD16 dim CD62L bright, have been observed in a 
range of inflammatory conditions including sepsis, cancer and trauma (345).  The CD16 
bright CD62L dim neutrophils are reported to be functionally different to the 
phenotypically normal neutrophil (CD16 bright CD62L bright) with increased expression 
of CD11b, increased production of hydrogen peroxide and inhibition of T cell responses in 
co-culture (345).  CD62L dim neutrophils have a banded hypersegmented nucleus and 
have been reported to be aged in comparison to the other two subsets.   However, recent 
research has suggested they may be an entirely separate subset recruited in acute 
inflammation independently of the other two subsets (346, 347).  Whilst the increase in 
this sub-population of neutrophils in frail older adults represents a doubling in the 
population the actual numbers are small and therefore unlikely to account for the 




Section 2.14 also demonstrates that neutrophils from frail older adults are neither 
senescent nor activated using a ‘traditional’ method classifying neutrophil sub-
populations developed in chronic inflammatory conditions and trauma (305-308, 348).  
This is also demonstrated in neutrophils from healthy older adults.  Possible explanations 
for the relative neutrophilia in frail older adults associated with the inflammatory profile 
include a chronic increase in the release of neutrophils from bone marrow in response to 
chronic inflammation which whilst resulting in increased immature granulocytes in the 
circulation would not be detectable by the methods utilised in this study, as the 
immature granulocytes mature to phenotypically normal neutrophils at the same rate 
and the proportions of the populations remain the same, this explanation would not 
explain differences in neutrophil function.  An alternative explanation might be that the 
chronic inflammatory environment results in a constant cycle of priming and then de-
priming of the circulating neutrophils resulting in longer lifespans for these neutrophils.  
Current evidence suggests that re-primed neutrophils are not functionally inferior to their 
unexposed counterparts (83) but little is known about neutrophils undergoing a 
perpetual cycle of priming and de-priming.   
There is an increase in CD16 expression in the frail older adult group both at baseline and 
on stimulation compared to the healthy older adults and also a failure to appropriately 
upregulate CD16 expression on stimulation.  CD16 expression has previously been 
demonstrated to be reduced in healthy older adults but has never been investigated in 
frail older adults (349).  CD16 is acquired by neutrophils as they mature in the bone 
marrow and in states of neutrophilia associated with acute inflammation there is both 




impairment including reduced chemotaxis and an impaired ability to upregulate CD16 on 
stimulation (353).  Whilst this chapter has demonstrated that neutrophils from frail older 
adults have functional impairment, reduced chemotaxis and impaired ability to 
upregulate CD16 on stimulation, and previous literature has demonstrated a neutrophilia 
in frail older adults (204, 210) the increased CD16 expression at baseline in the frail older 
adults suggests the neutrophilia is not a ‘traditional’ acute inflammatory response.  
Taking these data together suggests a polyclonal expansion of neutrophils in frail older 
adults rather than isolated expansion of one sub-population.     
Sections 2.15 and 2.16 report that neutrophils from healthy older adults are functionally 
activated despite cell surface marker phenotypes that suggest otherwise.  Healthy older 
adults have increased amounts of neutrophil elastase activity compared to healthy 
younger adults; a finding that replicates results from previous studies (163).  However, in 
the frail older adults there was significantly less neutrophil elastase activity compared to 
the healthy older adults and the neutrophil elastase activity of frail older adults was no 
different to that of healthy younger adults.   Section 2.11 demonstrated a pro-
inflammatory environment in both healthy and frail older adults and therefore a similar 
level of exposure to circulating activating factors.  Possible explanations of this 
phenomenon are poorer functional ability in the neutrophils from frail older adults to 
respond to these activating factors or an increased concentration of an unmeasured 
activating factor in healthy older adults that is not present in frail older adults.  
This chapter reports unique data investigating the functional ability of neutrophils from 




chemoattractant, fMLP, in healthy older and frail older adults and migratory inaccuracy 
towards the intermediate chemoattractant, IL-8, in just frail older adults.  This 
detrimental ‘frailty’ effect on neutrophil migration can be rescued by PI3kinase inhibitors 
and there was a trend towards inducing this phenotype in neutrophils from healthy 
young adults with pooled plasma from frail older adults.  Migratory inaccuracy in frail 
older adults is related to the expression of the adhesion molecules CD11a and CD11b and 
their regulatory cell surface markers CD66b, CD63 and CD62L.  An inflammatory 
environment has been demonstrated in both the healthy and frail older adults which will 
require exploration and this will be analysed further in Chapter 6.  This chapter has also 
demonstrated that migratory inaccuracy in frail older adults is not related to their 
oxidative burst.  Further work is required investigating the effect of priming on the 
chemotaxis of frail older adults particularly in a variety of concentrations and agents as 
well as confirming a dysregulated PI3kinase-Akt pathway in neutrophils from frail older 












6. Frailty and Sarcopenia 


















The relationship between frailty and sarcopenia is incompletely characterised but these 
conditions share many of the same clinical outcomes, associations and suggested 
pathophysiology and are therefore considered to be closely related.  There has been an 
assumption in the literature that because sarcopenia is more prevalent than frailty and, is 
in itself a component of physical frailty that it can be considered a pre-cursor syndrome.  
However, a recent isolated report investigating the concordance of frailty and sarcopenia 
in a geriatric clinic demonstrated both that frailty was more common than sarcopenia 
and the concordance between frailty and sarcopenia was poor suggesting a more 
complex relationship than a simple, unidirectional model of progression from sarcopenia 
into frailty (32).          
The underlying pathophysiology for both syndromes is only partially understood and 
believed to involve a complex dysregulation of multiple systems.  Immunesenescence and 
inflammageing are associated with both syndromes but a causative role in the 
development or propagation of both syndromes is as yet undefined.  Higher levels of pro-
inflammatory cytokines can predict a reduction in fat free mass and loss of grip strength 
but a causative role for inflammageing has yet to be fully established (187, 188).  The 
drivers behind the propagation and progression of each syndrome are unknown but the 
role of the dysregulated immune system is likely to be fundamental.  
This chapter describes a comprehensively characterised frail older adult group and 
investigates frailty models, screening and diagnostic tests in this population.  It 




using different models.  It then progresses to consider possible drivers behind the 
progression of sarcopenia and frailty.     
 
This chapter aims to 
 Describe the three different recruited groups in detail 
 Describe the differences in prevalence of frailty with the employment of different 
models 
 Consider the effect of different parameters on frailty severity 
 Review the value and accuracy of two different frailty screening tests and two 
different frailty diagnostic tests 
 Describe the prevalence of sarcopenia in both a healthy and frail older adult 
population using two different methods; EWGSOP and IWGS. 












6.2 Clinical Characterisation 
Individuals were recruited to three different groups: healthy young, healthy older and 
frail older adults.  40 individuals were recruited to the healthy young and older adult 
groups and 37 were recruited to the frail older adult group: 2 frail older adults were lost 
to follow up before they could undergo complete characterisation and 4 frail older adults 
did not have assessment of muscle size.  The clinical characteristics of the three groups 
are described in Table 6.1 and the details of the frailty assessments described in Table 
6.2. 
The frail older women were significantly older (85.5 years) than then healthy older 
women (71.0 years) but the frail older men (77.5 years) were not significantly older than 
the healthy older men (76.0 years).  The difference witnessed in age between the two 
genders was due to: one, the frail older men being younger than frail older women and 
two, the healthy older men being older than their female counterparts.  When both 
genders were analysed together there was still a significant difference between the two 
groups: healthy older adults 71.0 +/- 9.0, frail older adults 84.0 +/- 14.8; Independent 
samples Mann-Whitney U test p<0.001.  (Table 6.1.)  
There were significantly more falls, increased co-morbidity and number of medications 
prescribed in the frail older adults compared to both the healthy younger and older 
adults.  Frail older adults had significantly more cognitive impairment, as described by the 
Addenbrooks cognitive examination, than healthy younger and older adults: HY F - 96.0, 




assessment demonstrated a step-wise progression in cognitive impairment through 
ageing and frailty in both genders this was significant for all pairwise comparisons apart 
from healthy older adults to frail older adults: HY F - 58.0, HY - M 58.0, HO - F 44.5, HO - 
M 50.5, FO - F 38.5, FO M – 43.0.  (Table 6.1.)      
As discussed previously in chapter 3 the height of the men was constant throughout the 
groups but the women were shorter with both increasing age and frailty: height 
expressed in metres HY F - 1.63, HO F - 1.60, FO F - 1.54, HY M - 1.77, HO M - 1.77, FO M - 
1.75 .  There was no difference in weight for either gender but due to the differences in 
height in women there was a significant increase in BMI in the frail older women when 
compared to the healthy younger women:  HY F - 22.3, HO F - 24.3, FO F - 25.5, HY M - 
26.3, HO M - 23.3, FO M - 23.1.  As expected, and previously described in chapter 3, there 
is a stepwise reduction in BATT measured in mm throughout the groups for both genders: 
HY F - 58.0, HO F - 39.3, FO F - 25.2, HY M - 79.5, HO M - 47.5, FO M - 26.3.  There is a 
significant reduction in the MUAC for men with age and frailty measured in cm, HY M - 
32.5, HO M - 28.0, FO M - 25.5, but no real difference in the MUAC with age of frailty for 
women, HY F - 26.8, HO F - 28.0, FO F - 25.5.  There is an increase in ultrasound 
echogenicity for both healthy older males and females, HY F - 0.95, HO F - 1.50, HY M - 
0.95, HO M - 1.48.  There is a non-significant increase in ultrasound echogenicity in frail 
older women in comparison to healthy older women and no difference in ultrasound 
echogenicity for frail older men in comparison to healthy older men, FO F - 1.99, FO M - 




As expected there was increased frailty severity in the frail older adults for both genders 
for all the frailty assessments (FI, FP, PRISMA 7, CFS, EFS, walk speed).  There was no 
difference in frailty severity between the different genders apart from the PRISMA 7 
which had a one point higher average score in males for both healthy younger and older 
adults.  The frailty index demonstrated a significantly graduated response throughout the 
groups in women but not men: HY F – 0.00, HO F - 0.05, FO F - 0.41, HY M - 0.00, HO M - 
0.03, FO M – 0.40.  All other frailty assessments (FP, PRISMA 7, CFS, EFS, walk speed) did 
not differentiate between healthy younger and older adults.  This was similar for the 
short physical performance battery which also did not differentiate between healthy 
younger and older adults: HY F - 12.0, HY - M 12.0, HO F - 12.0, HO M - 11.0, FO F - 2.0, FO 
M - 2.0.  Of the assessments of physical performance only grip strength demonstrated a 
graduated response with age and frailty in both men and women: HY F - 30.0, HY M - 











Table 6.1 – Characteristics of healthy young adults, healthy older adults and frail older adults 




Frail Older Adults Female Male 
















     




















































p=0.656  p=0.185  












































p<0.001 HY-HO p=0.308 
HY-FO p<0.001 
HO-FO p<0.001 










Frail Older Adults Female Male 
















p<0.001 HY-HO p=0.221 
HY-FO p<0.001 
HO-FO p=0.004 
p<0.001 HY-HO p=0.712 
HY-FO p<0.001 
HO-FO p=0.004 












p<0.001 HY-HO p=0.457 
HY-FO p<0.001 
HO-FO p<0.001 


















p=0.003 HY-HO p=0.882 
HY-FO p=0.003 
HO-FO p=0.036 












































































































Table describing the different characteristics of the three different groups: healthy young adults, healthy older adults and frail older 
adults.   
Co-morbidity = number of chronic conditions (stroke, myocardial infarction, congestive cardiac failure, diabetes mellitus, chronic 
obstructive pulmonary disease, dementia, osteoporosis, fragility fracture, cancer and atrial fibrillation).  Falls = number of falls in the last 
year.  Medications = number of prescribed regular medications.  BATT = bilateral anterior thigh thickness (as described in Chapter 2 and 3).  
Ultrasound echogenicity = average measure of echogenicity of rectus femoris bilaterally.   
N= HY – 40, HO – 40, FO – 35.  Incomplete data sets for: Addenbrooks cognitive examination – HY – 40, HO – 40, FO – 29, Stroop 
Interference – HY – 39, HO – 38, FO – 8. BATT – HY – 40, HO – 40, FO – 31, Ultrasound echogenicity – HY – 26, HO – 33, FO – 16.  All data 
was not normally distributed except BATT which was normally distributed for each group and gender.  Data given is median +/- IQR except 
BATT which is mean with confidence intervals.  Statistical tests given are Independent Kruskall-Wallis with Bonferroni corrected pairwise 
comparisons expect BATT which is ANOVA with post-hoc Tukeys.  All p values in bold are significant (p<0.05).   
There are no differences in the reported data between the genders for each group except in HY – height p<0.001, weight p<0.001, BMI 
p=0.013, MUAC p<0.001, BATT p<0.001 in HO – stroop interference =0.033, height p<0.001, weight p<0.001 and BATT p=0.004 and FO – 
height p<0.001, weight p=0.048.  Mann-Whitney U test for not normally distributed data and independent t-test for normally distributed 





Table 6.2 – Frailty descriptors in heathy young adults, healthy older adults and frail older adults 




Frail Older Adults Females Males 
Female Male Female Male Female Male I K-W Pairwise 
comparisons 
I K-W Pairwise 
comparisons 












p<0.001 HY-HO p=0.006 
HY-FO p<0.001 
HO-FO p<0.001 

















p<0.001 HY-HO p=1.000 
HY-FO p<0.001 
HO-FO p<0.001 
p<0.001 HY-HO p=1.000 
HY-FO p<0.001 
HO-FO p<0.001 












p<0.001 HY-HO p=0.510 
HY-FO p<0.001 
HO-FO p<0.001 

















p<0.001 HY-HO p=0.087 
HY-FO p<0.001 
HO-FO p<0.001 

















p<0.001 HY-HO p=0.145 
HY-FO p<0.001 
HO-FO p<0.001 

















p<0.001 HY-HO p=0.079 
HY-FO p<0.001 
HO-FO p<0.001 
































Frail Older Adults Females Males 
 Female Male Female Male Female Male I K-W Pairwise 
comparisons 


















p<0.001 HY-HO p=0.473 
HY-FO p<0.001 
HO-FO p<0.001 





Table describing the different frailty characteristics of the three different groups: healthy young adults, healthy older adults and frail older 
adults.   
N= HY – 40, HO – 40, FO – 35.  Data given is median +/- IQR.  All data sets not normally distributed.  Statistical tests given are Independent 
Kruskal-Wallis with Bonferroni corrected pairwise comparisons.  Statistically significant p values are in bold (p<0.05).   
There are no differences in the reported data between the genders for each group except in grip strength for all three groups p<0.001 and 





6.3 Frailty Index identifies a higher prevalence of frailty than Frailty Phenotype  
35 individuals recruited to the frail group underwent a complete assessment of frailty; all 
35 were identified as frail using the frailty index.  88.6% (31 individuals) of the frailty 
index positive individuals were also identified as frail using the frailty phenotype.  The 
frailty index positive but frailty phenotype negative individuals, 11.4% (4 individuals), 
were all classified as pre-frail using the frailty phenotype. (Figure 6.1.)    
No individuals in the healthy older adult group were identified as frail using either the 
frailty index or frailty phenotype.  15% (6) of the healthy older adult group were positive 
in a single frailty phenotype criterion: 10% (4) had a grip strength indicative of frailty, 
these individuals were all women, 2.5% (1) reported exhaustion and 2.5% (1) had weight 



































Prevalence of frailty identified by Frailty Index and Frailty Phenotype.  Each individual 
is represented by a block.  Frailty Index a composite measure of 30 different 
characteristics using a continuous scale representing a variety of different 
biopsychosocial domains; a score greater than 0.2 diagnostic of frailty.  Frailty 
Phenotype a categorical definition of frailty; greater than or equal to three diagnostic 
of frailty.   
37 individuals recruited to frailty group.  35 individuals identified as frail using both 
frailty index and frailty phenotype (blue).  4 individuals identified as frail with Frailty 





6.4 Frailty severity measured by Frailty Phenotype and Frailty Index is comparable 
The distribution of frailty severity was different for each frailty identification model; less 
severe frailty was more common in the frailty phenotype model but the complete 
spectrum of frailty was relatively equally represented with the frailty index model apart 
from the least frail (FI skewness = 0.494, FI kurtosis - -0.319, FP skewness = 0.285, FP 
kurtosis = -0.703).  Frailty phenotype identification of frailty: 11.4% positive in two 
criteria, 45.7% positive in three criteria, 25.7% positive in four criteria and 17.1% positive 
in all five criteria.  Frailty as described by the frailty index was more representative of a 
complete spectrum of frailty peaking at a frailty index of 0.4-0.45.  (Figure 6.2.) 
Frailty severity as described by both models is comparable.  There are significant 
increases in the frailty index with increasing positive criteria for the frailty phenotype; this 
occurred in a stepwise fashion: positive in two frailty phenotype (FP) criteria frailty index 
(FI) 0.36, positive in three FP criteria FI 0.39, positive in four FP criteria FI 0.46 and 
positive in all five FP criteria FI 0.51.  Correlation of severity as measured by the two 
frailty models was high: R=0.885, p<0.001, Spearman’s correlation coefficient.  (Figure 




































































Distribution of frailty severity in frail older adults.  A - Frailty Index and B - Frailty 
Phenotype.    
A – Frailty Index a composite measure of 30 different characteristics using a 
continuous scale representing a variety of different biopsychosocial domains; a score 
greater than 0.2 diagnostic of frailty.   
B - Frailty Phenotype a categorical definition of frailty; two diagnostic of pre-frailty.  



















Figure 6.3 – Comparison of frailty severity measured by the Frailty Phenotype and the 
























Comparison of frailty severity measured by the Frailty Phenotype on the x axis and 
Frailty Index on the y axis in frail older adults.  Frailty phenotype a categorical 
definition of frailty; number of positive Fried’s criteria.  Frailty Index a composite 
measure of 30 different characteristics using a continuous scale; a score greater than 
0.2 diagnostic of frailty.   N=35.  Data shown is mean +/- SEM.  Data normally 
distributed.   
Frailty Index for Frailty Phenotype 2 – 0.33, Frailty Phenotype 3 – 0.39, Frailty 
Phenotype 4 – 0.46, Frailty Phenotype 5 – 0.51.   
ANOVA p=0.007.  Post hoc-Tukeys 2-3 p=0.528, 2-4 p=0.076, 2-5 p=0.012, 3-4 p=0.292, 
3-5 p=0.034, 4-5 p=0.637.   













6.5 Frailty is a state separate to disability and co-morbidity 
Frailty is a separate entity to disability and co-morbidity however; there is considerable 
overlap between the three states of health.  It is possible to exist in a state of frailty 
without being either disabled or co-morbid.  In the study population, 12.5% were defined 
as just frail, 15% had co-morbidity, 7.5% had both frailty and co-morbidity , 20% were frail 
and disabled and 45%  were frail, disabled and had co-morbidity. (Figure 6.4.)   
The addition of either a disabled or co-morbid state to a frailty state appeared to increase 
the frailty severity as measured by the frailty index: FI for frail state – 0.33, FI for frail plus 
one other state (either disability or co-morbidity) – 0.43 (p=0.061).  There is a significant 
increase in frailty severity with the combination of all the three states: FI for frail state – 
0.33, FI for frail state plus two states (disability and co-morbidity) – 0.45.  This suggests 
that the addition of different health states to frailty may not have a cumulative effect and 











Figure 6.4 – Overlap and prevalence of disability, frailty and co-morbidity in healthy and 



























Overlap and prevalence of disability, frailty and co-morbidity in healthy and frail older 
adults.  Venn diagram depicting the frequency of each health state in both healthy and 
frail older adults.  N = 40 (35 frail older adults and 5 healthy older adults).  35 healthy 
older adults were neither frail, disabled nor possessed a co-morbidity and are not 
included in the Venn diagram.  Frailty defined as positive frailty index (>0.2), disabled 
defined as help required with greater than one basic activity of daily living (bathing, 
dressing, toileting, transferring, feeding), co-morbidity defined as a past medical 
history of chronic disease (stroke, myocardial infarction, congestive cardiac failure, 
diabetes mellitus, chronic obstructive pulmonary disease, dementia, osteoporosis, 








































Frailty severity with addition of different health states in frail older adults.   X axis – 
health state: Frail = positive Frailty Index, Frail + 1 state = positive Frailty Index and 
either disabled or co-morbid, Frail + 2 states = positive Frailty Index and disabled 
and co-morbid.  Y axis – Frailty Index.  N = 35.  Data normally distributed.  Data 
shown is mean +/- SEM.   
Frailty Index for Frail – 0.33, Frailty Index for Frail + 1 state – 0.43, Frailty Index + 2 
states – 0.45. 
T-test; Frail - Frail + 1 state p=0.061, Frail – Frail + 2 states p=0.020, Frail + 1 state – 
Frail + 2 states p = 0.763  












6.6 The addition of sarcopenia to frailty increases frailty severity 
This chapter has so far demonstrated that the Frailty Index and Frailty Phenotype models 
identify different populations of frailty and whilst the distribution of frailty severity is 
different for each model it is related; increasing frailty in one model reflected in the 
second model.  It has also demonstrated that frailty is a separate health state to disability 
and co-morbidity but the addition of just one of these states to frailty has significant 
implications on frailty severity.   
To consider whether the frailty phenotype criteria are equally weighted in their 
discriminative ability each criterion was analysed separately.  The most frequently 
positive criteria were walk speed (91.4%), physical activity (82.9%) and grip strength 
(85.7%).  Weight loss (positive in 40%) and exhaustion (positive in 48.6%) were equally 
likely to be positive or negative.  Taken with the data already presented in this chapter 
which describes increasing risk of adverse outcomes (as identified by the Frailty Index) 
with each additional positive Frailty Phenotype criterion this suggests that weight loss 
and exhaustion may be discriminative for increased frailty severity.  However, the 
average Frailty Index for an individual positive for each Frailty Phenotype criterion 
suggests that exhaustion and, in particular, weight loss are not discriminative of adverse 
outcomes: FI of exhaustion positive 0.45, FI of exhaustion negative 0.40 p=0.084, FI of 
weight loss positive 0.44, FI of weight loss negative 0.42 p=0.539.  Physical activity and 
grip strength demonstrate more of a discriminative effect as dichotomous criteria: FI of 
physical activity positive 0.44, FI of physical activity negative 0.35 p=0.057, FI of grip 
strength positive 0.44, FI of grip strength negative 0.33 p=0.016.  Grip strength is integral 




sarcopenia and contributor to loss of muscle mass.  This suggests that the addition of 
sarcopenia to a diagnosis of frailty would increase frailty severity and results in worse 
outcomes.  (Table 6.3.)       






6.7 Value and accuracy of identification tools of frailty 
Diagnostic screening tests are valuable tools in identifying complex clinical syndromes 
such as frailty but are only suitable for clinical use if the screening tool is accurate. 
Figure 6.6 and Table 6.4 demonstrate that PRISMA 7 in this population is a more sensitive 
test than walk speed but walk speed is a more specific test when comparing both 
screening tests to the gold standard of frailty index.  PRISMA 7 - 100% sensitivity, 95% 
specificity, positive predictive value 94.6%, and negative predictive value 100%.  Walk 
Frailty Phenotype Criterion 
  Negative Positive  
Walk Speed Number 8.6% (3) 91.4% (32)  
Frailty Index 0.37 (0.29-0.44)  0.43 (0.39-0.47) p=0.312 
Weight Loss Number 60.0% (21) 40.0% (14)  
Frailty Index 0.42 (0.37-0.46) 0.44 (0.38-0.51)  p=0.539 
Exhaustion Number 51.4% (18) 48.6% (17)  
Frailty Index 0.40 (0.36-0.44) 0.45 (0.40-0.48)  p=0.084 
Physical Activity Number 17.1% (6) 82.9% (29)  
Frailty Index 0.35 (0.29-0.42) 0.44 (0.40-0.48) p=0.057 
Grip Strength Number 14.3% (5) 85.7% (30)  
Frailty Index 0.33 (0.26-0.39) 0.44 (0.40-0.48) p=0.016 
Frailty Index and frequency of each Frailty Phenotype criterion.  N=35 for each criterion.  
Number is frequency as percentage of total with actual number in brackets.  Frailty Index 
is mean with confidence intervals.  All normally distributed.  Independent t-tests. 




speed - 94.3% sensitivity, 100% specificity, positive predictive value 100%, and negative 
predictive value 95.3%.  Combining the two tests together and considering it positive for 
frailty if both tests are positive does not improve the predictive value.  PRISMA 7 and 
walk speed – positive predictive value 100%, negative predictive value 95.3%.  Due to the 
methods of recruitment it is not possible to consider the effect of combining the methods 
and taking either result.  The study design stipulated that only participants with either a 
positive PRISMA 7 or walk test could be included in the frail older adult group therefore it 
is impossible to determine whether accuracy is increased combining the tests. 
PRISMA 7 is in concept more aligned with the Frailty Index, a composite measure of 
multiple biopsychosocial domains, whereas walk speed is closer in concept to Frailty 
Phenotype, a descriptive measure of physical health.  However, figure 6.6 demonstrates 
that both screening tests are non-specific and can identify individuals described as frail 
using ether model.  Walk speed identified three individuals who were described as frail by 
the Frailty Index but not the Frailty Phenotype.  This suggests that the tests are applicable 









Table 6.4 – Accuracy of PRISMA 7 and walk speed individually and combined compared 
to Frailty Index 
 
  Frailty Index Positive Frailty Index Negative 
PRISMA 7 Positive  35 2 
Negative 0 38 
Walk Speed Positive  33 0 
Negative 2 40 
PRISMA 7 and 
Walk Speed 
Positive  33 0 














The accuracy of screening tests compared to the frailty index.  Screening test 
horizontally in rows and the frailty index in columns.  N= 75 (40 HY and 35 FO).  
PRISMA 7 and Walk Speed: positive if positive for both screening tests, negative if 



















Prevalence and accuracy of frailty identified by the screening tests: walk speed and 
PRISMA 7 in healthy and frail older adults.  37 individuals recruited to frailty group 
complete data available on 35.  Each ellipse represents those individuals positive for 
either that frailty model or screening test as identified above the ellipse.  Where the 
ellipses overlap the individual is positive for all those overlapping criteria.         
30 individuals identified as frail using walk speed, PRISMA 7 frailty index and frailty 
phenotype (dark blue).  3 individuals identified as frail with walk speed, PRISMA 7 and 
frailty index but not frailty phenotype (mid-blue).   1 individual identified as frail using 
PRISMA 7, frailty phenotype and frailty index but not walk speed (light blue). 1 
individual identified as frail using PRISMA 7 and frailty index but not walk speed and 
frailty phenotype (green).  2 individuals identified as frail using PRISMA 7 but not 
walk speed, frailty index or frailty phenotype (air force blue).  38 healthy older adults 





The Frailty Index and Frailty Phenotype are both perceived as being time consuming 
diagnostic models which are impractical for use in clinical practice.  In an attempt to 
reduce the time required for clinical assessment shorter tests have been developed that 
include an assessment of severity; these are conceptually similar to the Frailty Index and 
take a biopsychosocial multi-domain approach to frailty diagnosis.  Two tests were 
considered: the Clinical Frailty Scale a clinical diagnosis of frailty severity following 
comprehensive geriatric assessment and, the Edmonton Frail Scale a short questionnaire 
which can be administered by anyone.  A potential advantage of the EFS and CFS over 
PRISMA 7 and walk speed is they characterise frailty into severity which can allow 
improved prognostication.     
In this population the Edmonton frail scale and Clinical frailty scale were less accurate 
than PRISMA 7 and walk speed at identifying frailty compared to the gold standard of the 
frailty index.  Edmonton frail scale: 73.5% sensitivity, 100% specificity, positive predictive 
value 100%, negative predictive value 81.63%.  Clinical frailty scale: 91.4% sensitivity, 
97.5% specificity, positive predictive value 97%, negative predictive value 92.9%.  (Table 
6.5.) 
Whilst these tests offer the ability to score frailty severity and there is a step-wise 
increase in frailty severity, as measured by the frailty index, with progression through 
frailty group in both Edmonton frail scale and Clinical frailty scale there is a huge degree 
of variability in the frailty index severity.  Figure 6.7 demonstrates that a number of 
individuals scored as moderate severity using the Clinical Frailty Scale have lower frailty 




Frail Scale where some individuals scored as vulnerable have frailty indexes that are 
greater than those who are severely frail.  However, the overall correlation remains 
strong for both diagnostic tests: FI and CFS, R = 0.868, p<0.001; FI and EFS, R = 0.841, 
p<0.001.      
This data taken together suggests the Edmonton frail scale and Clinical frailty scale may 
not be as accurate as PRISMA 7 and walk speed in identifying frail individuals and the 
supposed advantage they confer of offering severity rating may be inaccurate compared 
to the frailty index.   
 
Table 6.5 – Accuracy of Clinical Frailty Scale and Edmonton Frail Scale in comparison to 
Frailty Index  




Clinical Frail Scale Positive  32 1 
Negative 3 39 
Edmonton Frail 
Scale 
Positive  25 0 







The accuracy of tests compared to the frailty index.  Diagnostic test horizontally in 





Figure 6.7– Comparison of frailty severity as defined by Frailty Index and Clinical Frailty 



































































A - Frailty severity as measured by clinical frailty scale and frailty index in healthy and 
frail older adults.  Clinical frailty scale a diagnostic test of frailty severity based on 
comprehensive geriatric assessment.  X axis – Clinical frailty scale.  Y axis – Frailty Index.   
B - Frailty severity as measured by Edmonton Frail Scale and frailty index in frail older 
adults.  Edmonton frail scale a diagnostic test of frailty severity based on a 
biopsychosocial questionnaire.  X axis – Edmonton  frail scale.  Y axis – Frailty Index.   
Frailty Index a composite measure of 30 different characteristics representing a variety 
of biopsychosocial domains using a continuous scale; a score greater than 0.2 
diagnostic of frailty.   CFS - N=75.  Data shown is mean +/- SEM.  Data normally 
distributed.  1 - 0.03 +/- 0.07, 2 – 0.03 +/-0.08 3 - 0.07+/-0.05, 4 - 0.21 +/- 0.27, 5 - 0.33 
+/- 0.15, 6 - 0.43 +/- 0.15, 7 - 0.63.  ANOVA - P<0.001.  Unable to run post-hoc Tukey’s 
test due to the low frequency in some CFS categories.    
Edmonton Frail Scale - not frail 0-4, vulnerable 5-6, mild frailty 7-8, moderate frailty 9-
10, severe frailty >11.  N=75.  Data shown is median +/- IQR.  Data normally distributed 
except not frail: not frail - 0.05+/-0.07, vulnerable - 0.37+/-0.16, mild frailty - 0.40+/-
0.07, moderate frailty - 0.47+/- 0.15, severe frailty - 0.51+/-0.22.  Statistical test 
Independent Kruskal-Wallis with Bonerroni corrected pairwise comparisons.  P < 0.001, 
No frail to vulnerable p = 0.006, no frail to mild frailty p < 0.001, no frail to moderate 
frailty p < 0.001, no frail to severe frailty p = 0.001.  All remaining pairwise comparisons 
p =1.000.   





















6.9 Prevalence of sarcopenia 
The prevalence of sarcopenia using the EWGSOP method of defining the diagnosis in the 
healthy older adult population was 2.5% (1).  52.5% (21) healthy older adults had low 
muscle mass and 5% (2) had low grip strength but adequate muscle mass.  The remaining 
40% (16) had adequate muscle mass, strength and physical performance.  Considering 
the different genders 76.9% (10) of the healthy older men had low muscle mass and 
23.1% (3) had adequate muscle mass, strength and physical performance whereas the 
healthy older women had a greater proportion with adequate muscle mass, strength and 
physical performance, 48.1% (13) and also with sarcopenia, 3.7% (1).  (Figure 6.8.)       
In the frail older adult population there was an increased prevalence of sarcopenia using 
the EWGSOP method, 90.3% (28), 80.6% (25) were categorised as severe sarcopenia and 
9.7% (3) as just sarcopenia.  Interestingly two individuals had both poor physical 
performance and low grip strength but adequate muscle mass; this diagnosis is not 
recognised by either the EWGSOP or IWGS method of classification of sarcopenia.  When 
considering the different genders all the women had an element of muscle strength 
impairment whereas 21.4% (3) men had adequate muscle strength; 14.3% (2) of these 
men had poor physical performance in addition to low muscle mass and 7.1% (1) had only 
low muscle mass.  (Figure 6.9.)   
This suggests that healthy older women are more likely to have sarcopenia than healthy 
older men but the healthy older men are more likely to have low muscle mass than 
healthy older women.  In frail older adults there is a similar prevalence of sarcopenia in 




poor physical performance and low muscle strength but the majority of individuals have 
low muscle mass.           
The IWGS method of diagnosing sarcopenia demonstrates an increased prevalence of 
sarcopenia in all of the measured populations.  This is not however significant and there 
is a good strength of association between the two diagnostic methods.  x2(1)=50.4, 
p<0.001. Phi =0.848, p<0.001.      
 
Table 6.6 – Prevalence of sarcopenia using IWGS and EWGSOP criteria 
 




HO All 40 2.5% (1)  12.5% (5) 
 Women 27 3.7% (1) 14.8% (4) 
 Men 13 0% (0) 7.7% (1) 
FO All 31 90.3% (28) 96.8% (30) 
 Women 17 88.3% (15) 100% (17) 








Prevalence of sarcopenia using IWGS and EWGSOP criteria.  EWGSOP – BATT < 2.5 
standard deviations healthy younger population and either hand grip strength < 20kg for 
women or < 30kg for men or walk speed <0.8 m/sec.  IWGS – BATT < 20% healthy 















































Venn diagram depicting the prevalence of sarcopenia using the EWGSOP criteria in healthy 
older adults in A – all healthy older adults, B – healthy older women, C – heathy older men.  
Low muscle mass is defined as less than two standard deviations of muscle mass in healthy 
younger adults – BATT < 38.55mm in women and BATT < 54.36mm in men.  Low grip 
strength < 20kg in women and < 30kg in men.  Poor physical performance < 0.8m/sec.  
Green area represents sarcopenia.  Blue area represents severe sarcopenia.   
A - N = 40.  16 adequate muscle mass, muscle strength and physical performance. 21 low 
muscle mass.  1 sarcopenia, 2 low grip strength with adequate muscle mass. 
B - N = 27. 13 adequate muscle mass, muscle strength and physical performance. 11 low 
muscle mass.  1 sarcopenia. 2 low grip strength with adequate muscle mass. 
C - N = 13. 3 adequate muscle mass, muscle strength and physical performance. 10 low 









































6.10 Overlap of frailty and sarcopenia 
In the frail older adult population there was a high degree of overlap between sarcopenia 
and frailty measured by the four different approaches, frailty index, frailty phenotype, 
EWGSOP and IWGS.  There was a higher diagnostic rate of sarcopenia using the IWGS 
approach but despite this there was still a single individual with frailty who did not have 
sarcopenia by any definition.  This suggests that in this population it was possible to have 
frailty without sarcopenia.  However, the likelihood was low.  The data from healthy older 





Venn diagram depicting the prevalence of sarcopenia using the EWGSOP criteria in frail 
older adults in A – all frail older adults, B – frail older women, C – frail older men.  Low 
muscle mass is defined as less than two standard deviations of muscle mass in healthy 
younger adults – BATT < 38.55mm in women and BATT < 54.36mm in men.  Low grip 
strength < 20kg in women and < 30kg in men.  Poor physical performance < 0.8m/sec.  
Green area represents sarcopenia.  Blue area represents severe sarcopenia.   
A - N = 31.  1 low muscle mass.  3 sarcopenia, 2 low grip strength and poor physical 
performance, 25 severe sarcopenia. 
B - N = 17.  1 sarcopenia.  2 low grip strength and poor physical performance, 14 severe 
sarcopenia. 



















Prevalence and overlap of frailty and sarcopenia in healthy and frail older adults.  75 individuals in 
total.  33 had neither sarcopenia nor frailty and are not depicted.  Each ellipse represents those 
individuals positive for either that frailty model or sarcopenia model as identified above the 
ellipse.  Where the ellipses overlap the individual is positive for all those overlapping criteria.         
24 individuals were positive for frailty and sarcopenia using all four models (light blue).  2 
individuals were positive for frailty using the frailty phenotype and frailty index models and also 
sarcopenia using the IWGS criteria but not EWGSOP criteria (purple).  1 individual was positive for 
frailty using both the frailty phenotype and frailty index models but was not sarcopenic (pink).  4 
individuals were positive for frailty using the frailty index model but not the frailty phenotype 
model and also positive for sarcopenia using both criteria (green).  1 individual was positive for 
sarcopenia using both EWGSOP and IWGS criteria but negative for frailty (dark blue).  4 
individuals were positive for sarcopenia using the IWGS criteria but not the EWGSOP criteria 











The relationship between frailty and sarcopenia is only partially understood and whilst 
there are likely to be multiple pathophysiological pathways resulting in frailty the 
development of low muscle mass, then sarcopenia, severe sarcopenia and finally frailty is 
probably a common pathophysiological pathway.  The drivers propagating the syndromes 
are uncharacterised but a pro-inflammatory environment is considered to be 
fundamental and longitudinal research has shown that higher levels of pro-inflammatory 
cytokines can predict a reduction in fat free mass and a loss of grip strength (187, 188).  A 
pro-inflammatory environment has also been associated with frailty leading to the 
hypothesis that a pro-inflammatory environment is driving the loss of muscle mass, 
strength and ultimately both frailty and sarcopenia.   
However, Chapter 5 suggested that pro-inflammatory cytokines do not always increase in 
a stepwise fashion with frailty.  This might suggest that frailty progression may not be 
driven by a pro-inflammatory environment once a state of frailty has been reached.  To 
explore this hypothesis further the groups were expanded to include: healthy young 
adults, healthy older adults, healthy older adults with low muscle mass and frail older 
adults.  Adults with sarcopenia were excluded from analysis due to their low frequency in 
the sample population (n=1).  A commercially available human cytokine multiplex was 
used and cytokines with greater than 50% of values within the detectable range and IL-1β 
(due to high proportion of individuals within healthy older and frail older adults with 
concentration of IL-1β within detectable range) were included for further analysis.  For 




There are three different significant patterns within the cytokines measured.  One, 
increased concentration of cytokine in the healthy older adults with low muscle mass 
compared to healthy younger adults: IL-4, IL-17, Eotaxin and FGF.  Two, increased 
concentration of cytokine in healthy older adults, healthy older adults with low muscle 
mass and frail older adults compared to healthy younger adults: IL-8, IP-10 and Mip1a.  IL-
1ra had a higher concentrations in both healthy older adults with low muscle mass and 
frail older adults compared to healthy younger adults.  Table 6.7 and Figure 6.11 
demonstrate the large inter-quartile ranges present in the frail older adults.  To consider 
the effect of physical parameters and frailty on the cytokines the data was analysed in a 
number of ways.     
When the cytokine data from only the frail older adults was correlated with physical 
parameters and frailty there were a number of significant correlations.  However, there 
were also a large proportion of non-significant correlations which makes the data very 
difficult to interpret especially in relation to the repeated statistical testing.  Relevantly 
MUAC negatively strongly correlated with five cytokines; increased MUAC was associated 
with lower concentrations of cytokines.  The cytokines correlating with MUAC displayed 
both patterns of changing cytokine concentration suggesting the differences witnessed in 
the cytokine concentration cannot be explained by physical parameters.  (MUAC and IL-4: 
R=-0.510, p=0.008, MUAC and IL-8: R=-0.393, p=0.047, MUAC and Eotaxin: R=-0.490, 
p=0.011, MUAC and FGF: R=-0.410, p=0.038, MUAC and MIP1a: R=-0.520, p=0.006).  Only 
IL-1ra correlated with frailty; increased frailty was associated with decreased IL-1ra.  (FI 




Table 6.7 – Concentration of cytokines   
 HY HO LMM HO FO I K-W Pairwise 








p=0.001 HY-LMM HO 
p=0.015 
HY-FO p=0.001 




0.96 +/- 0.8 0.83 +/- 
0.57 
p=0.069  
IL-4 5.7 +/- 3.3 9.4 +/- 3.8 11.3 +/- 4.1 9.3 +/- 8.4 p=0.006 HY-LMM HO 
p=0.006 
IL-7 12.0 +/- 6.0 16.0 +/- 
12.0 
16.0 +/- 5.7 14.1 +/- 
10.9 
p=0.520  











IL-17 4.56 +/- 
11.5 




p=0.025 HY-LMM HO 
p=0.034 

























































p=0.009 HY-LMM HO 
p=0.014 




p=0.010 HY-LMM HO 
p<0.001 
















   
 
 
The concentration of cytokines (pg/ml) in healthy young adults (HY), healthy older 
adults (HO), healthy older adults with low muscle mass (LMM HO) and frail older adults 
(FO).  N = HY -27, HO – 15, LMM HO – 20, FO – 29.   
Data is not normally distributed.  Median +/- IQR are shown.  Statistical tests are 










































































Cytokine concentration (pg/ml) of A – IL-1ra, B – IL- 4, C – IL-8, D – IL-17.  Data is 
not normally distributed.  Median +/- IQR are shown.  N = HY -27, HO – 15, LMM 
HO – 20, FO – 29.  Statistical tests are Independent Kruskal-Wallis with 
Bonferroni corrected pairwise comparisons.  Only cytokines with statistical 





















































































Cytokine concentration (pg/ml) of E – IP-10, F – MIP1α, G – Eotaxin, H – FGF.  
Data is not normally distributed.  Median +/- IQR are shown. N = HY -27, HO – 15, 
LMM HO – 20, FO – 29.  Statistical tests are Independent Kruskal-Wallis with 
Bonferroni corrected pairwise comparisons.  Only cytokines with statistical 















































A further analysis was conducted to consider the effect of inflammatory burden.  The 16 
cytokines described in table 6.7 were analysed as a composite measure, an Inflammatory 
Index.  (For each cytokine the individuals with a concentration in the highest 20% of the 
total sample were awarded a score of 1.  The scores for all 16 cytokines were summed 
and expressed as a proportion of the total number of cytokines.)  This is a similar method 
to the previously proposed biomarker based Frailty Index but far cruder as the 
relationship between frailty and cytokines is incompletely characterised (183).   
The healthy older adults with low muscle mass and the frail older adults had a 
significantly higher Inflammatory Index than the healthy younger adults.  (Table 6.8.)  
There was also a weak positive correlation between the Frailty Index and the 
Inflammatory Index: R=0.250, p=0.013 (Spearman’s Rank Correlation Coefficient).  
However, age was also associated with the Inflammatory index: R= 0.326, p=0.001, and 
after adjusting for age frailty was no longer associated with the Inflammatory index: R=-










Table 6.8 – Inflammatory Index 
 
 HY HO LMM 
HO 




























On plotting the data it was apparent there were two distinct populations within the two 
groups defined by the Inflammatory Index.   (Figure 6.12.)  It was not possible to draw 
significant conclusions about the differences between the groups due to the small sample 
size but there appeared to be no difference in the individuals with higher concentrations 
of Inflammatory Index as described by physical and cognitive parameters.  (Table 6.9.)         
This analysis suggests the interplay between frailty, inflammageing and physical 
parameters may be more complex than originally considered.            
 
 
The inflammatory index of the four groups.  HY – healthy young adults, HO – healthy 
older adults, LMM HO – healthy older adults with low muscle mass, FO – frail older 
adults.  Inflammatory Index composite measure of 16 cytokines with greater than 50% 
of whole sample within detectable range and IL-1β.  N = 27, N=15, N=20, N=29.  Data is 
not normally distributed.  Median +/- IQR are shown.  Statistical test is Independent 




Figure 6.12 – Association between Inflammatory Index and Frailty Index 
 




















The association between the Inflammatory Index and the Frailty Index in healthy 
older and frail older adults.  Frailty Index on the x axis and Inflammatory Index on the 
Y axis.   N = 70 in total, HO - 38 , FO - 32.  Red lines represent the separation of the 




































Age 73 +/- 10 70 +/- 6.5 p=0.223 80 +/- 15 84 +/- 14 p=0.273 



























ACE 93 +/- 3.0 98 +/-8 p=0.069 79 +/- 31 70 +/- 31 p=0.672 
































This chapter has extensively described and characterised three different groups: healthy 
young, healthy older and frail older adult groups.  It has demonstrated that individuals 
recruited to the frail older adult group are frail by multiple different definitions and 
considered the value of these definitions.  It has described the differences in prevalence 
of frailty and sarcopenia and the concordance between the two conditions in this 
Physical and cognitive parameters of the separate populations define by 
Inflammation Index.  Populations defined by Inflammation Index >0.6.  N = HO II<0.6 
– 31. HO II>0.6 – 10, FO II<0.6 – 25, FO II>7 . Data not normally distributed.  Median 









population and then progressed to consider the chronicity of the conditions and potential 
underlying mechanisms.   
This chapter has accurately described and characterised both a healthy and frail older 
adult group.  Parameters associated with frailty representing a variety of biopsychosocial 
domains are significantly increased or decreased as expected in the frail older adult group 
(7, 354).  The frail older adults are weaker and slower, with less muscle mass; they also 
have increased frequency of co-morbidities, falls and number of prescribed medications.  
There is increased prevalence of cognitive impairment in the frail older adult group as 
demonstrated by both the Addenbrooke’s cognitive examination and Stroop 
Interference.   
The clinical assessment described in Chapter 2 was devised to accurately identify and 
comprehensively describe frailty in the study population; it follows the form of a 
comprehensive geriatric assessment (CGA) and includes data from: cognitive 
assessments, nutritional assessments, reported and assessed physical function, 
assessments of independence, medical history and a physical examination (355).  The 
strengths and limitations of the clinical assessment are discussed below.   
Cognition is fundamental to well-being and health.  Frailty was originally described as 
physical frailty and mental frailty.  As our understanding of frailty has improved we have 
returned to the concept of mental frailty and its integral role within frailty as a whole.  It 
is therefore imperative to include an assessment of cognition when diagnosing frailty.  
The Addenbooke’s Cognitive Examination III (ACE – III) was originally developed to detect 




settings (240).  The Stroop Colour and Word test conversely is very quick to administer 
and therefore reduces the frustration often felt by participants undergoing assessment 
who are self-aware of their cognitive impairment (242).  It has been demonstrated that 
the linguistic decline in dementia can be accurately measured by the Stroop Colour and 
Word Test (356).  It is also less reliant on education attainment and existing intelligence 
than cognitive tests such as the ACE-III and adjustment for age is integral to the test 
(357).  The provision of informed consent as a requisite to inclusion within the study 
ensures that only mild cognitive impairment will be present within the study population.  
These two cognitive tests were therefore both considered ideal to identify mild cognitive 
impairment within the study population.  During the study period it was believed that the 
inclusion of two cognitive assessments was placing unnecessary burden on the frail older 
adults and therefore both assessments were not completed in all individuals.  The ACE-III 
was chosen preferentially over the Stroop Colour and Word Test because of familiarity 
and the validated criteria for diagnosis of cognitive impairment.  However, following 
analysis of the complete data sets it is apparent that Stroop Inference may in some 
circumstances be a superior test to ACE-III.  An important limitation that was not 
considered prior to the studies commencement was the reliance of both these 
assessments on good vision.  In a population with a high prevalence of visual impairment 
an alternative form of cognitive assessment such as the semantic verbal fluency test may 
also be necessary to provide a consistent standard (358).   
The maintenance of muscle mass is dependent on the intricate balance between muscle 
synthesis and breakdown.  Nutrition, in particular the availability of protein, is 




associated with low protein intake and nutritional supplementation has shown some 
success in the reversal of sarcopenia (362).  Recent research has also demonstrated an 
association between malnutrition and frailty (363-365).  Therefore in the assessment of 
frailty and sarcopenia it is essential to include an evaluation of nutritional status.   The 
Mini Nutritional Assessment – short form (MNA-SF) was chosen because it has been 
validated in an appropriate population and it is quick to complete (366).  It has been used 
extensively in research to identify those at risk of malnutrition and is more sensitive than 
BMI at identifying these patients (243).   
The original design of the study protocol assessed physical function with the Berg Balance 
test.  However, in practice this was quickly found to be lengthy and time consuming and 
this raised concerns that the Berg Balance would be potentially tiring for frailer subjects.  
A successful amendment for the substitution of the Berg Balance test for the SPPB was 
submitted to the ethics committee (2nd March 2015) (244).  The Berg Balance and SPPB 
are both tests of physical function with equal scientific merit and in practice the SPPB was 
quick and easy to administer (367, 368).     
The accurate screening of frailty was fundamental to the success of the study and 
therefore the tools used to identify frailty were carefully considered.  PRISMA-7 and gait 
speed were chosen on the basis of the results of a recent systematic review evaluating 
the diagnostic test accuracy of simple instruments used in the diagnosis of frailty (14).  
Whilst this is a systematic review of a relatively large number of participants, 3261, all of 
these participants are from a total of just three studies and therefore the findings lack 




phenotype which reports lower rates of frailty than the frailty index.  It is therefore not 
clear whether the reference population is accurate.  The review demonstrated that both 
the sensitivity and specificity of the PRISMA 7 were high but wide confidence intervals 
suggest this may not be reproducible.  The gait speed, using a 0.8m/s cut off, also had a 
very high sensitivity but lower specificity as did a timed get up and go test.  The gait 
speed and PRISMA 7 were chosen as the method of screening for frailty because of their 
reported high sensitivity and specificity.  The gait speed is a good indicator of physical 
function and was utilised in other assessments present in the study: diagnosis of 
sarcopenia, short physical performance battery and diagnosis of frailty by Fried 
Phenotype.  For simplification and reduction of duplicity within the study gait speed was 
chosen rather than a timed get up and go.  PRISMA 7, in contrast to gait speed reflects 
multiple domains, mobility, social support and health and is therefore more akin to the 
Frailty Index rather than the Frailty Phenotype.      
The Fried Phenotype is utilised by the majority of research studies due to the relative 
ease of measurements.  The phenotype relies entirely on physical parameters with no 
consideration of the psychological, social or behavioural (354).  The model was 
constructed from criteria already collected for the Cardiovascular Health Study which was 
designed to determine the importance of conventional cardiovascular disease risk factors 
in older adults.  It therefore relies on criteria not specifically chosen for their relatability 
to frailty.  Whilst this is the most widely utilised frailty model in the literature there is 
huge variation in how the different components are assessed and measured.  This 




research and make it widely applicable modifications to the Frailty Phenotype were 
limited to only those considered absolutely necessary.    
Physical inactivity was described by as: performing no weight bearing activity, spending 
more than four hours sitting in a twenty-four hour period and taking less than one short 
walk a month.  This criterion has been used in the Frailty Intervention Trial (38).  This was 
selected due to the inherent difficulties of utilising the Minnesota Leisure Time Physical 
Activity Questionnaire in practice.  There are alternative assessments of low activity 
suggested in the frailty literature but they take longer to complete.  The participants 
underwent extensive clinical assessments and it was important to limit the number and 
time of assessments to reduce burden.         
Slowness was measured over a 4 metre walk course rather than the 15 foot walk course 
used in the original Fried paper.  4 metres and 15 foot are a similar distance and 4 metres 
is the accepted distance for both screening of frailty and a diagnosis of sarcopenia (11, 
14).  To reduce the burden to participants gait speed has been calculated over a 4 metre 
walk course and extrapolated for the Fried Phenotype.      
The Frailty Index has been adopted less frequently as a model of diagnosis of frailty due 
to the perceived relative complexity of application (7).  It is however increasingly the 
more accepted concept of frailty.    
Data was collected for 63 different variables and from these 30 variables were identified 
to be included in the Frailty Index.  The seminal Rockwood paper ‘A standard procedure 
for creating a frailty index’ lists 40 variables that can be included in a frailty index (247).  




automatically selected.  The remaining five variables were identified as variables that 
adhered to the Rockwood criteria.  Variables were selected so as to adequately represent 
all the domains.  The new five variables were: polypharmacy, continence, anorexia, falls 
and Clinical Frailty Scale.                  
Polypharmacy is a recognised issue in geriatric medicine.  It has been associated with 
multiple adverse health outcomes including falls, cognitive impairment and urinary 
incontinence (370).  It increases in prevalence with age (371).  Polypharmacy is 
considered as more than 4 medications and excessive polypharmacy as more than 10 
medications.  Polypharmacy and excessive polypharmacy were both incorporated into 
the scoring criteria.   
Continence is another important condition in the geriatric population associated with 
poor outcomes including length of stay in hospital and mortality (372).  The criteria was 
scored trichotomously as it was discovered in practice that whilst the majority of 
participants denied partial or total incontinence of bladder or bowel more participants 
agreed they had ‘a problem with losing control of urine when they don’t want to’ 
suggesting a hierarchy to answers.      
Anorexia, or poor food intake, was included as it is one of two variables within the MNA-
SF that had not been included in some form already within the frailty index.  Anorexia has 
been suggested as an early risk factor for frailty (373).  
Falls, one of the original frailty syndromes, was included as a new variable.  The incidence 
of falls increases with age and are associated with adverse health outcomes such as 




on health, independence and psychological well-being this has been scored as a 
dichotomous event.      
The clinical frailty scale (CFS) was included as a physician’s assessment of the individual 
following a comprehensive geriatric assessment (15).   
A number of the variables described in the original Rockwood paper had their scoring 
criteria modified.   
The cognitive assessment utilised in the Rockwood paper was a mini-mental state 
examination (MMSE).  The ACE III was selected to describe our participant’s cognition 
because of its increased sensitivity in identifying mild and cortical dementias (375). The 
ACE III does not categorise respondents into mild, moderate and severe groups, like the 
MMSE.  The ACE III has two suggested cut off points with different degrees of sensitivity 
and specificity.  The lower cut off point, 82, was chosen because whilst the sensitivity is 
lower the specificity is higher.  In the study’s population which is likely to have a low 
prevalence of cognitive impairment due to the nature of informed consent it is more 
important to have a higher specificity to reduce the number of false positives.     
In the Rockwood paper walk speed was measured twice at usual and rapid pace.  For ease 
and reduction of duplication we have used a timed walk speed over a 4 metre course.  
The cut off point for sarcopenia was used for a half score and the cut off point for the 
frailty phenotype ‘slowness’ has been used for a full score.       
In the Rockwood paper weight loss was scored using a dichotomous criteria of either 




part of the Fried frailty phenotype ‘shrinking’, has been combined with the weight loss 
criteria utilised in the Edmonton Frail Scale ‘does clothing feel looser’ to create a 
trichotomous criteria for weight loss.  In practice some participants had not lost as much 
as 4.5kg or had failed to accurately measure any weight loss but felt their clothing was 
looser suggesting some weight loss.  This identifies participants who may be at an earlier 
point in frailty risk.     
The Clinical Frailty Scale (CFS) (15) and the Edmonton Frail Scale (EFS) (18) were both 
included as the CFS is more likely to be used by geriatricians and the EFS by other 
practitioners.  This makes the results more widely applicable.  On balance the clinical 
assessments described in Chapter 2 describe an accurate and comprehensive global 
assessment of frailty suitable for employment in frailty research.   
The frail older adult group is an accurate representation of frailty as a syndrome.  There 
are no individuals with a frailty index higher than 0.7 (0.64 highest FI).  A frailty index of 
greater than 0.7 is considered incompatible with life and therefore this is an important 
validation of the clinical data (376, 377).  The frailty phenotype has a gamma distribution, 
the distribution of data expected in frailty (247); with increasing frailty there is both 
increasing mortality and increasing isolation skewing a normal distribution towards 
increased frequency of less severe frailty.  The distribution of the frailty index is more 
even than the frailty phenotype; it is less skewed and has a lower kurtosis.  These 
differences in distribution could be due to the relatively low numbers of frail older adults 
or bias within the recruitment.  Frail older adults were recruited following a positive 




on more subjective information open to bias for example information from the 
individual’s usual care doctors.  There is a tendency to consider frailty solely as a physical 
phenotype and therefore less frail adults by the frailty index who do not display all the 
hallmarks of physical frailty may have been unintentionally excluded from the study 
population.     
The frail older adult group was older than the healthy older adult group.  This difference 
in age is more apparent in women with a larger difference in age between the healthy 
and frail older groups; the healthy older women are younger and the frail older women 
are older than their male counterparts.  In the frail older adult group the women were 
significantly older than men.  This is likely secondary to both longer life expectancies in 
women; women in the UK live on average three years longer than men and differences in 
co-morbidity patterns (378).  Analysis of these different groups therefore has to consider 
the effect of age as well as frailty on the sample.  In Chapter 5 this has been achieved in 
parts by modelling the data controlling for age.  A potential improvement to the study 
design, which would reduce the effect of age, would be to age match the frail individuals.  
In practice this may be difficult as the frail older adults were the most difficult group to 
recruit.          
There was no difference in gender frequency for either the healthy younger or frail older 
adults.  Individuals were actively recruited to the healthy younger and healthy older adult 
groups to reflect an equal gender split; this was not completely successful in the healthy 
older adult group because of the unequal gender representation in the 1000 Elders 




recruited regardless of their gender and the equal proportions of gender are reflective 
more of the epidemiology of frailty in the screening populations, consent of individuals 
and luck rather than active design.  The equal gender split is surprising because females 
are repeatedly reported to have increased prevalence of frailty (379, 380).  However, 
anecdotally male individuals were more likely to consent to involvement in the study, 
whereas women wanted to discuss their involvement with family members first or felt 
that it would be too burdensome and this may explain the equal gender split.  The 
unequal gender split in the healthy older adults does mean that the male morphology 
and physical parameter data needs to be interpreted with caution.            
There are differences in body morphology with increasing frailty for each gender which 
suggests that pathophysiological routes into sarcopenia and frailty may be different for 
men and women.  As expected men and women both have a decreasing BATT with ageing 
and frailty.  This reduction in BATT is reflected with a decrease in MUAC in men but not 
women.  There is a significant increase in the BMI of women with frailty but not men.  In 
men there is a trend to reduction in BMI with frailty but this is non-significant.  The 
ultrasound echogenicity increases in healthy older men and women but there are non-
significant changes with increasing frailty likely secondary to the small numbers of the 
frail population undergoing ultrasound echogenicity.  Data presented in Chapter 3 
demonstrates the correlation between increasing ultrasound echogenicity and decreasing 
muscle strength.  There was a significant increase in the proportion of adipose tissue 
compared to muscle with ageing but not frailty for women.  There was no significant 




a trend towards an increase in the thickness of subcutaneous tissue compared to muscle 
thickness.           
The differences in body morphology reported in this chapter may have been affected by 
socio-economic differences rather than frailty or ageing.  Increased obesity, reduced 
physical activity and poor health is associated with lower socio-economic groups (381).  
Individuals recruited to the healthy younger group were from the highest socio-economic 
group.  The levels of educational attainment were significantly different for all three 
groups: HY 21.0 +/- 0.0, HO 18.0 +/- 6.0, FO 15.0 +/- 2.0, Independent Kruskall-Wallis 
p<0.001, Bonferroni corrected pairwise comparisons all p<0.001.  The reported 
differences of increasing adiposity and lower muscle mass in both men and women with 
frailty could reflect lower socio-economic status rather than differences due to frailty.  
Whilst the data reported in this chapter may be biased by socio-economic status it does 
still reflect previous work which reports decreasing muscle mass and increasing adiposity 
with increasing age and frailty (271, 382).  Another consideration when analysing the data 
is the effect of generational differences on diet, physical activity and attitudes towards 
body image and health.  The healthy older and frail older adults were born between 1916 
and 1952 a period of time defined by rationing, limited access to personal motorised 
vehicles and less sedentary employment.  The healthy younger adults were born between 
1980 and 1996 a period of time defined by increasing obesity, the rise of convenience 
foods and stark changes in attitude to body image.  For these reasons cross-sectional 




After excluding the healthy young adults from analysis the differences between the data 
are less apparent.  Women are significantly shorter; this is discussed in Chapter 3 but in 
summary is secondary to osteoporosis and nutritional imbalances during puberty.  
Interestingly whilst there is no real difference in BMI between healthy older and frail 
older adults for either gender there is an increase in the inter-quartile range in both the 
frail older men and women suggesting an increased polarisation and an increased 
number of individuals within the obese and underweight categories.  Despite weight loss 
being a frailty defining criteria (383) and low BMI being associated with a higher risk of 
frailty (384) there is increasing awareness of the high prevalence of obesity in frailty and 
the association with an increased risk of mortality (385). As expected there is a significant 
reduction in BATT.  Alongside a reduction in muscle mass there is an increase in adipose 
tissue as suggested by the decrease in BATT to subcutaneous tissue ratio and changes in 
the ultrasound echogenicity.  The ultrasound echogenicity data does need to be 
interpreted with caution as there are small numbers in the frail older adult group.   
This data taken with currently available literature suggests there is a change in the 
distribution of adipose tissue and muscle with increasing frailty.  Frailty is associated with 
both being underweight and obese (385).  The highest mortality occurs in frail individuals 
who are underweight, normal weight or obese; being overweight ameliorates the risk of 
frailty entirely in frail individuals (386, 387).  There is also an association of frailty with 
central obesity: older adults with a large waist circumference had an increased risk of 
being frail at follow-up (388) and frail men were more likely to have a large waist 
circumference (389).  The data presented here suggests the volume of intra-muscular 




numbers are too small to draw conclusive results.  Frailty is associated with intra-
muscular adipose tissue (19, 20) and gender is known to have an effect on the 
distribution of adipose tissue in younger adults with increased central and visceral 
adiposity in men.  This difference is related to sex hormones and post menopause there is 
an increase in visceral adiposity in women (390).  Adipose tissue itself confers a pro-
inflammatory state through the release of adipokines and recent research has 
demonstrated that frail individuals had increased intra-muscular adipose tissue and 
elevated IL-6 mRNA and IL-6 protein content (391).  Changes in the distribution of 
adipose tissue can result in a localised inflammatory state which can be hypothesised 
contributes to propagating sarcopenia and frailty.  To date evidence has demonstrated 
associations between states of inflammation and frailty but has yet to prove a causal link.  
Longitudinal mechanistic analysis is required to investigate this further.      
The data presented in this chapter also identifies four parameters, Stroop interference, 
grip strength, BATT and frailty index, which are discriminative between healthy younger 
and healthy older adults.  The Stroop data does need to be interpreted with caution as it 
was only performed on eight frail older adults due to time constraints and perceived 
burden on the frail older participants.    However, this does suggest a number of 
parameters both physical and cognitive which could be used as sensitive indicators or 
descriptors in longitudinal research.  The alternative parameters were too insensitive to 
discriminate between healthy younger and older adults and would not be good 
descriptors of change in longitudinal research investigating transitions between health 




consuming assessment of cognitive impairment the Addenbrook’s cognitive examination 
may add value to frailty studies particularly in longitudinal research.    
There was a higher prevalence of frailty diagnosed by the Frailty Index than the Frailty 
Phenotype; 100% FI positive in frail older adult group and 88.6% FP positive in frail older 
adult group.  This was expected as the models are known to describe slightly different 
groups (8).  The concordance and correlation between the two models is higher than 
previously reported (8, 32).  This is likely secondary to the manner of recruitment and the 
introduction of bias towards screening more physically frail individuals.   
Due to nature of the study design, primary objective to recruit to three different groups, 
two healthy and one frail, there are two very distinct populations a healthy population 
and a frail population.  For this reason it is not a particularly good test of diagnostic test 
accuracy in an unselected population.  However, it does demonstrate that in healthy 
older adults with no chronic inflammatory conditions and in physically frail older adults 
both walk speed and PRISMA 7 are accurate tests to identify frailty with high sensitivity 
and specificity.  The calculated sensitivities of 100% for PRISMA-7 and 94.3% for walk 
speed and specificities of 95% for PRISMA 7 and 100% for walk speed are similar to 
reported results but do show an improved accuracy (14).  A further significant limitation 
to the study design is that the frailty assessments were not conducted in isolation and 
this could introduce bias as the investigator was not blinded to the results of the other 
frailty assessments.  An improvement in study design would be the involvement of a 
second investigator who could conduct the PRISMA 7 and walk speed assessments 




assessment and analysis.  An alternative approach would be to ask individuals to 
complete the PRISMA 7 questionnaire themselves prior to assessment but this would 
have been impractical in this cohort of frail older adults due to the high prevalence of 
visual impairment.   
The tests which categorised severity showed poorer test accuracy than the simpler tests: 
Edmonton frail scale: 73.5% sensitivity, 100% specificity, positive predictive value 100%, 
negative predictive value 81.63%, Clinical frail scale: 91.4% sensitivity, 97.5% specificity, 
positive predictive value 97%, negative predictive value 92.9%.  The diagnostic methods 
of frailty identification categorise the severity of frailty similar to the Frailty Index.  When 
compared to the Frailty Index the correlation for both diagnostic tests is good, 0.868 for 
Clinical frail scale and 0.841 for Edmonton frail scale but the variability within each group 
is large.  The accurate description of frailty severity is crucial in intervention studies 
where the heterogeneity of the studied population often precludes significant results and 
meaningful data.  A recent systematic review of interventions in frailty demonstrated that 
multiple different definitions of frailty are currently in use with the Fried phenotype being 
the most common but definitions not considered a gold standard are also in use (10).  
This supports the exclusive use of gold standard diagnostic tests such as the Frailty Index 
and Frailty Phenotype in frailty studies.    
The prevalence of sarcopenia in the healthy older adults was lower than expected; 
estimates of sarcopenia vary wildly from 3-30% depending on both definitions and 
methodology.  A recent study investigating sarcopenia in a male community dwelling UK 




sarcopenia prevalence reported in this chapter: 3.7% for women and 0% for men.  As 
discussed previously, the design of the study prioritises the immunesenescence work and 
therefore the healthy older adult group is not typical of a community dwelling older adult 
population: all adults with frailty, cancer and chronic inflammatory conditions were 
excluded.  Additionally the sample pool from which the healthy older adults were 
recruited contains a self-selected group of highly motivated, well-educated individuals 
interested in health research.   
There has been limited research into the concordance of frailty and sarcopenia.  Previous 
research has demonstrated that in certain populations, community dwelling attendees at 
an outpatient geriatric clinic (392) and community dwelling older adults in Japan (33) 
frailty is more prevalent than sarcopenia.  This is counter-intuitive to our current 
understanding because prevalence data suggests sarcopenia is more prevalent than 
frailty.  Interestingly in the outpatient geriatric clinic concordance between sarcopenia 
and frailty was poor: 16.7% of attendees had both sarcopenia and frailty and only 36.4% 
of frail older attendees by Fried criteria and 20% by Rockwood had sarcopenia (392).  The 
data presented in this chapter demonstrates a far higher concordance between the two 
conditions; depending on the definitions of sarcopenia used 96.8% (IWGS) or 90.3% 
(EWGSOP) of the frail older adults also had sarcopenia.  The difference in both 
concordance and prevalence of the two conditions in comparison to previous reports 
could be solely due to study design.  54.3% of the frail older adults were recruited during 
an inpatient hospital stay where they may have lost muscle mass secondary to 
immobilisation or cachexia increasing the prevalence of sarcopenia and the 




of physical characteristics of frailty including sarcopenia.  However, this data has 
demonstrated that in a population recruited for frailty the prevalence of sarcopenia is 
high and when analysing data from this population the high concordance should be 
considered as a potential limitation to the study design.  The data also confirms that 
frailty is a separate condition to sarcopenia not just an extension of sarcopenia.     
The data presented in this chapter confirms that frailty described in the frail older adult 
group is a separate entity to both co-morbidity and disability and whilst there is a large 
degree of overlap the differences described elsewhere in this thesis are not secondary to 
either just co-morbidity or disability.  This is similar to data presented elsewhere which 
suggests frailty is a separate condition which confers additional risk of adverse outcomes 
independent of disability and co-morbidity (5, 37).  The addition of either a disabled or 
co-morbid state to the frailty state increases the frailty severity.  The addition of either 
one or two states does not seem to make a difference to the frailty severity which 
suggests either: one, one of the states is not associated with increased frailty severity or 
two, a saturation point is reached where the addition of another state has no impact on 
frailty severity.  Due to the low numbers it was impossible to consider co-morbidity and 
disability separately but further investigation of the relationship between frailty, co-
morbidity and disability is essential to consider practical measures to prevent progression 
of frailty.              
The data presented suggests that the addition of sarcopenia to a diagnosis of frailty 
increases frailty severity.   Analysing all the Fried phenotype criteria separately suggested 




contributor and consequence of sarcopenia, resulted in more severe frailty.  This implies 
that the addition of sarcopenia to frailty worsens prognosis.  This analysis is reliant on 
frailty severity as described by Frailty Index being associated with mortality and poor 
outcomes but a recent paper by Rockwood has succinctly demonstrated this in multiple 
age groups and both humans and mice (393).  Further analysis of the effect of sarcopenia, 
co-morbidity and disability on frailty severity and therefore long-term outcomes is 
essential to better understand the effects of interplay and chronicity on all these 
conditions.  Longitudinal analysis would be the most appropriate form of investigation.      
The drivers propagating frailty and sarcopenia are incompletely uncharacterised but a 
pro-inflammatory environment is considered to be fundamental and longitudinal 
research has demonstrated that higher levels of pro-inflammatory cytokines can predict a 
reduction in fat free mass and a loss of grip strength (188, 394).  A pro-inflammatory 
environment has also been associated with frailty (179-181) leading to the hypothesis 
that a pro-inflammatory environment is driving the loss of muscle mass, strength and 
ultimately both frailty and sarcopenia.  However, the data in this chapter suggests the 
relationship is more complex than a simple association of systemic inflammation with 
sarcopenia and frailty.   
Although the data is inconclusive due to the small numbers there appears to be two 
patterns of changing inflammation with increasing frailty: one, the step-wise increase 
with frailty and two, the increase in inflammation with just low muscle mass but not 
frailty.  This is supported by significant increased concentrations of cytokines in just 




and significant increased cytokines in both healthy older adults with low muscle mass and 
frail older adults, IL-8, IP-10, MIP1a and IL-1ra.   
The second suggested pattern mirrors the differences reported in neutrophil elastase 
activity demonstrated in Chapter 5 and suggests that the production of cytokines is also 
vulnerable to immunesenescence.  It is unclear why certain cytokines appear to be more 
vulnerable to immunesenescence than others and whether in extreme frailty all cytokine 
expression is reduced.  Analysis of the relationship between physical and cognitive 
parameters of frailty and sarcopenia with inflammation did not reveal any definitive 
correlations.  MUAC significantly correlated with multiple cytokines but has to be 
interpreted with caution because of the incompletely described relationship of MUAC 
with frailty and sarcopenia in both genders.  MUAC is a crude measure of health 
incapable of distinguishing between muscle mass and adipose tissue; the proportion of 
adipose tissue to muscle is essential to consider due to the relationship of both muscle 
and adipose tissue with inflammation.   
The analysis of the burden of inflammation using the Inflammatory Index also does not 
reveal any significant relationships between frailty and sarcopenia with inflammatory 
burden apart from the increase with age.  The graphical representation of Frailty Index 
and Inflammatory Index suggests there are two separate populations within both healthy 
older adults and frail older adult.  Whilst the high Inflammatory Indexes in both groups 
could just represent individuals with infection or ongoing inflammatory process such as 
osteoarthritis this separate population does not exist in the healthy younger adults 




The Inflammatory Index is a crude composite measure based on the Frailty Index (395, 
396).  It does not consider the implications of pro or anti-inflammatory effects of each 
cytokine, the pathological concentration of each cytokine or accurately reflect a Frailty 
Index with at least 30 variables.  However, it could be a useful tool for investigating the 
inflammatory burden in frailty and sarcopenia particularly in longitudinal studies.     
This chapter has accurately described a frail older group recruited for cross-sectional 
analysis of immune parameters.  It has also demonstrated that for both the complex 
analysis of the interplay and relationship between sarcopenia and frailty and also the 
inclusion of non-phenotypically frail individuals in the frail sample whole older adult 
populations need to be screened to remove bias towards the phenotypically frail.  Whilst 
the concordance between sarcopenia and frailty reported in this chapter are much higher 
than expected it does confirm they are separate conditions able to exist in isolation.  This 
chapter has also demonstrated that co-morbidity and disability are separate conditions to 
frailty and suggests the addition of either co-morbidity, disability or sarcopenia to frailty 
worsens outcomes.  Changes in body morphology with frailty have been described and 
linked with existing data to suggest some of the drivers propagating both sarcopenia and 
frailty.  The role of inflammation in both frailty and sarcopenia has been previously 
considered fundamental to driving both syndromes but the data presented here suggests 
a more complex interplay between the different states of immunesenescence, 
inflammageing, frailty and sarcopenia which needs to be investigated further, particularly 
considering a non-linear relationship between frailty and inflammation.  The 
Inflammatory Index has been described for the first time and used to investigate the 




supports a proposal for more investigation into the relationships and interplay between 
frailty, sarcopenia, immunesenescence and inflammageing.  However, all the data 


























7.1 Summary and key findings  
This thesis has linked several key concepts in frailty, sarcopenia and immunesenescence 
and attempted to explain some of the shared pathophysiology.  As outlined in Chapter 1, 
frailty, and to a lesser extent sarcopenia, research faces a number of challenges.  Frailty is 
not a new concept but it has only relatively recently been medicalised and adopted as a 
geriatric syndrome [1, 2].  The initial lack of an internationally agreed clinical definition 
and two fundamentally different models of frailty with apparent equal scientific merit has 
narrowed frailty research over the previous twenty years.  Research has predominantly 
focused on description, epidemiology and outcomes of the syndrome and the 
investigation of pathophysiology and the relationship between frailty and sarcopenia has 
been neglected.  Consequently despite sarcopenia featuring as a central component of 
the frailty cycle, originally proposed by Fried in 1998, the first research reviewing the 
concordance of the two conditions was only published in 2016 (32, 397).  Additionally, 
apart from the consideration of the role of immunesenescence and inflammageing there 
has also been little advancement in the understanding of the causative and propagating 




One of the fundamental challenges facing frailty and sarcopenia research is the presence 
of multiple tools describing similar and overlapping conditions.  A hierarchical linear 
progression of the conditions with sarcopenia considered both a pre-cursor and a pre-
requisite of frailty is frequently proposed (11, 354).  However, research has demonstrated 
that the concordance of frailty and sarcopenia in a community based older adult 
populations was poor and the prevalence of frailty was higher than sarcopenia (8, 32, 33).  
The relationship between the different models of frailty is also incompletely described 
and understood.  Cross-sectional studies investigating both physical frailty, as described 
by Fried’s Frailty Phenotype, and frailty as an accumulation of deficits, as described by 
Rockwood’s Frailty Index demonstrate the models identify related but separate, distinct 
populations of frailty.  It has been suggested the models should be considered 
complementary rather than alternative methods of diagnosis (5, 7, 8).  Frailty is usually 
considered to be a separate entity to both disability and co-morbidity and although all 
three conditions are related the relationship is incompletely characterised (37).  The 
relationship between all these conditions is poorly understood particularly with respect 
to the common pathophysiology, including causative and propagating factors, and the 
temporal effect.  Longitudinal research comprehensively investigating the accumulation 
of these conditions in individuals over a period of time is essential to accurately describe 
the temporal and pathophysiological relationship.  Rockwood and colleagues have 
described an elegant computational approach to modelling health trajectories which 
identifies the connections between non-specific nodes as the determining factor in 
mortality and frailty (398).  This highlights the importance of the connections between 




modified to be used in a more focused manner to investigate the relationships between 
frailty, sarcopenia, disability and co-morbidity further.    
A second significant barrier to the advancement of understanding in frailty research is the 
separation of research of the clinical condition from fundamental science research.  
Ageing research investigating the effect of age on biological systems such as the immune 
and endocrine system has failed to consider the effect of frailty and co-morbidity 
whereas, frailty research has tended to concentrate on describing the condition and 
correlating it with outcomes.  There has been a lack of true translational research typified 
by rigorous clinical characterisation of an individual prior to the fundamental science 
research.  Amplifying this problem is both the perceived difficulties of conducting 
research in frail older adults and research interests and expertise in academic 
geriatricians that does not align with fundamental science.  Consequently the role of 
inflammageing and immunesenescence in the development and propagation of frailty 
and sarcopenia is poorly understood.            
Chapter 3 briefly précised the importance of the correct and timely diagnosis of 
sarcopenia in both clinical practice and research.  There are barriers to the identification 
of low muscle mass in an elderly and frail population and this work supports the use of 
ultrasound as a potential diagnostic tool in sarcopenia, which is also able to assess  
‘muscle quality’, utilising ultrasound echogenicity as a surrogate marker of intramuscular 
adipose tissue.   
Current gold standard diagnostic methods for the identification of low muscle mass are 




based within the community setting.  MRI, CT and DXA are expensive and multiple 
physical and cognitive barriers exist preventing a frail population from accessing these 
imaging techniques.  In addition, analysis of the images is not immediate and therefore 
diagnosis and management can be delayed; this is particularly important in a time-critical 
condition in a population who are frequently lost to follow up.  BIA, although a bedside 
test, has not been validated in a frail older adult population and the high prevalence of 
contra-indicated conditions, such as dependent oedema and heart failure, suggest it 
cannot be used widely in this population.     
Additionally, ultrasound can measure changes in muscle architecture and composition 
such as muscle echogenicity, pentation angle and fibre length.  Recent work in several 
large cohort studies has suggested that muscle strength is a more accurate predictor of 
poor functional outcomes than muscle mass (399-401).  Muscle quality, defined as 
muscle function (strength or power) per unit of muscle size (mass or cross-sectional 
area), is affected by: the morphological characteristics of the muscle, aerobic capacity, 
fibrous tissue, motor units and intramuscular adipose tissue.  The quantification of 
intramuscular adipose tissue by ultrasound echogenicity has been validated with muscle 
biopsy and high ultrasound echogenicity has been associated with poor outcomes and 
low muscle strength in older adults (257, 402, 403). 
The current work presents a simple ultrasound scanning protocol which includes 
measures of both muscle quantity (muscle thickness) and muscle quality (ultrasound 
echogenicity).  The work contained in this thesis includes a robust assessment of the 




be good when measuring muscle thickness but inadequate in measuring echogenicity 
when using different machines and sonographers.  This initial work suggests ultrasound 
echogenicity may be a useful tool in single centre research studies where it is possible to 
standardise machines and sonographers but is not currently appropriate for clinical use 
or in large multi centred studies. 
The chapter then proposes the BATT and the corresponding criteria for low muscle mass.  
The criteria for low muscle mass have been calculated from a group of healthy younger 
adults as suggested by EWGSOP (11).  The chapter then proceeds to test the BATT in both 
a healthy older and frail older adult population and demonstrates a relationship between 
increasing frailty and decreasing muscle thickness.  It also shows a correlation between 
frailty and the markers of physical function with ultrasound echogenicity.   
The key findings in Chapter 3 are the proposed BATT and the association of ultrasound 
echogenicity with frailty; these require further investigation but have potential to change 
clinical practice.  The comparison of BATT to a gold standard method such as MRI or CT in 
the target population is necessary before BATT can be utilised in clinical practice as a 
method of identification of low muscle mass.  A recent systematic review of thirteen 
studies conducted in older adults, both healthy and with chronic conditions, concluded 
that muscle measurements obtained using ultrasound were reliable when compared to a 
gold standard (404).  This suggests the suggested protocol using ultrasound to measure 
muscle thickness would be an accurate method of muscle measurement in an older adult 
population.  It should however be confirmed in a frail older adult population.  Whilst 




mass (249, 274, 275) comparing the BATT values with whole body or appendicular lean 
muscle mass would validate BATT, an unadjusted aggregate measure of muscle thickness, 
against muscle volume.   Once the method had been appropriately validated further 
studies expanding the BATT criteria to include values for different ethnicities are 
important.  The current BATT criteria presented in Chapter 3 has amalgamated data from 
healthy young adults of different ethnicities; to improve the reliability of the tool the 
study numbers should both be increased and re-analysed to produce criteria for each 
ethnicity.  The BATT is the first proposed criteria for low muscle mass in sarcopenia using 
ultrasound measurement of muscle thickness.  Repeating this study in different global 
populations would improve the validity of the method, increase the size of the reference 
population and therefore, improve the accuracy of the BATT criteria for low muscle mass.  
Criteria for reduced muscle mass based on a healthy young adult population are arbitrary 
and do not necessarily relate to functional outcome.  Linking data on muscle thickness 
with muscle strength and physical performance may establish more accurate criteria for 
the identification of low muscle mass in older adults.  However, an advantage of the 
current relatively high values for the BATT criteria is that it acts as a screening step.  This 
allows earlier identification of pathology and subsequently earlier intervention which is 
likely to be associated with the increased success (10).   
The relationship between sarcopenia and ultrasound echogenicity is less well defined and 
the data presented in Chapter 3 highlights the inconsistency in measurements of 
echogenicity in practice.  Research should therefore first be concentrated on 
standardising ultrasound echogenicity.  This will require liaison with industry to create an 




algorithms that account for overlying subcutaneous tissue and muscle depth.  Only once 
this is available could this be considered an appropriate tool for use in clinical practice.  
Combining a standardised measure of ultrasound echogenicity with automatic depth 
measurements in a portable ultrasound scanner would improve access to sarcopenia 
diagnosis and ultimately lead to increased diagnosis.     
Chapter 4 builds on the theme of ‘muscle quality’ to consider the measurement of muscle 
quality via tissue analysis of: the morphological characteristics of the muscle, aerobic 
capacity, intramuscular adipose tissue, fibrous tissue and motor units.  This analysis 
requires muscle tissue from frail older adults who are not acutely unwell (for example not 
taken intra-operatively in patients with a fractured neck of femur) and Chapter 4 reports 
on the difficulties in obtaining samples in a frail older adult population recruited primarily 
for investigation of immunesenescence and inflammageing.  The feasibility of muscle 
biopsy in a frail older adult population is considered in two respects: the 
contraindications to a percutaneous muscle biopsy using a needle biopsy technique and 
the prevalence of a muscle depth shallow enough to prevent a successful biopsy in older 
adults.  The chapter then discusses strategies to improve the success of muscle biopsy as 
a technique in both healthy older and frail older adults.   
The key finding in Chapter 4 is that muscle biopsy using a needle biopsy technique was 
not feasible in many of the adults recruited to this frail older adult cohort.  This is 
particularly relevant as it is contrary to previously published research and highlights the 
importance of proper study design (287, 289, 290).  Chapter 4 discussed many of the 




an ultrasound prior to biopsy and the different biopsy techniques.  It also discussed the 
importance of study design as previously successful biopsy studies have screened large 
population pools from which a small numbers of individuals were selected for inclusion 
within the study (287, 289, 290).  However, this group of frail individuals is unlikely to 
represent the frail population as a whole; they are likely to be less frail, with fewer co-
morbidities and disabilities.  Whilst the muscle biopsy data from frail individuals with no 
contraindications to muscle biopsy will be applicable for the investigation of certain 
hypotheses it is essential that the data is interpreted with caution and the results are not 
extrapolated to the frail population as a whole.   
There are a number of alternatives to elective muscle biopsy including techniques 
involving the removal of muscle tissue and techniques that circumvent the need for 
muscle tissue.  Muscle for many research studies is obtained intra-operatively and there 
are two main options, one during elective surgery and two, during emergency surgery.  
Elective surgery is preferential because it negates the effect of acute illness on the muscle 
sample.  However, elective surgery in older adults is often performed for musculoskeletal 
indications.  Alternative indications for surgery in older adults include semi-elective 
surgery for abdominal aorta aneurysmal repairs but these are only offered to fitter frail 
older adults.  The most frail older adults only undergo emergency operations for acute 
life-threatening conditions.  Samples obtained during these operations would be 
appropriate for the analysis of muscle architecture but not for accurate analysis of intra-
cellular proteins or intra-muscular inflammatory status.  An alternative to muscle biopsy 
that does not require muscle tissue is metabolomics.  Metabolomics, the systematic 




to analyse muscle synthesis and degradation amongst other biological processes (405).  It 
does not require muscle tissue but uses plasma or urine samples.  This is a relatively 
recent technique which warrants further investigation particularly for populations where 
muscle biopsy is contra-indicated.  However, a recent study found only modest 
correlations between muscle and plasma metabolite levels suggesting further work on is 
required before this can be accurately used as a substitute for muscle tissue (290).    
Chapter 5 describes neutrophil function in well-defined populations of healthy and frail 
older adults.  It is only the second investigation of innate immune function in frail older 
adults and the first to provide clear associations between parameters of frailty, including 
physical and cognitive function, and immunesenescence.  The chapter describes 
inaccurate neutrophil migration in frail older adults to two chemoattractants and 
investigates the fundamental processes that may be contributing to neutrophil 
immunesenescence including cell surface markers and the PI3kinase/Akt pathway.  It 
demonstrates that poor neutrophil accuracy in frail older adults can be rescued with the 
PI3kinase inhibitors which are most highly expressed in neutrophils (delta and gamma) 
and there was a trend towards this phenotype being induced in neutrophils from healthy 
young adults following incubation with pooled plasma from frail older adults.  It also 
describes a state of chronic inflammation in frail older adults and investigates the effect 
constant exposure of neutrophils to priming and stimulating agents may have on 
neutrophil function.  It proceeds to investigate neutrophil subpopulations and neutrophil 
states (for example primed and activated neutrophils) to consider the link between the 
demonstrated poor neutrophil function with the relative neutrophilia found in frail older 




The key finding from Chapter 5 is that inaccurate neutrophil migration in frail older adults 
is both age independent and associated with physical and cognitive makers of frailty.  
Inaccurate neutrophil migration is correctable with Class 1 A delta and Class 1 B gamma 
selective PI3kinase inhibitors and this suggests a potential therapeutic target for future 
research in both frailty and immunesenescence within frailty.   
Therapeutic PI3kinase inhibitors have already been developed for use in a number of 
malignancies and auto-immune and inflammatory driven conditions (406).  Idelalisib, a 
selective PI3kinase δ inhibitor, has been approved by the FDA for treatment of 
haematological malignancies and a number of other pan and selective PI3kinase 
inhibitors are in clinical development (407).  However, the side effect profile of these 
drugs may preclude their use in frail older adults.  Serious side effects reported for 
Idelalisib include neutropenia, liver damage and colitis (408, 409).  Even the mild side 
effects (nausea, diarrhoea and anorexia) reported in the phase one trials and tolerated 
well by middle-aged, previously healthy adults could have significant consequences in a 
frail older adult population (410).  The dose required in oncological management is far 
higher than would likely be required for the correction of immunesenescence in frail 
older adults but the side effect profile and expense may still prevent PI3kinase inhibitors 
from clinical use.   
A further consideration is the effect of PI3kinase inhibitors on intra-cellular feedback 
responses and whether long-term exposure will result in ‘resistance’ to the inhibitors.  
This has been described in cancer and is reported to be as a consequence of insufficient 




pathways (411).  The intra-cellular pathways and mechanisms resulting in pathology are 
very different in cancer and immunesenescence but the effect of chronic PI3kinase 
inhibition would have to be investigated before it could be considered as a viable 
therapeutic option in frail older adults.  The use of PI3kinase inhibitors as an adjuvant 
therapy during infection or periods of acute frailty, such as following a fractured neck of 
femur, may negate this potential effect but again would need to be investigated further.   
The repurposing of current treatments is popular for a number of reasons including the 
reduced cost of drug development and the subsequent cost of a prescription.  
Repurposed treatments are particularly attractive in frail older adults as the side effect 
profile has already been well characterised and characterised in a frail population rather 
than a study population.  Observational studies of statins have demonstrated an 
association with both a reduction in infections and mortality in a number of 
populations(412-414).  Statins reduce the production of all products down-stream of 3-
hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) including isoprenoid.  Isoprenoid is 
utilised by cells for post-translational modification and activation of small GTP-ases such 
as Ras and Rho (235).  These molecules are essential in a number of immune cell 
functions such as adhesion and migration and importantly are also down-stream of the 
PI3kinase-Akt pathway (235).  In a small clinical trial, statins were associated with 
improved neutrophil migration in a trial of healthy older adults (415) and adjuvant statins 
were associated with survival benefit in hospitalised patients with community acquired 
pneumonia including a cohort of older adults (236).  Statins target a downstream effector 




cheaper, safer and more readily available than PI3kinase inhibitors.  Whilst there are a 
number of issues that would need to be resolved prior to the consideration of statins as a 
therapeutic option for immunesenescence in frail older adults, particularly related to 
their effect on muscle at high doses, statins appear to be a better therapeutic option.   
The data presented in Chapter 5 demonstrated an association between physical and 
cognitive parameters of frailty and neutrophil function.  However, this study was limited 
to commenting on association and was unable to provide evidence of a causative link 
between immunesenescence and frailty.  There are a number of potential hypotheses: 
one, immunesenescence causes and drives frailty, two, frailty causes and drives 
immunesenescence, three, frailty is associated with immunesenescence but the 
conditions are not causally linked, four, and the most likely, frailty and 
immunesenescence are co-causative, each condition driving the other in a spiral of 
propagation.  A potential study method for considering causation would be the reversal 
of frailty and the investigation of the subsequent effect on immunesenescence.  To 
achieve this comprehensive clinical and immune characterisation should be conducted on 
a group of frail individuals before and after a frailty intervention programme.  If frailty 
reversal is associated with an improvement in immunesenescence then a causative link 
can be established.  However, this study design is unable to comment on initial causation 
and temporal associations.   
To investigate this further and comprehensively consider causation between 
immunesenescence and frailty multiple additional studies would be necessary.   The first 




multi-factorial intervention.  Additionally a second study investigating the effect on frailty 
of the in vivo reversal of immunesenescence with either a statin or PI3kinase inhibitor 
would be necessary.  If both the studies demonstrated a positive effect then the in vivo 
reversal of immunesenescence with either a statin or PI3kinase inhibitor and the reversal 
of frailty with a multi-factorial intervention could be investigated in conjunction to 
consider whether there is a synergistic effect of the two interventions together.    
Chapter 5 provides unique evidence of associations between parameters of frailty, 
including physical and cognitive function, and immunesenescence.   
Chapter 6 describes the three groups, healthy young, healthy older and frail older adults, 
in detail and demonstrates the experiments described within Chapters 3, 4 and 5 were 
conducted on appropriate populations.  The chapter does also highlight some differences 
between the groups, particularly the socio-economic class and age; this may have had 
some effect on the reported results.  The chapter then proceeds to examine the nature of 
the frailty identified in the frail older adult group and suggests this group may not be 
representative of all frail older adults.  The role of inflammation in frailty and sarcopenia 
is then considered with respect to the propagation of these conditions.  The experiments 
were underpowered for conclusive results but suggest the relationship between 
inflammation and frailty is more complex than a positive linear association.  The key 
finding from Chapter 6 is that it is feasible to recruit a well characterised frail older adult 
population for mechanistic immunesenescence work and relate parameters of physical 
health with immune health.  Chapter 6 also suggests multiple avenues for further 





7.2 Strengths and limitations 
The strengths and limitations of the work presented in this thesis are discussed in depth 
within each relevant chapter.  Validated and reputable laboratory techniques were 
employed throughout to ensure the results generated were accurate, representative and 
translatable.  This is discussed in more detail in Chapter 5.  The clinical methods were 
equally rigorously selected as discussed in Chapter 6.   
There are a number of additional limitations to the laboratory techniques and data that 
have not been adequately discussed in Chapter 5.  The study relied on isolated 
neutrophils extracted from whole blood for migratory and oxidative burst studies and 
neutrophils present in whole blood for flow cytometry studies.  These intravascular cells 
may not be representative of extravascular neutrophils and it is possible that impaired 
chemotaxis in frail older adults is not present in neutrophils transmigrating through 
tissue.  Throughout the experiments non-physiological methods were used: two-
dimensional model of migration without endothelial cells or laminar flow and non-
physiological concentrations of priming and stimulating agents.  Attempts were made to 
make conditions as physiological as possible, for example, the addition of albumin coating 
to the coverslips prior to neutrophil migration.   
The most significant limitation of the clinical methods utilised in this study is the use of 
ultrasound as the sole diagnostic tool for the identification of low muscle mass in 
sarcopenia.  Whilst this tool has been suggested before as a potential method for 




for the identification of low muscle mass are not available.  Chapter 3 provides some 
evidence for the utilisation of ultrasound as a diagnostic tool but due to cost limitations 
was unable to compare ultrasound to a gold standard technique.  
Throughout the results chapters one strength and one limitation of the work persist and 
therefore deserve further analysis and discussion.   
The rigorous characterisation of the three different groups is the greatest strength of the 
work presented in this thesis.  The results presented in these chapters link 
immunesenescence data with clinical characteristics.  The employment of a translational 
study design is particularly important in this study because older and, in particular, frail 
older adults are not heterogonous groups.  The meticulous characterisation of each 
individual allowed the relationships between the parameters of frailty, such as physical 
and cognitive performance, with immunesenescence and inflammageing to be 
considered.  Whilst not unique to this study it is the first time extensive investigations of 
neutrophil function have been associated with parameters of frailty.  Previous research 
reviewing neutrophil function in older adults has either neglected to consider the effect 
of frailty or assumed its presence without proper characterisation (290, 313).  The data 
presented in Chapter 5 succinctly illustrates the mirroring between the decline in physical 
and cognitive function, and neutrophil function.    
Whilst the meticulous characterisation of all the individuals in this study is unique in the 
field of immunesenescence the depth and breadth of characterisation is also unusual in 
more clinical studies of frailty.  The multi-faceted description of each individual permitted 




availability of this data facilitated the rigorous analysis of muscle biopsy failure in frail 
older adults, disparity in frailty severity measured by different methods and the 
association of frailty severity with different parameters of Fried phenotype and other 
unique conclusions.   
The greatest limitation of the study can also be considered a strength of the study.  The 
majority of the work described in this thesis had never been completed before in this 
population and therefore calculating accurate sample sizes prior to study recruitment 
was impossible.  The data is therefore unique but also has to be considered pilot data and 
as a consequence a number of the experiments were underpowered.  This makes it 
difficult to interpret the data conclusively and furthermore, most of the underpowered 
data followed a non-parametric distribution which makes calculating the desired sample 
size problematic.  The discussion in Chapter 5 reports on a number of post-hoc calculated 
sample sizes in data that was not originally statistically significant.  This suggests the 
sample sizes needed to be increased but not by a substantial number.  On occasions in 
the thesis data is presented where an alternative study design would be preferential.  
However, due to the paucity of research in frailty and sarcopenia particularly related to 
the association of these syndromes with immunesenescence and inflammageing it was 
important to report all these results as the data may contribute to current understanding 
and suggest future directions for research.   
A limitation with all the data presented in this study is that it is entirely cross-sectional.  
This is adequate to consider the main hypotheses of this thesis but when considering the 




sectional data it is an unsuitable form of investigation.  Perhaps the greatest limitation of 
this study was its inability to confirm whether witnessed dysregulation of PI3kinase was 
present in the muscle of frail and sarcopenic older adults.  The failure of muscle biopsy in 
frail older adults prevented the investigation of intra-myocyte PI3kinase dysrgulation and 
prohibited the coupling of frailty and sarcopenia with a single intra-cellular pathway.  .        
7.3 Future directions 
The work presented in this thesis has described immunesenescence and inflammageing in 
a cross-sectional population of older adults with both frailty and sarcopenia.  The results 
generated have inevitably led to further questions particularly regarding the relationship 
between frailty and sarcopenia and the drivers and propagators of both syndromes.   
Whilst Chapter 6 affirmed that sarcopenia and frailty can exist independently it also 
suggested that although they are intrinsically linked a simple progressive linear 
relationship is unlikely to fully describe the relationship.  Figure 7.1 depicts both the 
simplistic linear relationship and a more complex hypothesised relationship between the 
conditions that does not necessitate sarcopenia as a precursor to frailty.  Whilst many of 
the drivers of the conditions have been considered their role in the progression and 
pathophysiology of the syndromes is incompletely characterised and further research in 
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Relationship between sarcopenia and frailty.  Figure A depicts a simple linear relationship where 
low muscle mass is a pre-requisite of sarcopenia and sarcopenia is a pre-requisite of frailty.  
Figure B proposes a more complex relationship where all conditions can exist in isolation but also 
co-exist with each other in a variety of combinations.  The bubble below describes some of the 
potential drivers of the conditions and the arrows represent the multiple entry points to the 




Frailty as described by the Frailty Phenotype considers frailty a dichotomous event either 
present or absent.  Conversely frailty as described by the Frailty Index is a continuous 
variable which can be plotted against time to create a trajectory of frailty.  Patterns of 
health and functional decline before death have been described before (416).  However, 
they have often focused on specific diseases, such as cancer or single organ failure, to 
further our understanding of the process of dying rather than investigate the trigger points 
of declining function.  Accurate characterisation of changes in frailty severity using a Frailty 
Index to stratify frailty over a period of time would identify trigger points for both increasing 
and decreasing frailty.  Modelling this data with both clinical and immunological parameters 
would allow for rigorous investigations in to the pathophysiology of the frailty syndrome 
and clinical outcomes of the syndrome.  Figure 7.2 depicts several theoretical examples of 

































Trajectories and triggers of frailty.  X axis represents time and Y axis represents Frailty 
Index.  The Y axis is inverse and extends from 0.7 to 0 because a Frailty Index greater 
than 0.7 is not believed to be compatible with life.  Four lines are depicted each 
representing a different trajectory of frailty.  The red line depicts an initial gradual 
decline and then at the trigger point, denoted with a red arrow, a sharp decline in frailty.  
The purple line depicts a gradual descent in to frailty with no specific trigger points.  The 
blue line depicts a trajectory with two trigger points: the first where there is a rapid 
improvement in frailty perhaps during a period of rehabilitation and the second where 
there is rapid decline in frailty perhaps during a period of acute illness.  The orange line 
represents a step-wise progression in frailty with small incremental increases in frailty 






The key research questions generated by this thesis can be summarised as:  
1) Are frailty and sarcopenia separate syndromes, or different manifestations of the 
same pathophysiological process? 
a. What are the common pathophysiological pathways with particular respect 
to immunesenescence and inflammageing? 
b. Is there a final common pathophysiological intra-cellular pathway in both 
conditions? 
c. What are the triggers that result in the accumulation of an additional 
syndrome, either frailty or sarcopenia? 
d. What are the protective factors that prevent an individual from accumulating 
an additional syndrome?     
 
2) What are the protective factors and triggers that result in a change in frailty state?  
a. Is it possible to predict from biomarkers or measures of physical or cognitive 
health the trajectory of frailty state over time? 
b. Does a state of inflammation and immunesenescence mirror the progression 
or trajectory of a frailty state?      
To consider these two areas of investigation further work could be conducted using a 
longitudinal study design comparing multiple cohorts.  The cohorts that should be actively 
recruited to are: healthy older adults, healthy older adults with low muscle mass, healthy 
older adults with sarcopenia, frail older adults without physical frailty (Frailty Index positive 
but not Frailty Phenotype positive), frail older adults with physical frailty (both Frailty Index 




healthy younger adult group as the important comparison is between different states of 
health and function in old age rather than with changes with ageing itself.   
All individuals in these groups would undergo extensive characterisation as described in 
Chapter 2.  The results from the thesis have highlighted a few potential modifications to the 
original protocol which would improve the quality of future data.   
One, abdominal circumference measured in centimetres with a tape measure.  Previous 
research has highlighted the importance of obesity in frailty and sarcopenia and suggested 
that central abdominal obesity is associated with poorer outcomes (388, 389).  Data 
presented in Chapter 6, although inconclusive, suggest changes in body morphology with 
frailty and sarcopenia are different in men and women which may be related to hormonal 
changes.  The inclusion of abdominal circumference will allow more complex analysis of 
changes in body morphology particularly when reviewed in conjunction with the ratio of 
subcutaneous tissue to muscle thickness and BMI.   
Two, ensuring all individuals complete the Stroop Interference assessment.  This assessment 
was incomplete in the majority of frail older adults due to time constraints and perceived 
burden.  However, it is quick to administer and can be completed in five minutes and should 
be prioritised within the assessment.  As demonstrated in Chapter 6 the Stroop Interference 
test was sensitive in eliciting differences in cognition between healthy younger and healthy 
older adults.  This suggests it may be an excellent test for describing small changes in 
cognitive ageing which are not apparent on less sensitive tests such as the Addenbrooke’s 
cognitive examination.  It therefore may also be better able to describe change in cognition 




Three, a structured approach to the categorisation of socio-economic status, diet and 
exercise.  Diet, activity habits and lifestyle are important contributing and ameliorating 
factors in both frailty and sarcopenia.  It is therefore essential to document and consider 
these factors when analysing the data.  There are inherent difficulties in measuring both diet 
and exercise as they are often inaccurately self-reported.  There is also a lack of validated 
tools reviewing both these variables over an individual’s preceding lifetime rather than as a 
single cross-sectional assessment.  Therefore, the most appropriate tool for measuring 
these three variables would need to be first carefully considered.                 
It is anticipated the individuals recruited to the different groups would all be regularly 
reassessed using a combination of telephone interviewing and face to face comprehensive 
geriatric assessment.  Telephone interviewing would use structured assessments such as 
PRISMA 7, Katz and Lawton to gather information on health state.  It could also be possible 
to devise a Frailty Index comprised entirely of self-reported information and this would 
ensure a standardised regular assessment of frailty throughout the study period.  Face to 
face assessment would follow the comprehensive geriatric assessment described in Chapter 
2 with the addition of the suggested modifications detailed above.        
Data from both the local electronic hospital system and primary care electronic health 
records could be included to review changes in frailty state.  This would allow for more 
subtle assessment of trigger points and drivers of frailty and sarcopenia.  Certain events, 
such as change in the eFI or admission with delirium, could trigger a more detailed 
assessment.  
Alongside the rigorous clinical characterisation there would be regular assessment of 




using previously suggested biomarkers such as DHEA, DHEAS, GH and IGF-1 (417).  
inflammatory burden, the data presented in this thesis in Chapters 5 and 6 could be used to 
inform a unique frailty inflammatory ELISA kit.  This would include all the cytokines with a 
significant difference between either the three or four groups analysed in Chapters 5 and 6: 
Il-1ra, IL-1β, IL-4, IL-8, IL-17, IP-10, MIP1α, Eotaxin, FGF, MCP-1.  It will also include the 
cytokines, TNFα, IL-6 and IL-10; in this thesis there was no significant difference in the 
concentration of these three cytokines but previous work has demonstrated an association 
of these three cytokines with frailty and sarcopenia (169, 178, 185, 187, 195, 302).   
Characterisation of immunesenescence would be of importance.  In the quantification of 
immunesenescence it is impossible to study all the immune functions in each individual but 
it is important to consider the interaction and cross-talk between immune cells.  A practical 
biomarker of immunesenescence which allows serial testing of multiple samples in a short 
time-frame would be ideal for this type of longitudinal research but is as yet 
uncharacterised.   Neutrophil migration has been proved in this thesis to be compromised in 
frail individuals and is therefore a validated technique in frail older adults but it is a flawed 
choice because it is neither physiological nor time-efficient.   
The longitudinal study design including both rigorous clinical and biological characterisation 
of individuals will allow for complex modelling of the data to investigate patterns of change 
in severity of frailty and sarcopenia plus importantly identify the trigger points of descent in 
to more severe disease.                                   
This thesis has précised some of the difficulties with recruiting frail individuals to a cross-
sectional study investigating immunesenescence.  The complexities of recruiting frail older 




To capitalise on the potential for novel research the longitudinal study design could be used 
as a platform to perform spin-out cross-sectional research.  Important potential spin-out 
projects include comparing ultrasound with a gold standard diagnostic tool in the diagnosis 
of sarcopenia.  This would hopefully confirm the accuracy of ultrasound and the BATT as a 
tool in the identification of low muscle mass in sarcopenia and therefore allow the adoption 
of both these methods in research and clinical practice.  Another essential project would be 
in depth immune-phenotyping in frailty and sarcopenia. This would focus on not just 
neutrophils but also include other innate and adaptive immune cells.  This research could 
initially investigate whether previously reported effects with ageing are actually an effect of 
frailty rather than ageing per se.  The longitudinal research study would also offer a well-
characterised population amenable for intervention studies.  It would be particularly suited 
to intervention studies requiring mechanistic work investigating the effect of the 
intervention.   
 
7.4 Concluding remarks 
This study has proved it is feasible to recruit a well characterised frail older adult population 
for mechanistic immunesenescence work and relate parameters of physical health with 
immune health.  It has also reported some of the first evidence of the association of 
immunesenescence with parameters of frailty and demonstrated this effect is independent 
of age.  The breadth of the data reported in this thesis reflects not only geriatrics as a 
speciality but the lack of rigorous research into frailty.  The general discussion has not only 
highlighted some of the key findings of this work but has also suggested avenues for future 
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